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1 Introduction 
1.1 Older cancer patients  
Cancer is a disease of the elderly: The incidence of cancer substantially increases with higher 
age [1]. Due to demographic changes regarding a higher life expectancy and an aged 
population, the number of older cancer patients will continue to rise over the next years. This 
trend represents an increasing challenge since the therapy of older cancer patients is more 
complex than the therapy of younger cancer patients.  
Pharmacokinetics and pharmacodynamics are altered at advanced age. Regarding 
pharmacokinetics, the most important physiological change affecting clinical routine is the 
decrease of renal function [2]. The glomerular filtration rate subsides since the renal blood 
flow, as well as renal mass, declines with age [3]. Renal impairment may entail higher plasma 
concentrations of drugs, possibly causing toxicity. Moreover, the hepatic elimination is 
decreased due to reduced hepatic volume, less hepatic blood flow and declined hepatic 
phase I metabolism (e.g. oxidative reactions) [3]. Apart from the elimination organs, likewise 
other physiological changes contribute to altered pharmacokinetics in older patients: The 
proportion of total body water decreases whereas the proportion of total body fat increases 
with age. This may lead to a reduced volume of distribution regarding hydrophilic drugs [2]. 
Delayed gastric emptying, a higher gastric pH value and reduced gastric motility [2], may alter 
pharmacokinetics as well, being especially important for oral antineoplastic therapies [3]. 
Concerning pharmacodynamics, older patients commonly show modified efficacy and 
tolerability of drugs [2]. Due to decreased homeostatic capacities and physiological reserves 
(e.g. bone marrow reserves), older patients are more vulnerable to therapy-related toxicity 
[3]. For example, older patients are more sensitive to adverse effects of central nervous 
system (CNS) drugs like benzodiazepines [2] and at higher risk for cardiomyopathy caused by 
anthracyclines [3]. 
Furthermore, older cancer patients often suffer from concomitant chronic conditions. A 
prospective study indicated that comorbidity was more common for older cancer patients 
(76%) than for younger cancer patients (51%) [4]. Vascular disorders were observed as most 
frequent comorbidity [4]. Comorbidity impairs cancer therapy due to a higher risk of 
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chemotherapy-related toxicity and hospitalization [5]. Moreover, it complicates therapeutic 
decisions due to missing evidence regarding this particular cohort and due to reduced life 
expectancy [5]. Since severe comorbidity comprises a competing risk for mortality [5], the 
benefit of cancer therapies might be limited in those patients. In general, different priorities 
might be important for older cancer patients: Since life expectancy is globally attenuated, 
short term quality of life and the ability to continue self-care in daily life might be of higher 
importance for older patients than a small advantage in survival [6]. 
Medication risks like polymedication are also common in older cancer patients, affecting 
cancer therapy as well. This aspect is further discussed in section 1.2. 
Another issue comprises the paucity of evidence caused by the under-representation of 
elderly cancer patients in clinical trials [7]. Older patients are not enrolled as much as expected 
when considering cancer incidence in this age group [8]. Thus, there has recently been a call 
for pragmatic trials, facilitating the inclusion of older cancer patients. Pragmatic trials are 
characterized by a reduced burden on patients, broader eligibility criteria and a setting closer 
to everyday practice [9].  
Patients at advanced age have shown to experience a higher toxicity risk during cancer therapy 
than younger patients [10, 11]. Nevertheless, older patients can benefit from chemotherapy 
as well as younger patients: Lichtman et al. observed that older women with breast cancer 
experienced similar efficacy as younger women – despite the higher risk of toxicity at higher 
age [10]. Muss et al. found similar results [11]. Nonetheless, many older patients are 
undertreated: Bouchardy et al. reported that half of older breast cancer patients were 
undertreated in their study, substantially worsening their survival [12]. Presumably, physicians 
do not expect older patients to cope with a more aggressive treatment.  
However, older patients are a very heterogeneous population [2]. Aging does not simply 
depend on chronological age, counting the pure number of life years, but rather on the 
physiological age (“biological age”) which differs substantially: Some 80-year-old patients 
could be healthy and fit whereas others might be entirely frail, not being capable of self-care. 
Whether a patient will be able to go through a certain cancer therapy or not is thus difficult 
to judge, making therapy decisions highly complex. 
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Due to the heterogeneity of aging and the altered risk-benefit assessment, strategies for 
appropriate therapy individualization of older cancer patients are needed. The International 
Society of Geriatric Oncology (SIOG) recommends a comprehensive geriatric assessment 
(CGA) for individualizing cancer care in this population [13]. The geriatric assessment will be 
further discussed in section 1.3 of this thesis. Improvements in the treatment of older cancer 
patients are urgently warranted indeed: During the last years, the survival of older cancer 
patients increased slower than the survival of younger cancer patients, thereby leading to a 
larger survival gap between those cohorts [14].  
 
1.2 Medication risks in older cancer patients 
Drug-related problems are very common among older patients with cancer [15]. A drug-
related problem is defined as an event during pharmacotherapy which interferes with a 
desired health outcome, for example an inappropriate timing of drug administration or 
overdosing [16]. A retrospective analysis showed that 90% of older cancer patients exhibited 
drug-related problems (DRP); in median three DRP per patient were detected [15]. The most 
frequent DRP were interactions (36.4%), adverse drug reactions (31.7%), and non-adherence 
(8.9%) [15]. Another study by Nightingale et al. found a DRP prevalence of 95% in older cancer 
patients, with a mean of three DRP per patient [17]. Those drug-related problems may have 
severe consequences for patients: An observational study in a Norwegian hospital indicated 
that about 4% of deaths among cancer patients occurred due to adverse drug events [18]. The 
National Comprehensive Cancer Network (NCCN) recommends a periodic medication review 
for older cancer patients [19]. The evaluation of medication is also regarded as an essential 
aspect of the geriatric assessment (see section 1.3), being recommended by the SIOG [13, 20].  
There are in particular three aspects of medication risks which are usually highlighted for older 
cancer patients: Polymedication, potentially inadequate medication, and drug-drug 
interactions. 
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1.2.1 Polymedication 
Polymedication is usually defined as an intake of five drugs or more [21]. Different definitions 
of polymedication exist but the cut-off “≥ 5” is commonly used and has shown to be associated 
with adverse outcome in the elderly [22]. In general, older patients take more drugs than 
younger patients: In Germany, 55% of the defined daily doses (DDD) of drugs paid by the 
statutory health insurance was taken by patients ≥ 65 years in 2015 – although this age group 
only comprised 22% of the total population [23]. About one third of patients ≥ 65 years was 
found to be exposed to polymedication [24]. This high prevalence of polymedication was also 
detected in older patients with cancer: A study with 385 older cancer patients observed a 
prevalence of 57% for polymedication (≥ 5 drugs), with on average about six drugs per patient 
being taken [25]. Another study indicated that 80% of 117 older patients used five or more 
drugs prior to the start of cancer treatment [26]. Being associated with adverse outcomes like 
increased mortality or hospitalization, polymedication is of concern for the older population 
in general [25]. In older cancer patients, adverse outcomes were reported as well: 
Polymedication was associated with frailty and decreased physical function [25, 27]. 
Moreover, it was related to a 6-fold increased odds of experiencing severe chemotherapy-
related toxicity in older metastatic breast cancer patients [28]. 
 
1.2.2 Potentially inadequate medication 
When judging medication quality in older cancer patients, it is not only important to consider 
how many drugs, but also which drugs are being taken. There might be good reasons to 
prescribe many drugs to an older person. Hence, instead of only discussing the number of 
drugs, “appropriate polymedication” should rather be in focus, recognizing that patients can 
benefit from numerous medicines if they are chosen based on evidence and the clinical 
context [29]. The appropriateness of medication use is considered in this study via the 
screening of potentially inadequate medication (PIM). At higher age, some drugs may lead to 
an increased mortality risk, to a higher risk of falls or to more adverse reactions [21]. For these 
drugs, the risks may outweigh benefits in older patients [21]. Those PIM drugs for elderly can 
be determined in different ways: On the one hand, explicit PIM lists were developed, which 
are drug-oriented, explicitly stating specific drugs as being potentially inadequate [30]. On the 
other hand, implicit tools are available, which are judgment-based and patient-specific [30]. 
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Examples for explicit PIM lists comprise the Beers list [31] (mainly developed for the US), the 
PRISCUS list [32] (tailored to Germany), and the EU(7)-PIM list [33] (adapted to Europe). Also, 
FORTA (fit for the aged) [34] and START/STOPP (Screening Tool of Older Person's 
Prescriptions/Screening Tool to Alert Doctors to Right Treatment) criteria [35] are interesting 
to mention, since those additionally list drugs being useful in older patients (“positive list”). 
An example for implicit PIM lists comprises the Medication Appropriateness Index (MAI) which 
evaluates the medication regarding ten criteria (for instance: “Is the dosage correct?” or “Is 
there unnecessary duplication with other drug(s)?”) [36]. An advantage of the explicit tools 
comprises their applicability without clinical judgment. However, they do not take the 
individual patient into consideration for assessing appropriateness and need to be updated 
constantly [30]. In contrast, implicit lists individualize the assessment for each patient. 
However, the judgment depends on the expertise of the user and is time-consuming [30]. 
Depending on the instrument, different PIM prevalence was found in literature. A study with 
160 older patients receiving parenteral cancer therapy in an ambulatory clinic found that 
48.1% used at least one PIM (2015 Beers criteria) [37]. Another study detected a PIM 
prevalence of 38% according to the STOPP criteria [38]. PIM have shown to be associated with 
adverse outcomes in the general older population. Reich et al. found PIM to be associated 
with the hospitalization of patients [39]. In another study, PIM use was related to an increase 
of adverse drug events [40]. For older patients with cancer, only few studies exist regarding 
the association of PIM and adverse outcomes. So far, no association was found in respective 
studies [22]. 
 
1.2.3 Drug-drug interactions 
Since older cancer patients frequently experience polymedication, they are also at an 
increased risk of drug-drug interactions [41]: Riechelmann et al. found an increasing number 
of drugs to be associated with a higher risk of potential drug-drug interactions in the general 
population of cancer patients [42]. Potential drug-drug interactions are frequent among older 
cancer patients: Yeoh et al. detected potential drug-drug interactions as the most frequent 
drug-related problem (36.4%) in older patients receiving outpatient chemotherapy [15]. In 
another study, 75.4% of older cancer patients experienced potential drug-drug interactions 
during therapy [43]. Clinical consequences of those interactions might be serious: A study 
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reported that drug-drug interactions caused unplanned hospitalizations of cancer patients in 
about 2% of cases [44].  
 
1.3 Geriatric assessment  
The functional abilities of older cancer patients are heterogeneous [2].Therefore, it is essential 
to individualize therapy. Clinical judgment, chronologic age, or performance status are usually 
used for this in daily routine [45]. Commonly used scores are the Eastern Cooperative 
Oncology Group (ECOG) performance status or the Karnofsky performance status; see Table 
1-1. However, those approaches were not found to be adequate for therapy individualization. 
Clinical judgment was reported to be less effective in selecting older patients for aggressive 
chemotherapy than a comprehensive geriatric assessment (CGA) [45]. Chronologic age was 
observed to be less predictive for chemotherapy toxicity than overall health [46]. The 
performance status did not show adequate abilities either: Patients who scored normally on 
the Karnofsky performance status nevertheless exhibited substantial impairments identified 
by a geriatric assessment [47].  
Thus, for individualizing cancer care, a CGA is recommended for older cancer patients ≥ 70 
years by the SIOG [13]. A CGA is a multidimensional, interdisciplinary evaluation of older 
patients to identify care needs regarding e.g. physical health, psychosocial, or functional 
capabilities [13, 48]. Based on this, a treatment plan can be developed [13, 48]. In geriatrics, 
a CGA is based on the following four domains: physical health, functional status, psychological 
health, and socioenvironmental factors [48]. In geriatric oncology, the domains of a CGA have 
not been well defined and not all studies conducted a complete CGA [48]. The SIOG 
recommends evaluating the following domains for geriatric assessments in older cancer 
patients: functional status, fatigue, comorbidity, cognition, mental health status, social status 
and support, nutrition, and geriatric syndromes [20]. Geriatric syndromes include for example 
delirium, dementia, falls, incontinence, but also polymedication [20]. Different instruments 
for assessing those domains exist. However, the SIOG could not recommend one instrument 
above the other, advising to choose the specific instrument according to local preferences or 
resources [20]. An overview of essential domains of the geriatric assessment is given in Table 
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1-2. Furthermore, the NCCN recommends a periodic medication review in older cancer 
patients [19].  
Table 1-1 Comparison of the ECOG [49] and Karnofsky performance status [50], according 
to [51]; ECOG, Eastern Cooperative Oncology Group  
Score ECOG performance status 
 
Score 
Karnofsky performance 
status 
0 
Fully active, able to carry on 
all pre-disease performance 
without restriction 
 
100 
Normal, no complaints; no 
evidence of disease 
 
90 
Able to carry on normal 
activity; minor signs or 
symptoms of disease 
1 
Restricted in physically 
strenuous activity but 
ambulatory and able to carry 
out work of a light or 
sedentary nature 
 
80 
Normal activity with effort, 
some signs or symptoms of 
disease 
 
70 
Cares for self but unable to 
carry on normal activity or to 
do active work 
2 
Ambulatory and capable of all 
self-care but unable to carry 
out any work activities; up 
and about more than 50% of 
waking hours 
 
60 
Requires occasional assistance 
but is able to care for most of 
personal needs 
 
50 
Requires considerable 
assistance and frequent 
medical care 
3 
Capable of only limited self-
care; confined to bed or chair 
more than 50% of waking 
hours 
 
40 
Disabled; requires special care 
and assistance 
 
30 
Severely disabled; 
hospitalization is indicated 
although death not imminent 
4 
Completely disabled; cannot 
carry on any self-care; totally 
confined to bed or chair 
 
20 
Very ill; hospitalization and 
active supportive care 
necessary 
 10 Moribund 
5 Dead  0 Dead 
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Table 1-2 Domains of a geriatric assessment in the older cancer patients including 
examples for respective instruments; modified according to [20]; MOS, Medical 
Outcomes Study; START, Screening Tool to Alert Doctors to Right Treatment; 
STOPP, Screening Tool of Older Person’s Prescriptions 
Domain Instruments (examples) 
Social status 
Questions on living situation, marital status, financial resources 
MOS social support survey 
Comorbidity 
Charlson Comorbidity Index (CCI) 
Cumulative illness rating scale (CIRS) 
Functional status 
Timed get up and go 
Hand grip strength 
Activities of daily living (ADL) 
Instrumental activities of daily living (IADL) 
Barthel index 
Cognition 
Mini-Mental State Examination (MMSE) 
Clock-drawing test 
Depression 
Geriatric depression scale 
Hospital anxiety and depression scale 
Nutrition 
Body mass index (BMI) 
Mini Nutritional Assessment (MNA) 
Medication 
Beers criteria 
STOPP and START criteria 
Geriatric 
syndromes 
Polymedication 
Falls 
Constipation 
Pressure ulcus 
 
 
1.3.1 Usefulness 
The geriatric assessment was developed in geriatrics and has shown to be effective in the 
general older population: A CGA was found to increase survival and increase the probability 
of staying at home up to 12 months for older patients admitted to hospital [52].  
In older cancer patients, the geriatric assessment was found to identify age-related problems 
not being revealed by routine diagnostics: Kenis et al. observed that geriatric interventions 
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were initiated in 25.7% of patients based on a geriatric assessment [53]. Furthermore, the 
geriatric assessment affected therapy decisions in older cancer patients and thus 
demonstrated an impact on clinical routine: A systematic review reported that 21% to 53% of 
treatment regimens were altered after a geriatric assessment, in particular due to the 
functional or nutritional status [54]. In line with this, another review observed that cancer 
treatment plans were changed in a median of 28% of patients following a geriatric assessment 
[55].  
Moreover, the results from geriatric assessments were associated with adverse outcomes in 
older cancer patients: A systematic review by Versteeg et al. found that different geriatric 
assessment domains were associated with mortality in older cancer patients [54]. Nutritional 
status predicted mortality in all analyzed studies. No consistent parameters were found for 
predicting toxicity [54]. A systematic review by Caillet et al. reported that each geriatric 
assessment domain was associated in at least one study with therapy-related toxicity and 
survival. In particular, malnutrition, comorbidity, and functional decline seemed to be 
predictive [56]. A systematic review by Hamaker et al. found little consistency regarding the 
value of geriatric assessment parameters for predicting outcomes in older cancer patients. For 
instance, frailty was associated with toxicity, whereas cognitive function and ADL were 
associated with completion of cancer therapy [57].  
However, for determining the clinical impact of a geriatric assessment, it is also important to 
investigate if it may effectively improve outcomes of patients. Only few studies analyzed the 
impact of a geriatric assessment on outcomes. However, these studies showed mixed results. 
Corre et al. assessed the benefit of a geriatric assessment on outcomes in a randomized multi-
centric study, using the CGA versus a standard approach (based on ECOG performance status 
and age) for assigning patients to different therapy strategies [58]. The primary endpoint, 
treatment failure free survival, did not show an effect of the CGA. However, the CGA could 
significantly reduce treatment toxicity [58]. In a prospective cohort comparison study, Kalsi et 
al. found that patients with CGA were significantly more likely to complete the planned 
therapy regimen and underwent less therapy modifications [59]. Treatment toxicity was 
reduced as well but did not reach statistical significance [59]. A randomized pilot study by 
Magnuson et al. did not observe an improvement of outcomes (for example chemotherapy-
related grade 3-5 toxicity, hospitalization, or early treatment discontinuation) in patients with 
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geriatric assessment compared to standard care [60]. This might be explained by the low 
implementation rate of geriatric assessment recommendations by the primary oncologist in 
this study [60]. 
 
1.3.2 Implementation into daily routine 
The SIOG summarizes that a geriatric assessment may be helpful in daily practice for detecting 
geriatric deficits of patients, for adapting treatment choice, and for predicting severe therapy-
associated toxicity, as well as overall survival [20]. The main goal of a geriatric assessment 
should be to trigger interventions for geriatric deficits and to guide individualized treatment 
decisions [20]. The geriatric assessment should support decision-making. However, it is too 
early to deny or assign an oncological therapy only on grounds of a geriatric assessment [61]. 
Despite being recommended, a geriatric assessment is not always feasible in daily routine, 
being very time-consuming [62]. However, efforts have been made during the last years to 
implement the geriatric assessment into daily routine using interdisciplinary concepts. For 
instance, Schmidt et al. implemented an interdisciplinary care concept for older cancer 
patients in a German university hospital, including results of a geriatric assessment and 
patient-reported quality of life [63].  
For facilitating the implementation of the time-consuming geriatric assessment, several short 
frailty screening tools were developed for pre-selecting patients in need of a CGA. However, 
a systematic review by Hamaker et al. concluded that none of the available screening tools 
indicated sufficient discriminative abilities for selecting patients requiring a full CGA [64]. 
Nevertheless, due to time-savings, the SIOG concluded that screening tools might be used for 
pre-selecting patients in busy clinical routine [65]. No screening tool could be recommended 
above another by SIOG [65].  
 
1.4 Onco-geriatric scores 
Toxicity is an important aspect for therapy decisions in older cancer patients [66]. Prediction 
of toxicity may help oncologists as well as patients in the decision-making process regarding 
cancer therapy [67]. Short tools combining geriatric assessment parameters with oncologic 
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parameters were developed for individualized prediction of chemotherapy-related toxicity: 
the CARG (Cancer and Aging Research Group) and the CRASH (Chemotherapy Risk Assessment 
Scale for High-Age Patients) score [67, 68].  
An advantage of the onco-geriatric scores comprises the inclusion of oncological items for 
toxicity prediction [67, 68]. The geriatric assessment is recommended for therapy 
individualization [13] and has shown to be associated with therapy-related toxicity [56]; 
however, also oncological parameters (for example the therapy regimen [69]) play a role for 
the toxicity risk. In contrast to the onco-geriatric scores, other frailty screening tools focus on 
geriatric assessment items only [65]. Furthermore, the onco-geriatric scores offer an easier 
interpretation of the toxicity risk. A geriatric assessment itself does not inform about risk 
probabilities, whereas the scores yield a certain toxicity risk category [67, 68]. This facilitates 
the applicability of results to therapy decisions. Moreover, the onco-geriatric scores are short: 
Instead of incorporating the full geriatric assessment, only those domains predictive for 
toxicity were extracted [67, 68]. This also facilitates their use in clinical routine. 
The American Society of Clinical Oncology (ASCO) guideline for Geriatric Oncology 
recommends either the CARG or the CRASH score for predicting toxicity [70]. Although both 
scores are recommended in literature, it is unclear which score should be preferred [70]. 
Whereas the CARG score is a short prediction tool incorporating only few simple questions, 
the CRASH score is more time-consuming, including full geriatric assessment instruments 
(IADL, MMSE, MNA) [67, 68]. However, the CRASH score could possibly give a more detailed 
prediction, differentiating between hematologic and nonhematologic toxicity as well as 
between four categories while the CARG score only predicts a general toxicity incidence 
regarding three risk categories [67, 68]. In a review by Almodovar et al., a panel of six experts 
judged both scores as feasible tools in non-small cell lung cancer (NSCLC) treatment but 
considered CARG as the first option in clinical routine due to its ease of use [62]. However, no 
study has compared the predictive performance of the CARG and CRASH score so far.  
The CARG score was evaluated for different tumor entities, demonstrating mixed results: In 
lung cancer patients, toxicity incidence increased significantly with higher CARG risk 
categories, suggesting a predictive value of the CARG score [71]. For prostate cancer patients, 
the CARG score could not demonstrate a predictive value for therapy-related toxicity [72]. 
However, this study was limited by a relatively small sample size (46 patients) [72]. A recent 
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study investigated the CARG score in 126 patients with solid tumors, not finding a sufficient 
predictive value of the CARG score [73]. In contrast to that, another study with 58 older 
patients with solid tumors found that patients with a CARG score ≥ 10 experienced more often 
toxicity than patients with a CARG score of < 10 [74]. The CRASH score has not been assessed 
in further studies so far.  
Due to the conflicting results and lacking data, further evaluation and comparison of the onco-
geriatric scores is urgently needed to support the implementation of those promising tools in 
daily routine. The onco-geriatric scores may be of significance in different fields. In clinical 
routine, the onco-geriatric scores could allow for a more detailed weighting of risks and 
benefits of therapies. This might in consequence also reduce under- and overtreatment of 
older cancer patients. Furthermore, clinical trials may use these scores for risk stratification.  
 
Aim   13 
 
2 Aim  
The overarching goal of this work consisted in optimizing the treatment of older cancer 
patients. This was pursued by (I) evaluating onco-geriatric scores (the CARG and the CRASH 
score) and by (II) assessing medication risks in older cancer patients.  
Regarding the onco-geriatric scores, the primary aim was to compare the CARG and CRASH 
score concerning (I) the agreement of predictions and (II) the predictive performance 
regarding toxicity risks. The secondary aim consisted in comparing the score predictions with 
physicians’ judgment and with other commonly used predictors of toxicity. For investigating 
additional applications of the scores, exploratory analyses were conducted concerning the 
predictive value for time-related predictions, patient-reported symptom burden, and 
alterations of planned treatment.  
Moreover, this thesis aimed at analyzing the medication risks of older cancer patients. Those 
were investigated before and after start of cancer therapy regarding three aspects: 
polymedication, potentially inadequate medication, and drug-drug interactions.  
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3 Methods 
In the following section, the methods regarding the evaluation of onco-geriatric scores and 
the analysis of medication risks in older cancer patients are described. 
 
3.1  Evaluation of onco-geriatric scores 
Onco-geriatric scores (the CARG and the CRASH score) were developed for predicting the 
occurrence of severe therapy-associated toxicity in older cancer patients. This study evaluated 
and compared the predictive performance of both scores for determining which one is 
favorable to use in a clinical routine setting. 
 
3.1.1 Study design  
The study was a prospective, single-center, observational study. All study patients were not 
treated according to a pre-specified study protocol but solely according to clinical routine. The 
physicians’ decision on treatment, diagnosis, and monitoring was not affected by the study 
protocol. Legally, this study is therefore classified as a non-interventional trial according to §4 
of the German drug law (Arzneimittelgesetz) [75]. 
A positive vote of the ethics committee of the Faculty of Medicine of Bonn University was 
granted for this study (consecutive number 302/15). 
This study was conducted in cooperation with the Department of Geriatrics and Neurology 
(Prof. A. Jacobs) as well as the Department of Oncology and Hematology (Prof. Y.-D. Ko) at the 
Johanniter Hospital Bonn. The Johanniter Hospital Bonn features 364 beds and is part of the 
cancer center of the Bonn/Rhein-Sieg area, certified by the German Cancer Society (Deutsche 
Krebsgesellschaft e.V.) [76, 77]. It offers inpatient oncological care as well as an outpatient 
oncological clinic.  
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3.1.2 Pilot study 
This evaluation study was set up based on a previous pilot study by our research group 
(positive vote of the ethics committee of the Faculty of Medicine of Bonn University, 
consecutive number 011/15) conducted in the Johanniter Hospital Bonn between March and 
June 2015. The prospective, observational pilot study aimed at testing the feasibility of the 
CARG and the CRASH score performance in a clinical routine setting (see details of the CARG 
and the CRASH score in 3.1.5.1 and 3.1.5.2). The CARG and the CRASH score were performed 
in 20 patients ≥ 70 years who experienced a malignancy or condition requiring treatment with 
antineoplastic agents. Patients must not have started systemic cancer treatment yet. Eligibility 
criteria were consistent with the subsequent evaluation study, except regarding the 
performance of the systemic cancer treatment. In the pilot study, a systemic cancer treatment 
had to be indicated as standard therapy but, contrary to the evaluation study, the actual 
performance of the treatment was not required. If no systemic treatment was conducted, 
score items regarding cancer treatment were calculated using the standard therapy. Parts of 
the pilot study were published in the Master thesis of Monique Theissen Mendel [78]. Data of 
the pilot study were partly included into the analysis of medication risks (see section 3.2). 
 
3.1.3 Course of the study 
This study considered the design and eligibility criteria of the original development studies of 
the CARG and the CRASH score where possible. Patients were recruited at the oncology and 
internal medicine inpatient wards of Johanniter Hospital Bonn. In a patient interview, the 
geriatric assessment items for the CARG and CRASH score (see sections 3.1.5.1 and 3.1.5.2) as 
well as a baseline assessment of the symptom burden (PRO-CTCAE, see section 3.1.6.2) were 
captured. Additional laboratory data for the scores (see sections 3.1.5.1 and 3.1.5.2) and 
patient characteristics (see section 3.1.4.4) were collected from medical records. For the CARG 
and CRASH score calculation, either laboratory data of the day of inclusion or the most recent 
measurements were used. Before start of systemic cancer therapy, the treating physician was 
asked about the planned cancer treatment as well as the clinical judgment in terms of toxicity 
risk (physicians’ judgment; see section 3.1.5.3). Physicians were blinded to the score results; 
hence, the results did not influence either diagnosis, treatment decision, or monitoring.  
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As follow-up, toxicity during therapy course (CTCAE, see section 3.1.6.1) and symptom burden 
of patients (PRO-CTCAE, see section 3.1.6.2) were captured until the end of the planned 
therapy or for a maximum of six cycles. The toxicity during therapy course and possible 
alterations of planned treatment (therapy discontinuations, changes, delays, or reductions) 
were retrospectively recorded from medical records. Patients were contacted for the 
assessment of symptom burden one to two weeks after start of cycle. Follow-up data, 
including doctor letters and laboratory data, were collected in the Johanniter Hospital Bonn 
as well as in surrounding oncology practices if patients continued treatment there. The data 
collection, comprising the performance of the onco-geriatric scores and capturing of follow-
up data, was delivered by the author of this thesis (in the following referred to as 
“researcher”). Details regarding the course of the study are given in Figure 3-1. 
 
 
Figure 3-1 Course of the study and outcome measurements; PRO-CTCAE, Patient-Reported 
Outcomes version of the Common Terminology Criteria for Adverse Events; 
CTCAE, Common Terminology Criteria for Adverse Events  
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3.1.4 Patients 
The patient cohort consisted of older cancer patients starting a first-line systemic cancer 
treatment in an inpatient clinical routine setting. 
 
3.1.4.1 Inclusion and exclusion criteria 
Following inclusion and exclusion criteria were defined: 
Inclusion criteria 
 Diagnosis of any malignancy (solid tumor or hematologic malignancy) 
 Age ≥ 70 years 
 Understanding German  
 Systemic cancer treatment indicated (chemotherapy, targeted therapy, or 
immunotherapy) 
 Written informed consent 
Exclusion criteria 
 Cognitive impairment which prevents understanding of the course or purpose of the 
study (exclusion of patients with a Mini-Mental State Examination < 20) 
 Systemic cancer treatment had already started 
Broad inclusion criteria and only limited exclusion criteria were defined because the onco-
geriatric scores were designed to comprise a broad prediction scope across different cancer 
types and cancer therapies. Moreover, a heterogeneous study population better represents 
the real population of the hospital. The original development studies of the CARG and CRASH 
score had different inclusion criteria, see sections 3.1.5.1 and 3.1.5.2. For this evaluation 
study, eligibility criteria were selected based on both development studies.  
 
3.1.4.2 Recruitment 
For recruitment, patients at the oncology and internal medicine wards of the Johanniter 
Hospital Bonn were identified by the treating physicians and invited to participate. All patients 
fulfilling the defined inclusion and exclusion criteria were enrolled in the study. Patients were 
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informed about the study details, received a patient information brochure and signed a 
written informed consent. The patient information brochure and the informed consent form 
are presented in Appendix A. Patient data were pseudonymized by assigning a random 
number to each patient. After the end of the study, data were anonymized. 
 
3.1.4.3 Sample size determination 
In general, it is recommended to include 100 events and 100 nonevents for an external 
validation of prediction models [79]. However, since data about the incidence of severe 
toxicity in this patient cohort was missing, a sample size calculation was not possible. Based 
on the experiences from the pilot study, a recruitment rate of approximately six patients per 
month was estimated and 120 patients were sought to be included.  
 
3.1.4.4 Documentation 
The following patient characteristics were documented: demographic data, renal function 
(Cockcroft-Gault), comorbidity, diagnosis of cancer, cancer therapy regimen, and medication 
of the patient. For comorbidity, the Charlson Comorbidity Index (CCI) [80] in its original version 
was calculated since this tool was found to be reliable in older cancer patients and is the most 
widely used comorbidity tool [81, 82]. The cancer diagnosis was neglected for the CCI 
calculation since the focus of this index was to describe the additional conditions beside the 
primary cancer diagnosis. All required laboratory data were measured in routine care; thus, 
no additional blood draws were necessary. 
 
3.1.5 Risk assessment 
The risk of therapy-associated toxicity was assessed by the CARG score, the CRASH score, and 
physicians’ judgment. For details regarding study material of the CARG and CRASH score see 
Appendix B. 
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3.1.5.1 The CARG score 
The CARG score was developed by Hurria et al. in 2011 and externally validated in 2016 [67, 
83]. It was developed in a prospective, multicentric study with 500 patients ≥ 65 years [67]. 
All patients experienced solid tumors and were scheduled to start a new chemotherapy 
regimen in an outpatient oncology practice. The mean age was 73 years and most patients 
experienced lung cancer (29%) or gastrointestinal cancer (27%) during the development study. 
The predicted outcome was therapy-associated severe toxicity, defined as grade 3-5 toxicity 
according to the Common Terminology Criteria for Adverse Events (CTCAE). Two physicians 
reviewed chemotherapy courses for recording therapy-related toxicity. Toxicity was 
documented at each clinical encounter. Severe toxicity regarding blood values was only 
considered if it had occurred on the day of scheduled chemotherapy or at emergency visits. 
During the development study, 53% of patients experienced severe toxicity. Various geriatric 
assessment parameters, laboratory data, and tumor- or treatment-related oncological 
variables were investigated for associations with severe toxicity. For the CARG score, eleven 
of those variables were selected, including five geriatric assessment items, three clinical items, 
and three oncological items. The items included in the score are presented in Table 3-1, 
together with the assigned score points [67].  
The CARG score ranges from 0 to 23 points. Higher points indicate a higher risk. In this 
evaluation study, the original cut-offs for the score categories were used: Score results ranging 
from 0 to 5 points were assigned to predict a low risk of therapy-associated toxicity, 6 to 9 
points a mid risk, and ≥ 10 points a high risk. In the development cohort, the proportion of 
patients with low, mid, and high toxicity risk were 30%, 52%, and 83%, respectively [67].  
In this evaluation study, the CARG score online calculator was used for computing the toxicity 
score (http://www.mycarg.org, last accessed 2019 September 28). In order to determine if a 
regimen was categorized as “polytherapy or monotherapy”, all antineoplastic agents were 
counted, including targeted therapies or immunotherapies. The dosage was regarded as 
“reduced or standard” according to the treating physician, the summary of product 
characteristics, or therapy guidelines, as appropriate. The tumor entities “gastrointestinal or 
genitourinary” were classified following the definition of the National Cancer Institute [84]. In 
this evaluation study, all geriatric assessment items were captured in a patient interview; the 
clinical and oncological variables were extracted from medical records. The geriatric 
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assessment questions were translated into German based on the original English CARG version 
[67]. 
Table 3-1 Items of the CARG score with the assigned score points [67]  
Area Item Value Score points 
Patient 
characteristics 
Age 
≥ 72 years 2 
< 72 years 0 
Tumor 
characteristics 
Tumor entity 
Gastrointestinal or 
genitourinary 
2 
Other 0 
Therapy 
regimen 
Dosage 
Standard 2 
Reduced 0 
Number of 
chemotherapeutic 
agents 
Polytherapy 2 
Monotherapy 0 
Laboratory 
items 
Hemoglobin 
< 10 g/dL (female), < 11 g/dL 
(male) 
3 
≥ 10 g/dL (female), ≥ 11 g/dL 
(male) 
0 
Creatinine 
clearance (Jeliffe) [85] 
< 34 mL/min 3 
≥ 34 mL/min 0 
Hearing Hearing ability 
Fair/worse 2 
Good/excellent 0 
Functional 
status 
Number of falls (in the 
last 6 months) 
≥ 1 3 
0 0 
Help in taking 
medications 
Requires assistance 1 
No assistance 0 
Ability of walking one 
block 
Limited 2 
Not limited 0 
Decreased social 
activity due to 
physical/emotional 
health 
Some, most, all of the time 1 
A little, or none of the time 0 
 
In the development study, the CARG score resulted in an area under the receiver operating 
characteristic curve (ROC-AUC) of 0.72 [67], which implies rather moderate discriminative 
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abilities of the score (see section 3.1.7 for details on ROC analyses). In the validation study 
with 250 patients, a ROC-AUC of 0.65 was reached which was not statistically different from 
the ROC-AUC in the development cohort [83]. In both studies, the CARG score exhibited a 
better toxicity prediction than the Karnofsky performance status, a commonly used predictor 
for toxicity [50, 67, 83].  
Instead of using complete instruments from the geriatric assessment, the CARG score only 
uses single questions being extracted from those instruments (e.g. from the IADL only one 
question was incorporated: “help with medication intake”) [67]. Thus, the CARG score offers 
a quick estimation of the toxicity risk and can be completed in < 5 min [70] . However, only 
three different risk categories are used and it does not offer a risk prediction for different 
types of toxicity but only for overall toxicity [67]. 
 
3.1.5.2 The CRASH score 
The CRASH score was developed by Extermann et al. in 2012 [68]. The prospective, 
multicentric study included 562 patients ≥ 70 years with solid and hematologic tumors, 
starting a new chemotherapy regimen [68]. The score was concomitantly developed and 
validated in that study: The patient cohort was randomly split in a derivation and a validation 
cohort (ratio 2:1). The median age of the derivation cohort was 76 years and the most frequent 
tumors comprised lung cancer (21.5%), breast cancer (21.5%), and non-Hodgkin lymphoma 
(14.2%). As outcome, the occurrence of severe toxicity during therapy course was analyzed. 
“Severe toxicity” was defined as CTCAE grade 3-4 nonhematologic or grade 4 hematologic 
toxicity. Toxicity was captured via medical evaluation at start of each cycle and at the end of 
treatment as well as via screening of medical records. Weekly complete blood counts were 
considered. The chemotherapy follow-up was ended after a maximum of 6 months. During 
the development study, severe toxicity occurred in 64% of patients [68]. Different clinical 
variables, laboratory data, geriatric assessment instruments, and cancer-specific variables 
were investigated for toxicity prediction. The derived score was divided into three subscores 
predicting overall (combined CRASH score), hematologic (hematologic CRASH score), and 
nonhematologic toxicity (nonhematologic CRASH score). The combined score was constructed 
by combining the items of the hematologic and nonhematologic score into one score. The 
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items included in the CRASH score are presented in Table 3-2, together with the assigned score 
points [68].  
Table 3-2 Items of the CRASH score and the assigned score points regarding the three 
different subscores hematologic, nonhematologic, and overall toxicity [68]; ULN, 
upper limit of normal  
CRASH subscore Area Item Item value 
Score 
points 
Hematologic 
Cancer therapy 
MAX2 index [69] 
(Chemotherapy 
toxicity index) 
> 0.57 2 
0.45-0.57 1 
0-0.44 0 
Laboratory item 
Lactate 
dehydrogenase (LDH) 
> 0.74 x ULN 2 
0-0.74 x ULN 0 
Clinical item 
Diastolic blood 
pressure 
> 72 mmHg 1 
≤ 72 mmHg 0 
Functional 
status 
Instrumental 
activities of daily 
living (IADL) [86] 
10-25 1 
26-29 0 
Nonhematologic 
Cancer therapy 
MAX2 index [69] 
(Chemotherapy 
toxicity index) 
> 0.57 2 
0.45-0.57 1 
0-0.44 0 
Functional 
status 
Eastern Cooperative 
Oncology Group 
(ECOG) performance 
status [49] 
3-4 2 
1-2 1 
0 0 
Cognitive 
function 
Mini-Mental State 
Examination (MMSE) 
[87] 
< 30 2 
30 0 
Nutritional 
status 
Mini Nutritional 
Assessment (MNA) 
[88] 
< 28 2 
28-30 0 
Combined 
Addition of score points of hematologic and 
nonhematologic scores with MAX2 only counting once 
 
 
To adjust the score to the general toxicity of a chemotherapy regimen, the MAX2 index was 
used. This index has been previously developed by Extermann et al. and specifies the general 
per-patient toxicity risk of a chemotherapy regimen [69]. The index is derived from clinical trial 
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data by computing the average of the highest frequency of nonhematologic grade 3-4 toxicity 
and hematologic grade 4 toxicity of a regimen. Typically, three published studies with at least 
20 patients are include in the calculation [89]. Since taking into account the maximal frequency 
of both toxicity types, the index is called “MAX2” [69]. In the publication of the CRASH score, 
an overview of the MAX2 classifications was given for several typical chemotherapy regimens 
[68]. However, not all regimens were included in this list. In this case, an extended MAX2 list 
was used, which Extermann had provided to the author of this thesis on request. If the 
regimen was not listed there either, the regimen was classified by analogy, as recommended 
in the publication of the CRASH score [68]. The classification for the regimens not listed in the 
original publication of the CRASH score is presented in Appendix B. The German versions of 
the Mini-Mental State Examination (MMSE) [90] and the Mini Nutritional Assessment (MNA) 
[91] were used; the IADL [86] was translated into German based on the English original 
version. The geriatric assessment was performed by the researcher via a patient interview; 
clinical and laboratory data were recorded from medical records.  
The combined, hematologic, and nonhematologic CRASH scores range from 0 to 12, 0 to 6, 
and 0 to 8 score points, respectively [68]. With increasing risk score, the risk of toxicity 
increases. For calculating the CRASH score, an online calculator tool was used 
(https://www.moffitt.org, last accessed 2019 September 28). In this evaluation study, the 
original cut-offs of the score categories were applied for analysis. For the corresponding 
categories of the score results and the respective toxicity incidence in the derivation cohort 
see Table 3-3 [68].  
Table 3-3 Risk categories of the subgroups of the CRASH score, together with the observed 
proportion of toxicity incidence in the derivation cohort [68, 92]  
Risk category Combined Hematologic Nonhematologic 
Low 0-3: 50% 0-1: 7% 0-2: 33% 
Mid-Low 4-6: 58% 2-3: 23% 3-4: 46% 
Mid-High 7-9: 77% 4-5: 54% 5-6: 67% 
High > 9: 79% > 5: 100% > 6: 93% 
 
The score subgroups where hematologic and nonhematologic toxicity were evaluated 
separately differentiated better than the combined score [68]. The CRASH score reached a 
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ROC-AUC in the same range as the CARG score: In the derivation cohort, the combined, 
hematologic, and nonhematologic CRASH score yielded a ROC-AUC of 0.65, 0.76, and 0.66, 
respectively. In the independent sample validation, lower ROC-AUC values for the combined, 
hematologic, and nonhematologic CRASH score were observed: 0.64, 0.65, and 0.62, 
respectively [68]. 
Compared to the CARG score, the CRASH score is more time-consuming, requiring 
approximately 20-30 min to complete [70]. However, the CRASH score could be easily 
integrated into a CGA, already fully including various geriatric assessment instruments (IADL, 
MMSE, MNA) [70]. In contrast to the CARG score, the CRASH score offers a differentiation 
between the types of toxicity and a more detailed category distinction in four risk categories 
[68]. 
 
3.1.5.3 Physicians’ judgment 
Before the start of cancer therapy, the treating physicians were asked to estimate their 
patient’s individual toxicity risk during therapy course. The physicians should specify risk 
estimates for overall, hematologic, and nonhematologic severe toxicity, classified in the 
categories low, mid, or high. No detailed probability in percentage was requested because 
physicians are not trained for this detailed risk prediction and, therefore, would probably not 
be capable of giving such an exact estimate. All physicians were blinded to the score results; 
thus, the risk estimation was not influenced by the onco-geriatric assessment. 
 
3.1.6 Outcome measurement 
The primary endpoint was defined as severe toxicity during therapy course according to the 
Common Terminology Criteria for Adverse Events (CTCAE) [93]. Secondary endpoints 
comprised severe symptom burden of patients according to the Patient-Reported Outcomes 
version of the Terminology Criteria for Adverse Events (PRO-CTCAE) [94] and alterations of the 
planned treatment during therapy course.  
Baseline values of the outcome parameters were captured. Follow-up was pursued until the 
end of therapy or until a maximum of six therapy cycles was reached. Since the planned 
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treatment itself was also included in the score risk prediction, the follow-up was not pursued 
any longer if patients completely changed the planned treatment regimen or experienced 
dose reductions ≥ 50%. If minor changes of the treatment regimen occurred (e.g. delay of 
treatment for a few days), the follow-up was continued since, in general, this did not 
substantially alter score predictions. All patients with at least one cycle of follow-up were 
included into the outcome analysis in order to use the maximum information available. The 
duration of each cycle was retrieved from the cancer therapy plan of each patient. An 
overview of the outcome measurements during the study is illustrated in Figure 3-1 (see 
above).  
 
3.1.6.1 Toxicity  
The toxicity during therapy course was captured from medical records according to the 
Common Terminology Criteria for Adverse Events (CTCAE), version 4.03 [93]. The CTCAE were 
developed by the US National Cancer Institute as standardized terminology for reporting 
adverse events. The severity of adverse events is described by CTCAE grades, ranging from 1 
(mild) to 5 (death); for general definitions of grades see Table 3-4 [93].  
Table 3-4 General definitions of the CTCAE grades according to the National Cancer 
Institute [93]; grades defined as “severe toxicity” for this evaluation study are 
shown in bold; semi-colon signifies “or” 
Grade 1 
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated 
Grade 2 
Moderate; minimal, local or noninvasive intervention indicated; 
limiting age-appropriate instrumental activities of daily living  
Grade 3 
Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; 
limiting self-care activities of daily living 
Grade 4 Life-threatening consequences; urgent intervention indicated 
Grade 5 Death related to adverse events 
 
In this evaluation study, “severe toxicity” was defined as CTCAE grade ≥ 3. That definition is 
equal to the definition in the CARG score development study [67]. However, it differs from the 
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CRASH score development study where grade 3-4 nonhematologic toxicity or grade 4 
hematologic toxicity was considered as “severe toxicity” [68].  
An overview of all recorded types of toxicity is presented in Table 3-5. These were selected 
based on the toxicity captured during the CARG and CRASH score development studies [67, 
68]. Additional items relevant for targeted or immunotherapy were included (e.g. skin 
reactions, hypertension). The selection of additional items was undertaken by literature 
review and the discussion of relevant symptoms with an experienced oncologist. The toxicity 
documentation form being used for data collection is displayed in Appendix C.  
Table 3-5 Recorded types of toxicity during therapy course 
Hematologic 
toxicity 
Anemia, febrile neutropenia, neutropenia, leukopenia, thrombopenia 
Nonhematologic 
toxicity 
Acute coronary syndrome, atrial flutter, heart failure, hypertension, 
thromboembolic event, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), gamma-glutamyl-transpeptidase (GGT), 
bilirubin, creatinine, proteinuria, dyspnea, erythroderma, urticaria, 
palmar-plantar erythrodysesthesia syndrome, gastrointestinal 
bleeding, infections, dehydration, hyponatremia, hypokalemia, 
dysphagia, dry mouth, mucositis, pain, anorexia, constipation, diarrhea, 
nausea, vomiting, insomnia, fatigue, peripheral sensory neuropathy 
 
All medical records of the patients at Johanniter Hospital Bonn were retrospectively screened 
for toxicity. The highest CTCAE grade during each cycle was documented for each toxicity type. 
If no information was given about the severity of toxicity, CTCAE grade 1 was assumed. Further 
causality assessment was not performed, all detected toxicity was included. If a patient 
continued treatment in an outpatient clinic or oncology practice not located at the Johanniter 
Hospital Bonn, the clinic or practice was contacted for medical reports and laboratory data. 
Regular, weekly blood controls were considered for the toxicity evaluation. If these blood 
controls were not conducted at the Johanniter Hospital Bonn but e.g. at the general 
practitioner, the physician in charge was contacted for those data. Hence, the nadir of blood 
parameters, occurring approximately two weeks after the chemotherapy administration, 
were always considered. If treatment was changed completely, the patients were observed 
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until the start of a new cancer regimen; if treatment was discontinued, the patients were 
observed until four weeks after the last cycle, following Extermann et al. [68].  
For the toxicity analysis, only severe toxicity (grade ≥ 3) was considered. Overall, hematologic, 
and nonhematologic toxicity were analyzed separately. The incidence of severe toxicity was 
investigated for each patient and was assessed (I) for the complete therapy course and (II) at 
the start of therapy. Both time points were evaluated because severe toxicity is frequently 
experienced within the first cycle [95]. The “start of therapy” was defined as the first cycle of 
therapy or, in case of a shorter cycle length, as a minimum of three therapy weeks. Moreover, 
the time until occurrence of the first severe toxicity was investigated. Because toxicity was 
documented per cycle, the middle of the cycle was regarded as the time point of toxicity 
occurrence in this study. Time was documented in weeks. 
 
3.1.6.2 Patient-reported symptom burden 
Only focusing on physician-reported toxicity does not reveal the whole picture: Subjective 
adverse events during cancer therapy are at risk of being under-reported by physicians [96]. 
It was shown that patients themselves report symptoms earlier and more frequently than the 
treating physician [97]. Patient-reported outcomes (PRO) can complement physician-based 
toxicity reporting [97]. Therefore, in this evaluation study, the symptom burden of patients 
was measured by the Patient-Reported Outcomes version of the Terminology Criteria for 
Adverse Events (PRO-CTCAE). The PRO-CTCAE items were developed by the US National 
Cancer Institute as standardized tools for measuring symptoms during cancer therapy from a 
patient’s perspective [94]. The PRO-CTCAE was validated for the German language [98] and 
consists of 78 symptoms which are assessed regarding different attributes (e.g. frequency, 
severity) [99]. From this PRO-CTCAE item pool, items can be selected as needed. The PRO-
CTCAE items used in this evaluation study were selected based on a general core item set 
covering relevant toxicity during cancer therapy [100]. Thirteen symptoms were assessed in 
this study, regarding 21 attributes. The attributes comprised severity, frequency, or 
interference with daily activities (see Table 3-6; for study materials see Appendix C).  
Patients rated the PRO-CTCAE items on a 5-point Likert scale, ranging from zero (not at all; 
never) to four (very; almost always); see Appendix C. As the National Cancer Institute has not 
Methods   29 
 
published a scoring manual for the PRO-CTCAE, it was calculated following the validation of 
the German PRO-CTCAE by Hagelstein et al. [98]. They computed the score following the 
scoring manual of the EORTC-QLQ C30, a questionnaire for assessing the quality of life from 
cancer patients, developed by the European Organisation for Research and Treatment of 
Cancer (EORTC) [101].  
Table 3-6 The PRO-CTCAE items of this evaluation study 
Symptom Attributes 
Dysphagia Severity  
Dry mouth Severity  
Mucositis Severity, interference with daily activities 
Pain Frequency, severity, interference with daily activities 
Anorexia Severity, interference with daily activities 
Constipation Severity 
Diarrhea Frequency 
Nausea Severity, frequency 
Vomiting Severity, frequency 
Insomnia Severity, interference with daily activities 
Fatigue Severity, interference with daily activities 
Dyspnea Severity  
Peripheral sensory neuropathy Severity, interference with daily activities 
 
First, for each symptom scale, the different attributes were summarized by calculating the raw 
score (RS) derived from the mean of the corresponding attributes (Equation 3-1) [101]. In case 
of missing attributes, the raw score was only calculated if ≥ 50% of the values were present. 
 
I1 = Value of item 1 
I2 = Value of item 2 
In = Value of item n 
n = Number of items per scale 
RS =  
I + I +. . . + I 
n
 Equation 3-1 
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Subsequently, the raw score of the respective symptoms was linearized following Equation 
3-2 [101]. It was transformed on a scale from 0 to 100% where higher values indicated a higher 
severity of toxicity. A score of ≥ 75% was defined as severe symptom burden.  
 
The recall period of the PRO-CTCAE comprises seven days [94]. In this study, the PRO-CTCAE 
was measured once per cycle. Preferably, it was performed one to two weeks after the start 
of a cycle, for enhancing the comparability between regimens. The questionnaires were 
performed orally in a patient interview; patients not being present in the Johanniter Hospital 
Bonn were contacted by phone. The PRO-CTCAE was validated for different modes of 
administration. Nevertheless, regarding oral administration modes, it was only investigated 
for interactive voice response systems [94, 102]. All PRO-CTCAE items were also captured as 
physician-reported CTCAE in this study, in order to allow for comparison. Permission for using 
the PRO-CTCAE was gained from the NCI in a material transfer agreement. 
 
3.1.6.3 Alterations of planned treatment 
Toxicity-associated alterations of planned treatment were captured from medical records. 
Alterations which occurred for other reasons (e.g. progress of cancer) were excluded. The 
toxicity-associated alterations were classified as “discontinuations” if a patient discontinued 
the planned treatment early without continuing a systemic cancer treatment. All alterations 
where patients completely changed the therapy regimen and subsequently continued another 
systemic cancer therapy were regarded as “changes”. “Dose reductions” were defined as 
reduction of regimen dosages or omitting one of the drugs from the regimen. Alterations were 
considered “delays” if the regimen was postponed for several days due to toxicity but was not 
stopped. Discontinuations and changes were summarized as “major alterations”; delays and 
reductions were classified as “minor alterations”. The middle of the respective cycle (in weeks) 
was recorded as the time to occurrence of the first alteration of planned treatment.  
  
      =   
  
     
   ∙ 100 Equation 3-2 
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3.1.7 Statistical analysis 
Data entry and statistical analysis were performed using Microsoft® Excel® 2007 (Microsoft 
Corporation, Redmond, USA) and IBM® SPSS® Statistics Version 25.0 for Windows (IBM 
Corporation, Armonk, USA). Figures were generated with GraphPad Prism® Version 6.01 
(GraphPad Software, San Diego, USA) and IBM® SPSS® Statistics Version 25.0.  
Descriptive statistics were performed for summarizing patient characteristics, risk 
assessment, and outcome results. A mean with standard deviation (SD) or a median with 
interquartile range (IQR) was calculated, as appropriate. The frequencies were given as 
numbers and percentages. 
For the inductive statistics in the exploratory analyses, a p-value of < 0.05 was considered as 
statistically significant. Confidence intervals (CI) of 95% were computed.  
 
3.1.7.1 Relationship between risk assessments 
For assessing if the CARG score, the CRASH score, and physicians predict consistent risks, the 
relationship between the CARG and the CRASH score as well as between the scores and the 
physicians’ judgment were analyzed. 
The correlation of the CARG and the CRASH score was tested with the two-sided Spearman’s 
rho (rs) for ordinal data [103] and illustrated by a scatter plot. The score results were treated 
as continuous variables. The strength of a correlation increases with higher values of rs. 
However, a high correlation does not necessarily mean that two ratings have a high agreement 
[103]. Therefore, the agreement was assessed by (weighted) kappa and Fisher’s exact test 
(exact chi-square test). Kappa is the gold standard for assessing agreement [104, 105]. It 
accounts for the possibility of agreement occurring by chance; see Equation 3-3 [105].  
 
κ = kappa coefficient 
ρ0 = proportion of observed agreement 
ρe = proportion of agreement by chance 
κ =  
ρ  − ρ 
1 −  ρ 
 Equation 3-3 
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For data with more than two categories, the extension of kappa, the weighted kappa (κw), is 
used [106]. The weighted kappa also considers the distance of disagreement: The 
disagreement of larger distances (for instance between the categories low and high) is 
assigned a higher weight than for smaller distances (for instance between the category low 
and mid-low). The linear weighting scheme according to Agresti was applied [107]. As an 
essential condition of weighted kappa, the number of categories must be equal for both 
scores. Therefore, the CRASH score was pooled into three categories, in order to have as many 
categories as the CARG score. Results of different poolings of the CRASH score were 
investigated as sensitivity analysis (e.g. pooling mid-low/mid-high vs pooling low/mid-low for 
analysis). (Weighted) Kappa was interpreted according to Landis and Koch [108], see Table 
3-7. Higher values indicate better agreement, whereas negative values imply an agreement 
worse than chance. 
Table 3-7 Kappa statistic and strength of agreement, according to Landis and Koch [108]  
Kappa statistic Strength of agreement 
< 0.00 Poor 
0.00-0.20 Slight 
0.21-0.40 Fair 
0.41-0.60 Moderate 
0.61-0.80 Substantial 
0.81-1.00 Almost perfect 
 
The actual agreement (not adjusting for agreement occurring by chance) was investigated by 
assessing the proportion of the respective CRASH score categories in different CARG score 
categories. This was illustrated in a stacked bar chart and evaluated by Fisher’s exact test. 
Usually, a chi-square test is applied to analyze if categorical data are statistically significantly 
associated with each other. However, the chi-square test is not accurate if the expected 
frequencies are less than five [109]. Since the Fisher’s exact test estimates the exact 
probabilities of chi-square statistics and is also precise at lower sample size [109], this 
evaluation study with limited sample size used the Fisher’s exact test for assessing the 
statistical significance of the agreement.  
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3.1.7.2 Predictive performance 
The predictive performance for severe toxicity was assessed regarding the CARG and the 
CRASH score (combined, hematologic, and nonhematologic), as well as physicians’ judgment. 
It was analyzed concerning two time frames: For the toxicity incidence during therapy course 
and at start of therapy. Moreover, the predictive performances for patient-reported 
symptoms and for toxicity-associated alterations of the planned treatments were 
investigated. In order to compare the scores with other commonly used predictors, the 
predictive performance for severe toxicity regarding the predictors age and ECOG 
performance status were examined as well. The scores were treated as continuous and 
physicians’ judgment as categorical data, allowing to use the maximal information available.  
For judging the predictive performance of scores, in general, two essential aspects should be 
investigated: calibration and discrimination [110–112]. Calibration assesses if the predicted 
outcome corresponds with the real outcome; discrimination evaluates if a score can 
differentiate between patients with a certain outcome versus patients without that outcome 
[110, 112].  
To assess calibration, Fisher’s exact test and univariate logistic regression were used. The 
Fisher’s exact test analyzed the association between the proportion of patients with severe 
toxicity and the predicted risk category of the scores [109, 110]. The proportion of patients 
with severe toxicity per category was illustrated with bar charts. The categories of the scores 
were pooled into “low vs high” (CARG: low/mid vs high; CRASH: low/mid-low vs mid-
high/high) to ensure an adequate number of patients per group. Furthermore, the proportion 
of patients with severe toxicity per score value from the development studies of the scores 
was compared with the proportion of patients with severe toxicity per score value in our 
study. A logistic regression tests the influence of risk factors on a binary outcome, usually using 
the Wald statistics [109, 113]. In this evaluation study, we computed a logistic regression with 
Wald statistics to analyze if the score predictions were significantly associated with the 
incidence of severe toxicity, severe symptom burden, or toxicity-associated alterations of the 
planned treatments. The score values were treated as continuous variables, physicians’ 
judgment as categorical variable.  
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To evaluate discrimination, receiver operating characteristic curves (ROC curves) were 
calculated [114]. In ROC curves, the x-axis displays 1-specificity (false positive rate) and the y-
axis sensitivity (true positive rate) [115]. A larger area under the ROC curve (ROC-AUC) 
indicates a better discrimination because in this case, the score features a low false positive 
rate while exhibiting a high true positive rate [115]. A ROC curve close to the line of identity 
corresponds to a score predicting as well as chance alone, whereas a curve close to the left 
upper corner indicates an almost perfect test. The ROC-AUC can be interpreted according to 
Carter [116]: 1 = perfect; ≥ 0.9 = excellent; ≥ 0.8 = good; ≥ 0.7 = fair; ≥ 0.5 = poor; 0.5 = no 
value. Furthermore, ROC curves display the trade-off between sensitivity and specificity along 
the course of the curve. Each point of the curve represents the respective specificity and 
sensitivity for a certain cut-off value. Cut-off values divide the score results into different 
categories, e.g. low or high risk. To detect the best cut-off values for a score, the specific cut-
offs with a maximum of sensitivity at a maximum of specificity must be determined. For 
assessing this optimal trade-off between specificity and sensitivity, the Youden Index was 
applied [117]:  
 
3.1.7.3 Time until occurrence of first toxicity 
For cancer patients, not only the total occurrence of toxicity but also the time until occurrence 
is important. If severe toxicity occurs at a later stage, this allows e.g. for a longer period of 
treatment before dosage would be reduced due to toxicity. The time until occurrence of the 
first severe toxicity was analyzed by Kaplan-Meier analysis [118, 119]. The log-rank test was 
used to compare the risk categories regarding statistically significant differences of time to 
toxicity [120]. In order to allow for a larger patient cohort in each group, the CARG and CRASH 
score risk categories were also pooled into “low vs high” (CARG: low/mid vs high; CRASH 
low/mid-low vs mid-high/high). A univariate proportional hazard model (Cox regression) was 
assumed to investigate the influence of the score categories on the time to toxicity [121, 122]. 
In addition, a sensitivity analysis for cycles instead of weeks was carried out. 
 
  =         {            +             − 1} Equation 3-4 
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3.1.7.4 Predictive factors of toxicity 
For determining which factors are associated with overall, hematologic, and nonhematologic 
toxicity, a univariate logistic regression was conducted. All single factors of the CARG and 
CRASH score were tested, as well as eight further patient-specific factors.  
 
3.1.7.5 Comparison of toxicity and symptom burden  
To analyze the agreement between severe patient-reported symptom burden and severe 
toxicity reported by health care providers, kappa statistics was applied (see 3.1.7.1).  
 
3.1.7.6 Missing Data and study drop-out 
Incomplete follow-up data bear the risk of misclassification, leading to either over- or 
underprediction of the predictive performance. Therefore, only those patients whose medical 
records could be completely collected for follow-up were considered for the outcome analysis 
regarding severe toxicity and alterations of planned treatment. If no measurements for certain 
laboratory parameters had been performed during a cycle, this parameter was classified as 
missing.  
 
3.2 Medication risk analysis 
Older patients commonly exhibit higher risks in their medication. A review of medication is 
considered as an important aspect of a geriatric assessment. Therefore, this analysis sought 
to complement the evaluation of the onco-geriatric scores by investigating the risks of 
polymedication, potentially inadequate medication, and potentially relevant drug-drug 
interactions in older cancer patients. 
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3.2.1 Study design  
This analysis comprises the medication data captured during the pilot study as well as the 
evaluation study, i.e. patients of both studies were pooled. Inclusion criteria were similar but 
differed regarding systemic cancer therapy which was not mandatory in the pilot study. To 
match eligibility criteria, only patients who were actually treated with a systemic cancer 
treatment were included from the pilot study. The medication was captured from medical 
records and analyzed at two time points. First, the medication was investigated at the time of 
admission to hospital for determining the risks in long-term medication which patients 
experienced even before start of treatment. Additionally, after start of cancer treatment, the 
medication risks due to cancer therapy were analyzed regarding antineoplastic agents and 
supportive care medication. An overview of this analysis is illustrated in Figure 3-2.  
 
Figure 3-2 Overview of the medication risk analysis 
 
3.2.2 Medication  
In general, the medication was counted per active ingredient and not per medicinal product 
itself. Therefore, if combination medicines comprised for example two active ingredients, they 
were counted twice. In the following, the term “drug” is always used in terms of “active 
ingredient”. All active ingredients with systemic effects and an Anatomical Therapeutic 
Chemical Classification (ATC code) [123] were collected. They were classified according to the 
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ATC code, level 2 (therapeutic subgroups) [123]. The official ATC index 2017 of the DIMDI 
(German Institute for Medical Documentation and Information, Deutsches Institut für 
Medizinische Dokumentation und Information) was used for the ATC classification [123]. If an 
active ingredient did not have its own ATC code (for example Naloxone with Tilidine), it was 
not counted separately. Electrolyte solutions (e.g. sodium chloride infusions) or medical gases 
(e.g. oxygen) were not included. All over-the-counter (OTC) drugs including minerals or 
vitamins, were considered if they were reimbursable according to the German drug directive 
(Arzneimittelrichtlinie) [124]. Topical substances (e.g. corticoid ointments), dietary 
supplements, and medical devices (e.g. sodium chloride nasal sprays) were neglected.  
The complete long-term medication which patients took before admission to hospital was 
included. The medication was recorded from anamnesis in medical records and was only 
considered if it was continued at least on the first day of admission to hospital. All paused 
drugs and all drugs just used in case of acute symptoms were excluded because the focus of 
this analysis was on long-term medication. Risks in long-term medication are usually of higher 
relevance for patients, compared to drugs just taken once in a while. All anti-infectives (ATC-
Code J05) were excluded unless being documented as used for long-term prevention. 
Different dosages of the same active ingredient were only counted once. 
For assessing the antineoplastic agents and supportive care medication, all respective 
antineoplastic and supportive medication reported on the therapy plan of the first cycle 
(including rescue medication) was collected and verified in the medical records.  
 
3.2.2.1 Polymedication 
In this analysis, polymedication was defined as the concomitant use of ≥ 5 drugs. This cut-off 
value is commonly used and has shown to be associated with adverse outcome in the elderly 
[22]. Excessive polymedication (“hyperpolymedication”) was defined as the use of ≥ 10 drugs 
as discussed by Sharma et al. [22].  
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3.2.2.2 Potentially inadequate medication  
Different criteria can be used to identify potentially inadequate medication (PIM) in older 
adults. However, none of those criteria has been studied in detail for geriatric cancer patients 
[125]. A review by Whitman et al. recommends the concomitant use of different screening 
tools for detecting PIM in older cancer patients [125]: the START/STOPP criteria [35], Beers 
criteria [31], and MAI criteria [36]. However, implicit tools like the MAI are not reasonable to 
use in this retrospective setting where comprehensive information about indications or 
anamnesis was missing [36]. The START/STOPP criteria would require more information as 
well. The explicit Beers criteria, however, are in particular tailored to the US [31]. Therefore, 
the EU(7)-PIM list was used in this analysis [33], an explicit PIM list, being objective and 
appropriate to use in this setting. Moreover, the EU(7)-PIM list also includes recent medication 
(since being developed in 2015), is widely applicable across Europe and was based on the 
German PRISCUS list, making it well suited for the application in a German hospital setting. 
The EU(7)-PIM list states 282 drugs or drug classes from 34 therapeutic groups as PIM [33]. 
Some drugs are only regarded as PIM under certain conditions, above a certain dose, or 
duration of treatment. This was also considered for the analysis. However, information was 
frequently missing for duration. Proton-pump inhibitors (PPI) are regarded as PIM according 
to the EU(7)-PIM list, if they are taken longer than eight weeks [33]. In this study, all PPI were 
classified as PIM except if any evidence was found that the PPI was applied for less than eight 
weeks. For supportive medication during cancer therapy, PIM drugs were only considered if 
they were applied more than once per cycle for enhancing the clinical relevance of findings.  
 
3.2.2.3 Relevant potential drug-drug interactions  
Drug-drug interactions were classified according to the ABDA (Federal Union of German 
Associations of Pharmacists, Bundesvereinigung Deutscher Apothekerverbände) interaction 
database [126]. The ABDA interaction database is provided by the Avoxa – Mediengruppe 
Deutscher Apotheker GmbH [126] and is a commonly used interaction database in German 
community pharmacies. Since further clinical information was missing, all observed drug-drug 
interactions were assumed to be potential. For enhancing the clinical impact, this analysis 
focused on the severe potential drug-drug interactions, the so called “relevant potential drug-
drug interactions” (rPDDI). All interactions were defined as relevant which usually require an 
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intervention or action by health care providers. These included the following five ABDA 
classifications: “Serious consequences possible – contraindicated”; “serious consequences 
possible – in certain cases contraindicated”; “serious consequences possible – as precaution 
contraindicated”; “simultaneous usage not recommended”, or “monitoring/modification 
needed”. The following three ABDA classifications were excluded: “In some cases 
monitoring/modification needed”; “monitoring as a precaution”; and “in general no action 
needed”. The last access to the ABDA interaction database was carried out on 9th and 11th of 
April 2018 in order to review if any interaction classification had changed.  
Regarding cancer therapy, only the rPDDI between the antineoplastic agents or supportive 
care medication and the long-term medication were included. Interactions between the 
antineoplastic agents and supportive care medication were excluded because respective 
cancer therapy regimens are regularly and successfully used in clinical routine. “Desired” 
rPDDI like methotrexate and folic acid were not counted either. Drugs were only considered 
for rPDDI if they were applied more than once per cycle for enhancing clinical relevance. If 
rPDDI occurred with different active ingredients (for example different insulins), the 
interactions were counted for each substance.  
For determining the risk of a drug class being involved as an interaction partner in rPDDI, a 
prevalence-corrected ratio was calculated. This ratio will be referred to as “interaction 
propensity”. The interaction propensity was calculated following Equation 3-5: 
 
IP = Interaction propensity 
Fi = Frequency of a drug class being involved as interaction partner in rPDDI 
Pd = Prevalence of a drug  
  
3.2.3 Statistical analysis 
Descriptive analyses were carried out for polymedication, PIM, and rPDDI regarding long-term 
medication and antineoplastic agents/supportive care medication. The median and 
   =  
  
  
 Equation 3-5 
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interquartile range of the number of drugs, PIM, and rPDDI per patient were computed as well 
as the prevalence of the substances in the patient cohort. For determining whether 
medication risks in long-term medication were associated with overall, hematologic, and 
nonhematologic toxicity, a univariate logistic regression was carried out. All types of 
medication risks in long-term medication (polymedication, PIM, rPDDI) were tested being 
treated as continuous as well as categorial variables.  
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4 Results 
4.1 Evaluation of onco-geriatric scores 
4.1.1 Patient recruitment and follow-up 
Patient recruitment was conducted between November 2015 and August 2017 at Johanniter 
Hospital Bonn; follow-up and data collection were carried out until March 2018. The flow chart 
of patient recruitment and follow-up is presented in Figure 4-1. In total, 174 patients were 
assessed for eligibility and 120 (69%) patients were enrolled. Patients mostly refused to 
participate because they felt the study was too much psychological stress (23/54, 43%) or they 
experienced physical constraints (13/54, 24%). Six (11%) patients were excluded because of 
cognitive dysfunction and 6 (11%) patients because they did not receive systemic cancer 
therapy. One hundred thirteen patients were available for outcome analysis: 3/7 patients 
could not be evaluated because data from oncology practices were not accessible and 4/7 
patients because the site of further therapy was unknown. For all excluded patients, the loss 
to follow-up occurred early in therapy course: Most patients (5/7) were lost during or after 
the first cycle; 2/7 patients after the second cycle. 
 
Figure 4-1 Flow chart of patient recruitment  
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The time between the geriatric assessment and the first therapy cycle was in median 1 day 
(range 0-53 days). The majority of patients continued with inpatient therapy after the first 
cycle (63/113, 55.8%), 35/113 (31.0%) with outpatient therapy and 15/113 (13.3%) with in- 
and outpatient therapy. Most patients were treated at the Johanniter Hospital Bonn during 
the entire therapy course (87/113, 77.0%). As defined in the study protocol, the follow-up 
ended after a maximum of six cycles. Forty-seven patients (41.6%) were followed until six 
therapy cycles. In 66/113 (58.4%) patients, follow-up ended earlier: Twenty-one of sixty-six 
(31.8%) patients discontinued treatment early (e.g. because of toxicity), 17/66 (25.8%) 
patients completely changed therapy regimen (e.g. due to progress or toxicity), and 14/66 
(21.2%) patients reached the scheduled end of therapy after less than six cycles. In median, 4 
cycles were observed during a median of 11 weeks (range 1-45). Eleven patients out of the 
113 patients (9.7%) died during follow-up, mostly due to infections or multi-organ failure. 
 
4.1.2 Patient characteristics 
The patient characteristics of the study cohort are presented in Table 4-1. Patients had a mean 
age of 77.2 years at inclusion into the study (SD 4.5, range 70-88) and the cohort was equally 
distributed between male and female (female 60/120, 50.0%). The study cohort did not 
represent a typical frail population: Most patients experienced no or little comorbidity 
according to the CCI (mean 1.1, SD 1.17, range 0-6) and were fully active or at least capable of 
all self-care according to the ECOG performance status (ECOG 0-2: 105/120, 87.5%). The most 
frequent CCI conditions comprised diabetes (22/120, 18.3%) and secondary solid tumors 
(16/120, 13.3%). Renal function was on average mildly decreased (mean 65.6, SD 21.4). 
Patients took a high number of drugs even before start of cancer therapy (mean 5.1, SD 3.7, 
range 0-18).  
Cancer-related patient characteristics are illustrated in Table 4-2. More than half of patients 
experienced solid tumors (68/120, 56.7%); the most frequent tumor entities were lung cancer 
(29/120, 24.2%) and lymphoma (33/120, 27.5%). The majority of patients was treated with 
chemotherapy (72/120, 60.0%) or a combination of chemotherapy and targeted or 
immunotherapy (41/120, 34.2%). The most frequent therapy regimens were weekly 
carboplatin/paclitaxel (16/120, 13.3%) and (R)-CHOP (15/120, 12.5%). Thirty-seven of 
hundred twenty (30.8%) patients received concomitant radiotherapy. 
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Table 4-1 Patient characteristics of the evaluation study at inclusion (n = 120); ECOG, 
Eastern Cooperative Oncology Group; BMI, body mass index; *for normalized 
body surface area (BSA) per 1.73 m2 
 n % 
Age [years]   
70-74 37 30.8 
75-79 47 39.2 
80-84 26 21.7 
≥ 85 10 8.3 
Sex   
Female 60 50.0 
Male 60 50.0 
BMI, WHO    
Underweight (< 18.5 kg/m2) 4 3.3 
Normalweight (18.5-24.9 kg/m2) 58 48.3 
Overweight (25-29.9 kg/m2) 44 36.7 
Obese (≥ 30 kg/m2) 14 11.7 
ECOG performance status   
Fully active (0) 40 33.3 
Capable of all self-care (1-2) 65 54.2 
Limited or no self-care (3-4) 15 12.5 
Charlson Comorbidity Index 
No comorbidity (0) 51 42.5 
Little Comorbidity (1-2) 57 47.5 
Moderate comorbidity (3-4) 11 9.2 
High comorbidity (≥ 5) 1 0.8 
Stages of renal insufficiency*  
Normal/high (≥ 90) 10 8.3 
Mildly decreased (60-89) 58 48.3 
Mildly/moderately decreased (40-59) 26 21.7 
Moderately/severely decreased (30-44) 22 18.3 
Severely decreased (15-29) 2 1.7 
Kidney failure (< 15) 2 1.7 
 
44  Results 
 
Table 4-1 (continued) 
 n % 
Polymedication (long-term medication before start of therapy) 
No polymedication (< 5) 58 48.3 
Polymedication (≥ 5-9) 48 40.0 
Hyperpolymedication (≥ 10) 14 11.7 
 
Table 4-2 Cancer-related patient characteristics (n = 120); CUP, cancer of unknown 
primary; *categorized by body location according to the National Cancer 
Institute (NCI) 
 n % 
Tumor type   
Solid tumors 68 56.7 
Hematological tumors 52 43.3 
Tumor entity*   
Respiratory 29 24.2 
Lung 29 24.2 
Hematological 52 43.3 
Lymphoma 33 27.5 
Leukemia 11 9.2 
Multiple myeloma/plasma cell neoplasm 7 5.8 
Myeloproliferative neoplasm 1 0.8 
Gynecological 3 2.5 
Endometrium 2 1.7 
Ovarial 1 0.8 
Genitourinary 3 2.5 
Urothel 2 1.7 
Renal cell 1 0.8 
Unknown primary 4 3.3 
CUP 4 3.3 
Musculoskeletal 1 0.8 
Sarcoma 1 0.8 
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Table 4-2 (continued) 
 n % 
Digestive/gastrointestinal 15 12.5 
Colorectal 5 4.2 
Esophageal 4 3.3 
Pancreatic 3 2.5 
Gastric  1 0.8 
Bile 1 0.8 
Breast 11 9.2 
Breast 11 9.2 
Neuroendocrine 1 0.8 
Neuroendocrine  1 0.8 
Germ cell 1 0.8 
Testicular  1 0.8 
Metastasis   
No 24 20.0 
Yes 42 35.0 
Not applicable/missing 54 45.0 
Relapse   
No 104 86.7 
Yes 16 13.3 
Cancer stage   
I 7 5.8 
II 10 8.3 
III 29 24.2 
IV 58 48.3 
Missing  16 13.3 
Treatment type   
Chemotherapy 72 60.0 
Targeted or immunotherapy 7 5.8 
Combined chemotherapy and targeted or 
immunotherapy 
41 34.2 
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Table 4-2 (continued) 
 n % 
Therapy regimen   
Carboplatin/paclitaxel weekly 16 13.3 
(Rituximab)-CHOP(cyclophosphamide, 
doxorubicin, vincristine, prednisone) 
15 12.5 
Carboplatin/paclitaxel 3-weekly 10 8.3 
Bendamustine/rituximab 9 7.5 
Mini-(rituximab)-CHOP 6 5.0 
Decitabine 5 4.2 
Cisplatin/etoposide 4 3.3 
Others 55 45.9 
Treatment intention   
Palliative 62 51.7 
Curative 48 40.0 
Others 8 6.7 
Missing 2 1.7 
Additional therapy   
None 69 57.5 
Radiotherapy 31 25.8 
Surgery 14 11.7 
Radiotherapy and surgery 6 5.0 
 
 
4.1.3 Risk assessment 
4.1.3.1 The CARG score 
For the CARG score, a median of 9 (IQR 4, range 4-20) was obtained. Most patients were 
classified as mid category (61/120, 50.8%) and as high category (52/120, 43.3%). Only 7/120 
(5.8%) patients were categorized as low. The CARG score results are presented in Figure 4-2. 
Results of the CARG score items are illustrated in Table 4-3. 
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Figure 4-2 Distribution of the CARG score toxicity predictions; solid line shows median of 
score results (n = 120); green: low risk; yellow: mid risk; red: high risk  
 
Table 4-3 Items of the CARG score (n = 120); GI, gastrointestinal; GU, genitourinary 
 n % 
Socio-demographics   
Age [years]   
≥ 72  111 92.5 
< 72 9 7.5 
Tumor/treatment variables   
Cancer type   
GI/GU tumor 19 15.8 
Other  101 84.2 
Dose   
Reduced 17 14.2 
Standard 103 85.8 
Number of treatment agents 
Monotherapy 18 15.0 
Polytherapy 102 85.0 
Laboratory variables   
Hemoglobin [g/dL]   
≥ 10 (female), ≥ 11 (male) 79 65.8 
< 10 (female), < 11 (male) 41 34.2 
CARG score
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Table 4-3 (continued) 
 n % 
Creatinine clearance Jeliffe [mL/min] [85]   
< 34  12 10.0 
≥ 34  108 90.0 
Geriatric assessment variables    
Hearing abilities   
Good/excellent 77 64.2 
Fair/worse 43 35.8 
Falls in past six months   
0 96 80.0 
≥ 1 24 20.0 
Medication intake   
No assistance 117 97.5 
Requires assistance 3 2.5 
Limited in walking one block 
Not limited at all 65 54.2 
Limited 55 45.8 
Decreased social activity because of health/emotional problems 
A little or none of the time 83 69.2 
Some, most, or all of the time 37 30.8 
 
4.1.3.2 The CRASH score 
The combined CRASH score exhibited a median of 8 (IQR 2, range 2-11). Patients were mostly 
stratified as mid-high (72/120, 60.0%). Twenty-two of hundred twenty (18.3%) patients were 
classified as mid-low and 23/120 (19.2%) as high. Only 3/120 (2.5%) patients were categorized 
as low. The hematologic CRASH score showed a median of 4 (IQR 2, range 0-6). The majority 
was classified as mid-high (71/120, 59.2%) and mid-low 40/120 (33.3%). Only 5/120 (4.2%) 
patients were stratified as low and 4/120 (3.3%) as high. The nonhematologic CRASH score 
exhibited a median of 6 (IQR 2, range 0-8). Patients were mostly categorized as mid-high 
(68/120, 56.7%), 24/120 (20.0%) patients as mid-low and 22/120 (18.3%) as high. Only few 
patients were classified as low (6/120, 5.0%). 
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The CRASH score results are illustrated in Figure 4-3; the CRASH score items are displayed in 
Table 4-4. 
 
Figure 4-3 Distribution of the combined (A), hematologic (B), and nonhematologic (C) 
CRASH score (n = 120); dark green: low risk; light green: mid-low risk; orange: 
mid-high risk; red: high risk 
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Table 4-4 Items of the combined, hematologic, and nonhematologic CRASH score 
(n = 120); IADL, instrumental activities of daily living; LDH, lactate 
dehydogenase; ECOG, Eastern Cooperative Oncology Group; MMSE, Mini-
Mental State Examination; MNA, Mini Nutritional Assessment; MAX2, 
chemotherapy toxicity index 
 n % 
Hematologic score   
Diastolic blood pressure [mmHg]   
≥ 72  51 42.5 
< 72 69 57.5 
IADL   
26-29 97 80.8 
10-25 23 19.2 
LDH [U/L]   
> 167 113 94.2 
≤ 167 7 5.8 
Nonhematologic score   
ECOG performance status   
0 40 33.3 
1-2 65 54.2 
3-4 15 12.5 
MMSE   
30 22 18.3 
< 30 98 81.7 
MNA   
28-30 15 12.5 
< 28 105 87.5 
All subscores   
MAX2    
0 (0-0.44) 27 22.5 
1 (0.45-0.57) 48 40.0 
2 (< 0.57) 45 37.5 
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4.1.3.3 Physicians’ judgment 
Hundred eighteen judgments from physicians were available; two physicians’ judgments were 
missing because the physicians could not be contacted in time before cancer therapy started. 
Mostly, physicians estimated a mid toxicity risk for overall (65/118, 55.1%), hematologic 
(65/118, 55.1%), and nonhematologic (61/118, 51.7%) toxicity. A low toxicity risk was 
expected more often by physicians than a high risk. The distributions of judgments for 
different toxicity types were similar. Physicians’ judgments are illustrated in Figure 4-4. 
  
Figure 4-4 Distribution of physicians‘ judgments regarding overall (A), hematologic (B), and 
nonhematologic (C) toxicity risk (n = 118); green: low risk; yellow: mid risk; red: 
high risk 
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4.1.4 Outcome 
4.1.4.1 Toxicity  
Hundred thirteen patients were available for outcome analysis. Baseline values indicated that 
39.8% (45/113) of patients experienced hypertension of grade ≥ 3 toxicity even before start 
of cancer therapy. For all other types of toxicity, the baseline was generally below grade ≥ 3 
toxicity. Hypertension was planned to be assessed since this is a frequent side effect of 
targeted therapy agents like anti-angiogenic drugs. However, CTCAE criteria definitions are 
apparently not appropriate for elderly patients who frequently experience hypertension as 
comorbidity: Due to the strict CTCAE definitions, the baseline prevalence of hypertension 
grade ≥ 3 was very high. Thus, by including hypertension, the results would have been diluted 
by “severe” adverse events which are common in the special population of older patients. In 
order to receive results with a higher clinical relevance, hypertension was neglected for 
toxicity analysis.  
Only a low percentage of laboratory data was missing for follow-up; a median of 2.8% (range 
0-19.4%) was not available per patient.  
The majority of patients showed signs of overall, hematologic, and nonhematologic grade ≥ 3 
toxicity during therapy course. Hematologic toxicity occurred more often than 
nonhematologic toxicity. The respective findings are displayed in Figure 4-5.  
  
Figure 4-5 Percentage of patients experiencing grade ≥ 3 toxicity during therapy course 
(n = 113) 
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The most frequent hematologic grade ≥ 3 toxicity was leukopenia (54/113, 47.8%); the most 
frequent nonhematologic grade ≥ 3 toxicity comprised infections (37/113, 32.7%). Details 
regarding the different types of toxicity with corresponding CTCAE grades 3-5 are presented 
in Table 4-5. Details on the toxicity distribution per patient characteristics and score items are 
illustrated in Appendix D, Table D-1 to Table D-3.  
Table 4-5 Toxicity incidence during therapy course per CTCAE grades 3-5 (n = 113); AST, 
aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-
glutamyl transferase  
 Grade ≥ 3 Grade 3 Grade 4 Grade 5 
 n % n % n % n % 
Overall toxicity  92 81.4 88 77.9 50 44.2 4 3.5 
Hematologic  
toxicity 
76 67.3 70 61.9 41 36.3 0 0.0 
Anemia 46 40.7 46 40.7 0 0.0 0 0.0 
Febrile Neutropenia 15 13.3 15 13.3 0 0.0 0 0.0 
Neutropenia 52 46.0 24 21.2 35 31.0 0 0.0 
Leukopenia 54 47.8 33 29.2 32 28.3 0 0.0 
Thrombopenia 20 17.7 10 8.8 13 11.5 0 0.0 
Nonhematologic  
toxicity 
67 59.3 66 58.4 14 12.4 4 3.5 
Acute coronary 
syndrome 
4 3.5 2 1.8 0 0.0 2 1.8 
Atrial flutter 1 0.9 1 0.9 0 0.0 0 0.0 
Heart failure 3 2.7 2 1.8 1 0.9 0 0.0 
Thromboembolic 
event 
3 2.7 3 2.7 0 0.0 0 0.0 
AST 10 8.8 9 8.0 1 0.9 0 0.0 
ALT 8 7.1 7 6.2 1 0.9 0 0.0 
GGT 18 15.9 14 12.4 5 4.4 0 0.0 
Bilirubin 1 0.9 1 0.9 0 0.0 0 0.0 
Creatinine 5 4.4 4 3.5 2 1.8 0 0.0 
Proteinuria 0 0.0 0 0.0 0 0.0 0 0.0 
Dyspnea 12 10.6 11 9.7 2 1.8 0 0.0 
Erythroderma 0 0.0 0 0.0 0 0.0 0 0.0 
54  Results 
 
Table 4-5 (continued) 
 Grade ≥ 3 Grade 3 Grade 4 Grade 5 
 n % n % n % n % 
Urticaria 0 0.0 0 0.0 0 0.0 0 0.0 
Palmar-plantar 
erythrodysesthesia 
syndrome 
0 0.0 0 0.0 0 0.0 0 0.0 
Gastrointestinal 
bleeding 
2 1.8 1 0.9 1 0.9 0 0.0 
Infections 37 32.7 32 28.3 3 2.7 2 1.8 
Dehydration 6 5.3 6 5.3 0 0.0 0 0.0 
Hyponatremia 11 9.7 11 9.7 0 0.0 0 0.0 
Hypokalemia 11 9.7 10 8.8 1 0.9 0 0.0 
Dysphagia 2 1.8 2 1.8 0 0.0 0 0.0 
Dry mouth 0 0.0 0 0.0 0 0.0 0 0.0 
Mucositis 2 1.8 2 1.8 0 0.0 0 0.0 
Pain 15 13.3 15 13.3 0 0.0 0 0.0 
Anorexia 10 8.8 10 8.8 0 0.0 0 0.0 
Constipation 0 0.0 0 0.0 0 0.0 0 0.0 
Diarrhea 5 4.4 4 3.5 1 0.9 0 0.0 
Nausea 6 5.3 6 5.3 0 0.0 0 0.0 
Vomiting 5 4.4 4 3.5 1 0.9 0 0.0 
Insomnia 2 1.8 2 1.8 0 0.0 0 0.0 
Fatigue 14 12.4 14 12.4 0 0.0 0 0.0 
Peripheral sensory 
neuropathy 
1 0.9 1 0.9 0 0.0 0 0.0 
 
The median time to first grade ≥ 3 toxicity was 2 weeks. Most patients (78/113, 69.0%) 
exhibited overall grade ≥ 3 toxicity already shortly after start of cancer therapy (during the 
first cycle or at least the first three weeks of therapy). Details regarding the toxicity incidence 
at start of therapy are presented in Appendix D, Table D-4. 
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4.1.4.2 Patient-reported symptom burden 
From the 113 patients available for toxicity follow-up, 100 patients could be contacted at least 
once for collecting the symptom burden via PRO-CTCAE. Thirteen patients could not be 
reached at all, usually due to death or deteriorated general health condition directly after the 
first cycle. Fifty patients were followed during the complete therapy course; in 38 patients, all 
cycles except one or two were observed; for the remaining patients, more than three cycles 
were missing. Reasons for the incomplete follow-up were commonly a bad general health 
condition, difficulties in contacting the patient, or patient’s refusal.  
At least one severe symptom (PRO-CTCAE symptom ≥ 75%) was reported by 79% of patients 
during therapy course. Most frequently, patients reported a severe symptom burden for 
fatigue, anorexia, and dry mouth. The incidence per symptom scale is presented in Table 4-6. 
Table 4-6 Number of patients with severe symptom burden (PRO-CTCAE ≥ 75%) per 
symptom scale 
Symptom scale (attributes) 
Number of patients with 
severe symptom burden 
Dysphagia (severity) 12 
Dry mouth (severity) 34 
Mucositis (severity, interference with daily activities) 6 
Pain (frequency, severity, interference with daily activities) 20 
Anorexia (severity, interference with daily activities) 34 
Constipation (severity) 19 
Diarrhea (frequency) 18 
Nausea (severity, frequency) 17 
Vomiting (severity, frequency) 10 
Insomnia (severity, interference with daily activities) 14 
Fatigue (severity, interference with daily activities) 45 
Dyspnea (severity) 8 
Peripheral sensory neuropathy (severity, interference with 
daily activities) 
9 
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4.1.4.3 Agreement of toxicity and symptom burden  
For all symptoms except dyspnea, severe symptom burden (≥ 75% PRO-CTCAE) was reported 
more often by patients than severe toxicity (CTCAE grade ≥ 3) was reported by health care 
providers. A comparison of the proportion of patients with severe symptom burden and the 
proportion of patients with severe toxicity is depicted in Figure 4-6. Differences were 
especially obvious for the symptoms constipation and dry mouth where numerous patients 
reported severe symptoms whereas health care providers did not report any toxicity at all in 
the medical records. Severe dysphagia was reported approximately six times more often by 
patients than by health care providers, severe insomnia seven times and severe peripheral 
sensory neuropathy about nine times more frequently. Kappa values demonstrated only low 
agreement between PRO-CTCAE and CTCAE (see Table 4-7). According to Landis and Koch, 
Kappa values below 0.4 indicate fair, below 0.2 slight, and below 0.0 poor agreement [108]. 
Insomnia, mucositis, and peripheral sensory neuropathy exhibited poor agreement, the other 
symptoms slight or fair agreement.  
Table 4-7 Kappa values for the agreement between the ≥ 75% PRO-CTCAE symptoms and 
the grade ≥ 3 CTCAE toxicity;* if no result is given: no kappa value computable 
due to a zero value for CTCAE 
Symptom  Kappa* P value 
Dysphagia 0.260 0.013 
Dry mouth -  
Mucositis - 0.031 1.000 
Pain 0.265 0.013 
Anorexia 0.070 0.439 
Constipation -  
Diarrhoe 0.147 0.083 
Nausea 0.212 0.033 
Emesis 0.214 0.077 
Insomnia - 0.019 1.000 
Fatigue 0.113 0.130 
Dyspnoe 0.321 0.016 
Peripheral sensory neuropathy - 0.018 1.000 
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Figure 4-6 Comparison of severe patient-reported symptom burden according to ≥ 75% 
PRO-CTCAE (n = 100) and severe toxicity reported by health care providers 
according to ≥ 3 CTCAE (n = 113); PNP, peripheral sensory neuropathy  
 
4.1.4.4 Alterations of planned treatment 
Hundred thirteen patients were available for analyzing alterations of the planned treatment. 
Therapy was discontinued in 31/113 (27.4%) patients after a median of 1 cycle and complete 
changes of therapy regimen in 11/113 (9.7%) patients after a median of 2 cycles. Therapy 
delays occurred in 38/113 (33.6%) patients after a median of 1 cycle and therapy reductions 
in 20/113 (17.7%) patients after a median of 2 cycles. About two-thirds of patients 
experienced alterations of the planned treatment during therapy course. Major alterations 
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(changes or discontinuations) occurred in more than one third of patients, minor alterations 
(delays or dose reductions) in almost half of patients; see Figure 4-7.  
 
Figure 4-7 Percentage of patients who experienced alterations of their planned treatment 
during therapy course (n = 113) 
 
Frequent reasons for the alteration of a planned treatment comprised infections, 
neutropenia/leukopenia, or a deterioration of the general health condition. In 44.2% (50/113) 
of patients, alterations of the planned treatment already occurred during the first cycle of 
therapy or during the first three therapy weeks. 
 
4.1.5 Relationship between risk assessments 
4.1.5.1 CARG score vs CRASH score 
Between the CARG and the combined CRASH score, only a low correlation was found (rs = 
0.203, p = 0.026). Moreover, the chance-corrected agreement between the scores was low, 
exhibiting a weighted Kappa of 0.057 (CI, -0.074-0.188; p = 0.394). To satisfy the weighted 
Kappa assumption of equal category numbers, the CRASH score was pooled into three 
categories by combining the mid-low and mid-high category. Pooling of different categories 
indicated similar results: The pooled low and mid-low categories exhibited a weighted Kappa 
of 0.085 (CI, -0.037-0.207; p = 0.141). The proportions of the combined CRASH score 
categories per CARG score categories did not indicate an association of both scores either 
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0
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(p = 0.394, Fisher’s exact test). These poor results in agreement and correlation indicate that 
the CARG and the CRASH score predict different risks for patients. The proportions of the 
combined CRASH score categories per CARG score categories, as well as the correlation of the 
CARG score with the combined CRASH score are illustrated in Figure 4-8. Correlation and 
agreement of the hematologic and nonhematologic CRASH score with the CARG score resulted 
in poor results as well; see Appendix D, Table D-5.  
 
Figure 4-8 Agreement (A) and correlation (B) of the risk categories of the CARG score and 
the combined CRASH score (n = 120); rs, Spearman’s rho 
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4.1.5.2 Physicians’ judgment vs onco-geriatric scores 
The correlation was poor between physicians’ judgment for overall toxicity and the CARG 
score (rs, 0.011; p = 0.908) as well as between physicians’ judgment for overall toxicity and the 
combined CRASH score (rs, 0.012; p = 0.897). The chance-corrected agreement yielded poor 
results as well, both with the CARG score (κw, -0.010; CI, -0.115-0.094; p = 0.833) and with the 
combined CRASH score (κw, 0.026; CI, -0.074-0.126; p = 0.589). Fisher’s exact test did not 
suggest a relationship, neither for physicians’ judgment with the CARG score (p = 0.133) nor 
for physicians’ judgment with the combined CRASH score (p = 0.734). These poor results in 
agreement and correlation indicate that physicians and the onco-geriatric scores predict 
different, complementary risks.  
The hematologic and nonhematologic physicians’ judgments demonstrated similar poor 
agreement and correlation for the hematologic and nonhematologic CRASH score, 
respectively. Details are displayed in Appendix D, Table D-6. 
 
4.1.6 Prediction of severe toxicity by onco-geriatric scores 
4.1.6.1 Toxicity during therapy course 
Overall toxicity  
The CARG and the combined CRASH score exhibited a similar predictive performance for 
overall grade ≥ 3 toxicity. The risk increased in both scores with higher risk category (CARG: 
p = 0.051; combined CRASH: p = 0.382; Fisher’s exact test). The proportion of patients with 
grade ≥ 3 toxicity per category is presented in Figure 4-9.  
In univariate logistic regression, both scores were found to be significant predictors of toxicity. 
With each CARG score point, the odds of experiencing overall grade ≥ 3 toxicity increased by 
about 1.3 (odds ratio (OR), 1.266; CI, 1.048-1.530; p = 0.015); with each CRASH score point, 
the odds increased by approximately the same factor (OR, 1.337; CI, 1.031-1.734; p = 0.029).  
The CARG and the combined CRASH score indicated a similar ROC-AUC of 0.681 (CI, 0.551-
0.811; p = 0.010) and 0.650 (CI, 0.519-0.782; p = 0.032), respectively. The ROC curves of both 
scores are displayed in Figure 4-10.  
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Figure 4-9 Proportion of patients with grade ≥ 3 toxicity in low vs high categories of the 
CARG score (A) and the combined CRASH score (B); n = 113 
 
  
Figure 4-10 ROC curves of the CARG score and the combined CRASH score for overall grade 
≥ 3 toxicity predictions (n = 113); solid line: CARG score; dashed line: combined 
CRASH score; thin line: line of identity 
 
The Youden Index determined the optimal cut-off, where a maximum of sensitivity at a 
maximum of specificity is reached, at ≥ 9 for the CARG score and at ≥ 8 for the combined 
CRASH score. For the CARG score, at the optimal cut-off, 63.0% of patients with toxicity would 
be correctly classified as high risk (sensitivity 0.630) and 71.4% of patients without toxicity 
would be accurately identified as low risk (specificity 0.714). For the combined CRASH score, 
68.5% of patients with toxicity would be correctly categorized as high risk (sensitivity 0.685) 
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and 61.9% of patients without toxicity would be accurately identified as low risk (specificity 
0.619).  
The proportion of patients with severe toxicity at a certain score value in our study differed 
from the proportion of patients with severe toxicity at a certain score value in the original 
development studies of the CARG or CRASH score; see Table 4-8 and Table 4-9. The toxicity 
risk in our study cohort tends to be higher at a certain score value than being expected based 
on the percentages of patients with toxicity in the original development cohorts of both 
scores. 
Table 4-8 Proportion of patients with overall severe toxicity during therapy course per 
CARG score value in our study compared with the proportion of patients with 
toxicity per score value in the original CARG development study; * derived from 
the development study by the CARG online calculator (http://www.mycarg.org) 
 
  
CARG score 
value 
Number of patients 
per score value in our 
study 
Proportion of patients 
with toxicity in our 
study [%] 
Proportion of patients 
with toxicity in 
development study 
[%]* 
4 5 60.0 30 
6 18 61.1 44 
7 5 100.0 51 
8 21 71.4 59 
9 14 92.9 66 
10 12 100.0 72 
11 11 90.9 78 
12 8 62.5 82 
13 4 75.0 86 
14 6 100.0 90 
15 1 100.0 92 
16 4 100.0 94 
17 2 100.0 95 
18 1 100.0 97 
20 1 100.0 98 
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Table 4-9 Proportion of patients with overall severe toxicity during therapy course per 
combined CRASH score value in our study compared with the proportion of 
patients with toxicity in the original CRASH development study; * from the 
CRASH development study [68] 
CRASH score 
value 
Number of patients per 
score value in our 
study 
Proportion of patients 
with toxicity in our study 
[%] 
Proportion of patients 
with toxicity in 
development study [%]* 
2 1 100.0 50 
3 2 0.0 50 
4 1 100.0 58 
5 6 66.6 58 
6 14 85.7 58 
7 18 61.1 77 
8 26 88.5 77 
9 24 87.5 77 
10 14 92.9 79 
11 7 85.7 79 
  
Hematologic toxicity 
The hematologic CRASH score indicated a better predictive performance than the CARG score 
for hematologic grade ≥ 3 toxicity. Using the hematologic CRASH score, toxicity increased with 
higher risk category (p = 0.002; Fisher’s exact test). However, using the CARG score, toxicity 
increased only slightly (p = 0.687; Fisher’s exact test). The proportions of patients with 
hematologic toxicity per category are presented in Figure 4-11. In univariate logistic 
regression, only the hematologic CRASH score predicted toxicity significantly (hematologic 
CRASH: OR, 1.602; CI, 1.135-2.261; p = 0.007; CARG: OR, 1.048; CI, 0.925-1.186; p = 0.462). 
The hematologic CRASH score exhibited a better ROC-AUC than the CARG score: 0.665 (CI, 
0.554-0.776; p = 0.005) and 0.564 (CI, 0.445-0.683; p = 0.271), respectively (see Figure 4-12). 
The Youden Index determined the optimal cut-off for the CARG score at ≥ 9 and for the 
hematologic CRASH score at ≥ 4. At this optimal cut-off, for the CARG score, sensitivity was 
0.632 and specificity 0.568; for the hematologic CRASH score sensitivity was 0.724 and 
specificity 0.595. In our study cohort, the percentages of patients with hematologic toxicity 
per hematologic CRASH score value tended to be higher than the percentages being observed 
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in the original CRASH development study; see Appendix D, Table D-7. Since the CARG score 
was not developed for the prediction of hematologic toxicity, no exact percentages of 
hematologic toxicity were available from the development study for comparison.  
 
Figure 4-11 Proportion of patients with hematologic grade ≥ 3 toxicity in low vs high 
categories of the CARG score (A) and the hematologic CRASH score (B); n = 113 
 
 
Figure 4-12 ROC curves of the CARG score and the hematologic CRASH score for predictions 
of hematologic grade ≥ 3 toxicity (n = 113); solid line: CARG score; dashed line: 
hematologic CRASH score; thin line: line of identity  
  
P
at
ie
n
ts
 w
it
h
 h
em
at
o
lo
gi
c 
to
xi
ci
ty
 [
%
]
Pa
ti
en
ts
 w
it
h
 h
e
m
at
o
lo
gi
c 
to
xi
ci
ty
 [
%
]
Results   65 
 
Nonhematologic toxicity  
The CARG and the nonhematologic CRASH score demonstrated a similar predictive 
performance for nonhematologic grade ≥ 3 toxicity. In both scores, toxicity risk increased with 
higher risk category (CARG: p = 0.007; nonhematologic CRASH: p = 0.081; Fisher’s exact test; 
Figure 4-13). In univariate logistic regression, both scores were significant predictors of 
toxicity. The CARG score indicated an OR of 1.219 (CI, 1.062-1.398; p = 0.005), the 
nonhematologic CRASH score an OR of 1.363 (CI, 1.044-1.781; p = 0.023). The CARG score and 
the nonhematologic CRASH score denoted a similar ROC-AUC; 0.662 (CI, 0.561-0.763; 
p = 0.003) and 0.651 (CI, 0.550-0.752; p = 0.007), respectively (Figure 4-14). The Youden Index 
determined the optimal cut-off for the CARG score at ≥ 10 (sensitivity: 0.552; specificity: 0.717) 
and for the nonhematologic CRASH score at ≥ 6 (sensitivity: 0.672; specificity: 0.565). A 
comparison of the nonhematologic toxicity proportions per score value in our study versus 
the proportions per respective score value in the original CRASH development study are 
displayed in Appendix D, Table D-8. Since the CARG score was not developed for the prediction 
of nonhematologic toxicity, no exact percentages of nonhematologic toxicity were available 
from the development study for comparison. 
 
Figure 4-13 Proportion of patients with nonhematologic toxicity grade ≥ 3 in low vs high 
categories of the CARG score (A) and the nonhematologic CRASH score (B); 
n = 113 
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Figure 4-14 ROC curves of the CARG score and the nonhematologic CRASH score for 
nonhematologic grade ≥ 3 toxicity predictions (n = 113); solid line: CARG score; 
dashed line: nonhematologic CRASH score; thin line: line of identity 
 
4.1.6.2 Toxicity at start of therapy 
Overall toxicity 
In line with the results for the complete therapy course, both scores indicated similar 
predictive performance regarding the prediction of overall grade ≥ 3 toxicity at start of 
therapy. The risk increased in both scores significantly with higher category (CARG: p = 0.002; 
combined CRASH: p = 0.044; Fisher’s exact test); see Figure 4-15. In univariate logistic 
regression, the CARG and combined CRASH score both significantly predicted toxicity at start 
of therapy. The CARG score exhibited an OR of 1.224 (CI, 1.054-1.421; p = 0.008), the 
combined CRASH score an OR of 1.372 (CI, 1.085-1.735; p = 0.008). Both scores resulted in 
similar ROC-AUC values (CARG: 0.670, CI 0.562-0.778, p = 0.004; combined CRASH: 0.668, CI 
0.559-0.777, p = 0.004); see Figure 4-16.  
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Figure 4-15 Proportion of patients with overall grade ≥ 3 toxicity at start of therapy in low vs 
high categories of the CARG (A) and the combined CRASH score (B); n = 113
  
 
 
Figure 4-16 ROC curves of the CARG score and the combined CRASH score for overall grade 
≥ 3 toxicity predictions at start of therapy (n = 113); solid line: CARG score; 
dashed line: combined CRASH score; thin line: line of identity 
 
Hematologic toxicity 
Contrary to the results for the complete therapy course, predictive performance of the 
hematologic CRASH was not superior to the CARG score regarding grade ≥ 3 hematologic 
toxicity at start of therapy. In both scores, the proportion of patients with toxicity at start of 
therapy increased with higher category. Differences in categories were statistically significant 
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for the CARG score as well as for the hematologic CRASH score (CARG: p = 0.014; hematologic 
CRASH: p = 0.034; Fisher’s exact test); see Figure 4-17. The univariate logistic regression 
indicated that neither the CARG score nor the hematologic CRASH score significantly predicted 
hematologic toxicity at start of therapy (CARG: OR 1.116, CI 0.991-1.258, p = 0.071; 
hematologic CRASH: OR 1.300, CI 0.948-1.783, p = 0.103). The ROC-AUC of the hematologic 
CRASH score was slightly lower than the ROC-AUC of the CARG score (hematologic CRASH: 
0.592, CI 0.486-0.698, p = 0.092; CARG: 0.638, CI 0.534-0.742, p = 0.012); see Figure 4-18. 
 
Figure 4-17 Proportion of patients with hematologic grade ≥ 3 toxicity at start of therapy in 
low vs high categories of the CARG score (A) and the hematologic CRASH score 
(B); n = 113  
 
 
Figure 4-18 ROC curves of the CARG score and the hematologic CRASH score for hematologic 
grade ≥ 3 toxicity predictions at start of therapy (n = 113); solid line: CARG score, 
dashed line: hematologic CRASH score; thin line: line of identity  
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Nonhematologic toxicity 
The results for the grade ≥ 3 nonhematologic toxicity at start of therapy resembled the findings 
obtained for the complete therapy course. Incidence of nonhematologic toxicity increased in 
both scores with higher category (CARG: p = 0.023; nonhematologic CRASH: p = 0.084; Fisher’s 
exact test); see Figure 4-19. Both scores exhibited significant predictions in univariate logistic 
regression (CARG: OR 1.162, CI 1.027-1.315, p = 0.018; nonhematologic CRASH: OR 1.351, CI 
1.029-1.774, p = 0.030). Both ROC-AUC were similar as well: The CARG score indicated a ROC-
AUC of 0.629 (CI, 0.527-0.732; p = 0.018) and the nonhematologic CRASH score a ROC-AUC of 
0.633 (CI, 0.531-0.735; p = 0.015); see Figure 4-20. 
 
Figure 4-19 Proportion of patients with nonhematologic grade ≥ 3 toxicity at start of therapy 
in low vs high categories of the CARG score (A) and the nonhematologic CRASH 
score (B); n = 113 
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Figure 4-20 ROC curves of the CARG score and the nonhematologic CRASH score for 
nonhematologic grade ≥ 3 toxicity predictions at start of therapy (n = 113); solid 
line: CARG score, dashed line: nonhematologic CRASH score; thin line: line of 
identity  
 
4.1.6.3 Time-related prediction  
Overall toxicity 
A difference in time until onset of overall grade ≥ 3 toxicity was found between low and high 
categories of the CARG score (low/mid vs high) as well as the combined CRASH score (low/mid-
low vs mid-high/high). In the high category, toxicity occurred faster than in the low category 
(see Figure 4-21 and Figure 4-22). This finding was statistically significant for the CARG score 
(p = 0.001, log-rank test), however, not for the combined CRASH score (p = 0.063, log-rank 
test). The Kaplan-Meier curves of the CRASH score crossed after approximately 20 weeks of 
therapy but this was not further considered due to the very low patient numbers in each 
category at this point. In total, half of the patients experienced severe toxicity after 2 weeks 
of therapy (CI, 1.701-2.299). For the CARG score, the median time to toxicity resulted in 
3 weeks (CI, 2.243-3.757) for the low category and 1.75 weeks (CI, 1.483-2.017) for the high 
category. The risk of experiencing severe toxicity almost doubled in the high CARG score 
category compared to the low category: Cox regression resulted in a hazard ratio (HR) of 1.908 
(CI, 1.250-2.911, p = 0.003). The combined CRASH score indicated a median time to toxicity of 
4 weeks (CI, 0.000-8.019) for the low category and 2 weeks (CI, 1.858-2.142) for the high 
category. The high category exhibited a 1.6-fold risk of toxicity (HR, 1.590; CI, 0.945-2.678; 
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p = 0.081). The Kaplan-Meier estimates are listed in Appendix D, Table D-9 to Table D-12. An 
exploratory analysis with cycles as time unit instead of weeks yielded similar results. 
Hematologic toxicity 
The CARG score as well as the hematologic CRASH score exhibited both a significant difference 
in the time until hematologic grade ≥ 3 toxicity occurred (CARG: p = 0.019, hematologic CRASH: 
p = 0.014; log-rank test). Kaplan-Meier plots are illustrated in Figure 4-23 and Figure 4-24. The 
crossing of the Kaplan-Meier curves in the hematologic CRASH score was neglected due to the 
very low patient numbers in both categories at this time-point. The median time until onset 
of hematologic toxicity was in total 3.5 weeks (CI, 2.165-4.835). For the CARG score, half of 
patients had experienced hematologic toxicity after 5 weeks (CI, 1.839-8.161) in the low 
category and after 2 weeks (CI, 1.637-2.363) in the high category. For the hematologic CRASH 
score, half of patients had shown signs of hematologic toxicity after 8 weeks (CI, 0.013-15.987) 
in the low category and after 3 weeks (CI, 1.844-4.156) in the high category. The hazard ratio 
of both scores was similar, indicating 1.691 (CI, 1.063-2.692; p = 0.027) for the CARG score and 
1.822 (CI, 1.099-3.022; p = 0.020) for the hematologic CRASH score.  
Nonhematologic toxicity 
In both scores, the nonhematologic grade ≥ 3 toxicity occurred earlier in the high category 
than in the low category. However, this was only significant for the CARG score (CARG: 
p = 0.003; nonhematologic CRASH: p = 0.096; log-rank test). The respective Kaplan-Meier plots 
are presented in Figure 4-25 and Figure 4-26. In general, half of the patients had experienced 
the first severe nonhematologic toxicity after 4 weeks (CI, 0.453-7.547). For the CARG score, 
the median time to toxicity was 14 weeks (CI, 1.123-26.877) in the low category and 2 weeks 
(CI, 1.146-2.854) in the high category. For the nonhematologic CRASH score, the median time 
until onset of toxicity was 18 weeks (CI, 0.906-35.094) in the low category and 3 weeks (CI, 
1.533-4.467) in the high category. Patients in the high CARG category exhibited an almost 
doubled risk of experiencing nonhematologic toxicity compared to the low category (HR, 
1.991; CI, 1.227-3.229; p = 0.005). The hazard ratio regarding the nonhematologic CRASH score 
categories was slightly lower (HR, 1.638; CI, 0.891-3.009; p = 0.112).   
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Figure 4-21 Kaplan-Meier analysis of the time to the first occurrence of severe overall toxicity 
dependent on the category of the CARG score (low-mid versus high); censored: 
low 25.4 %, high 10.0%; green line: low CARG score; red line: high CARG score; 
vertical line: censored data; n = 113 
 
 
Figure 4-22 Kaplan-Meier analysis of the time to the first occurrence of severe overall 
toxicity dependent on the category of the combined CRASH score (low/mid-low 
versus mid-high/high); censored: low 25.0%, high 16.9%; green line: low CRASH 
score; red line: high CRASH score; vertical line: censored data; n = 113 
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Figure 4-23 Kaplan-Meier analysis of the time to the first occurrence of severe hematologic 
toxicity dependent on the category of the CARG score (low-mid versus high); 
censored: low 34.9%, high 30.0%; green line: low CARG score; red line: high 
CARG score; vertical line: censored data; n = 113 
 
 
Figure 4-24 Kaplan-Meier analysis of the time to the first occurrence of severe hematologic 
toxicity dependent on the category of the hematologic CRASH score (low/mid-
low versus mid-high/high); censored: low 51.2%, high 21.4%; green line: low 
CRASH score; red line: high CRASH score; vertical line: censored data; n = 113 
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Figure 4-25 Kaplan-Meier analysis of the time to the first occurrence of severe 
nonhematologic toxicity dependent on the category of the CARG score (low-
mid versus high); censored: low 52.4%, high 26.0%; green line: low CARG score; 
red line: high CARG score; vertical line: censored data; n = 113 
 
 
Figure 4-26 Kaplan-Meier analysis of the time to the first occurrence of severe 
nonhematologic toxicity dependent on the category of the nonhematologic 
CRASH score (low/mid-low versus mid-high/high); censored: low, 55.2% and 
high, 35.7%; green line: low CRASH score; red line: high CRASH score; vertical 
line = censored data; n = 113  
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4.1.7 Prediction of severe toxicity by other predictive factors  
4.1.7.1 Physicians’ judgment 
One hundred eleven patients were available for assessing the predictive performance of 
physicians’ judgment. For two patients, physicians’ judgment was missing.  
Overall toxicity  
The physicians’ judgment did not exhibit adequate predictive performance for overall 
grade ≥ 3 toxicity and resulted in worse predictive performance than the onco-geriatric scores. 
The toxicity incidence increased only slightly with a higher toxicity risk according to physicians’ 
judgment (p = 0.576, Fisher’s exact test); see Figure 4-27. The physicians’ judgment did not 
significantly predict overall toxicity in logistic regression (low vs mid: OR 1.664, CI 0.585-4.731, 
p = 0.339; low vs high: OR 2.240, CI 0.417-12.042, p = 0.347). The ROC-AUC demonstrated only 
low discrimination (ROC-AUC, 0.573; CI, 0.433-0.712; p = 0.311); see Figure 4-27. These data 
indicate that the CARG and the CRASH score are complementary to clinical judgment alone.  
  
Figure 4-27 (A) Proportion of patients with overall grade ≥ 3 toxicity per physicians’ 
judgment of overall toxicity during therapy course; (B) ROC curve of the 
physicians’ judgment for overall grade ≥ 3 toxicity during therapy course; solid 
line: physicians’ judgment; thin line: line of identity; n = 111 
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Hematologic toxicity 
Physicians predicted hematologic grade ≥ 3 toxicity better than overall toxicity. The toxicity 
risk increased with a higher physicians’ judgment of risk (p = 0.068); see Figure 4-28. In 
univariate logistic regression, physicians estimated the differences in toxicity risk significantly, 
but only between the categories low and mid (low vs mid: OR 2.547, CI 1.056-6.144, p = 0.037; 
low vs high: OR 3.765, CI 0.894-15.851, p = 0.071). The ROC curve yielded an AUC of 0.621 (CI, 
0.508-0.734; p = 0.039); see Figure 4-28. 
 
Figure 4-28 (A) Proportion of patients with hematologic grade ≥ 3 toxicity per physicians’ 
judgment of hematologic toxicity during therapy course; (B) ROC curve of the 
physicians’ judgment for hematologic grade ≥ 3 toxicity during therapy course; 
solid line: physicians’ judgment; thin line: line of identity; n = 111 
 
Nonhematologic toxicity 
Nonhematologic grade ≥ 3 toxicity was not adequately predicted by physicians. The toxicity 
risk increased slightly with a higher physicians’ judgment of risk (p = 0.562); see Figure 4-29. 
Physicians did not significantly predict nonhematologic toxicity in logistic regression (low vs 
mid: OR 1.257, CI 0.545-2.897, p = 0.592; low vs high: OR 2.040, CI 0.598-6.961, p = 0.255). 
The ROC-AUC demonstrated only low discrimination (ROC-AUC: 0.555, CI 0.447-0.664, 
p = 0.325), see Figure 4-29.  
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Figure 4-29 Proportion of patients with nonhematologic grade ≥ 3 toxicity per physicians’ 
judgment of nonhematologic toxicity during therapy course (A); ROC curve of the 
physicians’ judgment for nonhematologic grade ≥ 3 toxicity during therapy 
course (B); solid line: physicians’ judgment; thin line: line of identity; n = 111 
 
4.1.7.2 ECOG and age 
Other commonly used predictors for the risk of severe toxicity are the ECOG performance 
status and chronological age. In our analysis for overall grade ≥ 3 toxicity, neither the ECOG 
performance status nor the age exhibited a sufficient predictive performance for justifying 
their use as predictor. The proportion of patients with overall grade ≥ 3 toxicity increased with 
higher ECOG category (p = 0.413, Fisher’s exact test). For age, no consistent trend could be 
observed (p = 0.178, Fisher’s exact test); see Figure 4-30. Neither the ECOG performance 
status nor the age predicted overall severe toxicity significantly in univariate logistic regression 
(ECOG: OR 1.712, CI 0.946-3.097, p = 0.075; age: OR 1.001, CI 0.900-1.112, p = 0.989). The 
discrimination was rather low for the ECOG performance status (ROC-AUC, 0.620; CI, 0.492-
0.747; p = 0.088) and worthless for age (ROC-AUC, 0.460; CI, 0.339-0.580; p = 0.567), see 
Figure 4-31.  
For hematologic toxicity, similar results were found; for nonhematologic toxicity, the ECOG 
performance status predicted toxicity adequately. Respective details are illustrated in 
Appendix D, Table D-13. 
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Figure 4-30 Proportion of patients with overall grade ≥ 3 toxicity during therapy course per 
ECOG (Eastern Cooperative Oncology Group) performance status (A) and per age 
(B); n = 113 
 
 
Figure 4-31 ROC curve of ECOG (Eastern Cooperative Oncology Group) performance status 
(A) and age (B) as continuous predictors for overall grade ≥ 3 toxicity during 
therapy course (n = 113); solid line: (A) ECOG, (B) age; thin line: line of identity  
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4.1.7.3 Individual CARG score items 
From all items of the CARG score, only hemoglobin significantly predicted overall grade ≥ 3 
toxicity during therapy course. Patients with a hemoglobin value below 10 g/dL (female) or 
below 11 g/dL (male) exhibited a four-fold higher risk of toxicity compared to patients with 
higher hemoglobin values (OR, 4.036; CI, 1.110-14.683; p = 0.034). All other items of the CARG 
score did not significantly predict overall toxicity when used separately from the CARG score, 
indicating that especially hemoglobin plays an important role for the predictive value of the 
CARG score in this patient cohort. Univariate logistic regression results of the CARG score 
items are displayed in Table 4-10. The distribution of grade ≥ 3 toxicity per score item is 
presented in Appendix D, Table D-1. 
 
4.1.7.4 Individual CRASH score items 
As only item from all CRASH score items, lactate dehydrogenase (LDH) significantly predicted 
overall severe toxicity during therapy course when analyzed separately from the score. 
Patients with higher LDH values featured an almost seven-fold risk compared to patients with 
lower LDH values (OR, 6.980; CI, 1.432-34.035; p = 0.016). The univariate logistic regression 
results of the CRASH score items are presented in Table 4-11. 
 
4.1.7.5 Other patient- or cancer-related characteristics 
Patients with targeted or immunotherapies instead of chemotherapy demonstrated a 
significantly lower risk of overall grade ≥ 3 toxicity (OR, 0.031; CI, 0.003-0.297; p = 0.003). All 
other patient or cancer-related characteristics did not show significant predictions. The results 
of the univariate logistic regression are illustrated in Table 4-12.  
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Table 4-10 Univariate logistic regression for the CARG score items regarding overall grade ≥ 
3 toxicity during therapy course (n = 113); item categories are based on the 
original cut-offs in the CARG score; reference: in italic; nd, not determinable; CI, 
confidence interval; GI, gastrointestinal; GU, genitourinary 
 Odds ratio (CI) P value 
Age 
<72 vs ≥ 72 
0.607 (0.071-5.218) 0.649 
Cancer type  
Other vs GI/GU tumor 
2.000 (0.423-9.457) 0.382 
Dose  
Standard vs Reduced  
1.705 (0.357-8.148) 0.504 
Number of treatment agents  
Monotherapy vs Polytherapy 
1.111 (0.284-4.349) 0.880 
Hemoglobin [g/dL]  
≥ 10 vs <10 (female), ≥ 11 vs <11 (male) 
4.036 (1.110-14.683) 0.034 
Creatinine clearance Jeliffe [mL/min] 
≥ 34 mL/min vs <34mL/min  
nd  
Hearing abilities  
Good/excellent vs Fair/worse 
2.991 (0.932-9.594) 0.065 
Falls in past six months  
0 vs ≥ 1 
1.562 (0.416-5.860) 0.509 
Medication intake 
No assistance vs Requires assistance 
nd  
Limited in walking one block  
Not limited at all vs Limited 
0.965 (0.374-2.494) 0.942 
Decreased social activity because of 
health/emotional problems  
A little or none of the time vs Some, most, 
all of the time 
3.200 (0.876-11.687) 0.078 
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Table 4-11 Univariate logistic regression for the CRASH score items regarding overall grade 
≥ 3 toxicity during therapy course (n = 113); item categories are based on the 
original cut-offs in the CRASH score; reference: in italic; CI, confidence interval; 
ULN, upper limit of normal; IADL, instrumental activities of daily living; LDH, 
lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; MMSE, 
Mini-Mental State Examination; MNA, Mini Nutritional Assessment; MAX2, 
chemotherapy toxicity index 
 Odds ratio (CI) P value 
Diastolic blood pressure [mmHg]  
≤ 72 vs > 72 
1.292 (0.499-3.346) 0.598 
IADL  
26-29 vs 10-25 
1.562 (0.416-5.860) 0.509 
LDH [U/L] 
≤ 0.74 x ULN vs > 0.74 x ULN 
6.980 (1.432-34.035) 0.016 
ECOG performance status   
0  -  
1-2 1.786 (0.663-4.811) 0.252 
3-4 5.000 (0.580-43.071) 0.143 
MMSE 
30 vs <30 
2.229 (0.738-6.725) 0.155 
MNA 
28-30 vs <28 
0.640 (0.133-3.077) 0.577 
Therapy toxicity (MAX2)   
0  -  
1  1.233 (0.387-3.928) 0.723 
2  2.467 (0.663-9.176) 0.178 
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Table 4-12 Univariate logistic regression for other potential predictors of overall grade ≥ 3 
toxicity during therapy course (n = 113); categorial variables: reference in italic; 
if no categories are stated, the variable is treated as continuous; CI, confidence 
interval; ECOG, Eastern Cooperative Oncology Group  
 Odds ratio (CI) P value 
Age 1.001 (0.900-1.112) 0.989 
Sex  
male vs female 
1.100 (0.426-2.841) 0.844 
ECOG performance status 1.712 (0.946-3.097) 0.075 
Charlson Comorbidity Index 0.979 (0.657-1.457) 0.916 
Creatinine Clearance (Cockcroft-Gault) 
[mL/min] 
0.999 (0.977-1.021) 0.921 
Number of drugs before start of cancer 
treatment 
1.145 (0.979-1.340) 0.090 
Tumor type  
Solid tumors vs Hematological tumors 
0.884 (0.342-2.286) 0.800 
Treatment type   
Chemotherapy -  
Targeted or immunotherapy 0.031 (0.003-0.297) 0.003 
Combined chemotherapy and targeted or 
immunotherapy 
0.732 (0.249-2.146) 0.569 
 
Details regarding the univariate logistic regression for hematologic and nonhematologic 
grade ≥ 3 toxicity for different items are displayed in Appendix D, Table D-14 and Table D-15. 
For hematologic toxicity, hemoglobin (OR, 2.636; CI, 1.066-6.520; p = 0.036) and treatment 
type (targeted or immunotherapy vs chemotherapy: OR, 0.091; CI, 0.010-0.831; p = 0.034) 
were both significant predictors. Moreover, the MAX2 index predicted hematologic toxicity 
significantly. For nonhematologic toxicity, multiple variables showed significant predictions, 
also including hemoglobin and treatment type.  
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4.1.8 Prediction of severe symptom burden by onco-geriatric scores  
The patients’ total severe symptom burden (PRO-CTCAE ≥ 75%) was better predicted by the 
combined CRASH score than by the CARG score. In both scores, the proportion of patients 
with severe symptom burden increased with higher risk category (CARG: p = 0.459; combined 
CRASH: p = 0.356; Fisher’s exact test); see Figure 4-32. In univariate logistic regression, only 
the combined CRASH score significantly predicted severe symptom burden. With each CRASH 
score point, the chance of developing severe symptom burden increased by 1.3-fold (OR, 
1.344; CI, 1.028-1.757; p = 0.031). The CARG score denoted an OR of 1.119 (CI, 0.948-1.322; 
p = 0.184). The discriminative abilities of the combined CRASH score were superior to those 
of the CARG score (CRASH: ROC-AUC 0.66, CI 0.536-0.784, p = 0.024; CARG: ROC-AUC 0.581, 
CI 0.443-0.719, p = 0.253); see Figure 4-33. 
 
Figure 4-32 Proportion of patients with severe symptom burden (PRO-CTCAE ≥ 75) during 
therapy course per CARG score categories (A) and combined CRASH score 
categories (B); n = 100 
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Figure 4-33 ROC curves of the CARG score and the combined CRASH score for severe 
symptom burden (PRO-CTCAE ≥ 75) during therapy course (n = 100); solid line: 
CARG score; dashed line: combined CRASH score; thin line: line of identity 
 
4.1.9 Prediction of alterations of the planned treatment by onco-geriatric scores  
For major alterations of the planned treatment (therapy discontinuations or changes), the 
CARG score as well as the combined CRASH score indicated a sufficient predictive 
performance. However, none of the onco-geriatric scores exhibited an adequate predictive 
performance for total alterations of planned treatment or minor alterations (delays/dose 
reductions). Corresponding details are shown in Appendix D, Table D-16 and Table D-17. The 
proportion of patients with therapy discontinuations or changes increased significantly with 
higher category in both scores (CARG: p = 0.002; combined CRASH: p = 0.031; Fisher’s exact 
test). Figure 4-34 displays the proportion of patients with major alterations per score category. 
In univariate regression, both scores significantly predicted major alterations. With each 
increase of a CARG score unit, the risk of experiencing major alterations increased by 1.3-fold 
(OR, 1.261; CI, 1.102-1.443; p = 0.001). For the combined CRASH score, the risk increased with 
each unit by 1.5-fold (OR, 1.499; CI, 1.160-1.939; p = 0.002). Both scores denoted a similar 
ROC-AUC: A ROC-AUC of 0.696 (CI, 0.599-0.793; p = 0.001) was calculated for the CARG score 
and 0.682 (CI, 0.583-0.781; p = 0.001) for the combined CRASH score; see Figure 4-35. Both 
scores exhibited ROC-AUC values for the prediction of major treatment alterations close to 
those reached for the prediction of severe toxicity.  
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Figure 4-34 Proportion of patients with major alterations of the planned treatment 
(discontinuations or changes) during therapy course per CARG score categories 
(A) and combined CRASH score categories (B); n = 113 
 
 
Figure 4-35 ROC curves of the CARG and the combined CRASH score for major alterations 
of the planned treatment (discontinuations or changes); solid line: CARG score; 
dashed line: combined CRASH score; thin line: line of identity; n = 113 
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The onco-geriatric scores were not associated with the time until onset of total alterations or 
minor alterations (delays or dose reductions) of planned treatment; see Appendix D, Table D-
18 and Table D-19. Those findings correspond to the results regarding the predictive 
performance for total and minor alterations.  
However, both scores were associated with the time until onset of major alterations of the 
planned therapy (discontinuations or changes). A significant difference between low and high 
score categories was detected for the time to major alterations (CARG: p = 0.004; combined 
CRASH: p = 0.040; log-rank test). The Kaplan-Meier curves are illustrated in Figure 4-36 and 
Figure 4-37; for Kaplan-Meier estimates see Appendix D, Table D-20 to Table D-23. The Kaplan-
Meier curves for the CRASH score crossed after about 2 weeks. However, this was not further 
taken into account since it was assumed to be caused by the documentation method: Since 
exact dates of the therapy alterations were not available, the middle of the cycle was 
considered as time point of alteration and thus time points in this short 1-2 week period might 
be imprecise. The median time to major alterations was not calculable for the low category in 
both scores because the event did not occur in at least half of patients. Regarding the high 
category, a median time to major alterations of 12.5 (CI, 9.573-15.427) weeks was estimated 
for the CARG score and a median time of 14.5 (CI, 12.456-16.544) weeks for the combined 
CRASH score. For both scores, the Cox regression demonstrated a higher risk for the high 
category (CARG: Hazard ratio (HR) 2.402, CI 1.277-4.516, p = 0.007; combined CRASH: HR 
2.773, CI 0.989-7.781, p = 0.053). An exploratory analysis with cycles instead of weeks as time 
units yielded similar results. 
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Figure 4-36 Kaplan-Meier analysis of the time to major alterations of the planned treatment 
(discontinuations or changes) dependent on the category of the CARG score 
(low-mid versus high); censored: low 76.2%; high 46.0%; green line = low CARG 
score; red line: high CARG score; vertical line: censored data; n = 113 
 
Figure 4-37 Kaplan-Meier analysis of the time to major alterations of the planned treatment 
(discontinuations or changes) dependent on the category of the combined 
CRASH score (low/mid-low versus mid-high/high); censored: low 83.3%; high 
57.3%; green line: low CRASH score; red line: high CRASH score; vertical line: 
censored data  
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4.2 Medication risk analysis 
4.2.1 Patient characteristics 
For the analysis of medication risks, the data from the pilot and evaluation study were pooled, 
resulting in 136 included patients. The majority of patients originated from the evaluation 
study. An overview of the patients included in this analysis is given in Figure 4-38. 
 
Figure 4-38 Flow chart of patients for medication risk analysis 
 
The patient characteristics correspond mainly to those of the evaluation study (section 4.1.2); 
for details see Table 4-13.  
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Table 4-13  Characteristics of the patients included into the medication risk analysis 
(n = 136); ECOG, Eastern Cooperative Oncology Group; * by body location 
according to the National Cancer Institute (NCI) 
Age [years]   
Mean (SD) 76.9 (4.53)  
Min-max 70-88  
Charlson Comorbidity Index   
Mean (SD) 1.05 (1.237)  
Min-max 0-7  
Creatinine Clearance (Cockcroft-Gault) [mL/min]  
Mean (SD) 67.2 (22.89)  
Min-max 10-131  
 n % 
Sex   
Female 68 50.0 
Male 68 50.0 
ECOG performance status   
Fully active (0) 45 33.1 
Capable of all self-care (1-2) 74 54.4 
Limited or no self-care (3-4) 17 12.5 
Tumor entity * 
Respiratory 34 25.0 
Hematological 57 41.9 
Gynecological 5 3.7 
Genitourinary 3 2.2 
Unknown primary 4 2.9 
Musculoskeletal 1 0.7 
Digestive/gastrointestinal 16 11.8 
Breast 13 9.6 
Others 3 2.1 
Relapse   
No 118 86.8 
Yes 18 13.2 
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Table 4-13 (continued) 
 n % 
Cancer stage   
I 7 5.1 
II 11 8.1 
III 31 22.8 
IV 68 50.0 
Missing  19 14.0 
Treatment type   
Chemotherapy 81 59.6 
Targeted or immunotherapy 9 6.6 
Combined chemotherapy and targeted or 
immunotherapy 
46 33.8 
 
4.2.2 Long-term medication 
Almost all patients were on long-term medication before the start of cancer therapy, only 
8/136 (5.9%) patients did not take any regular long-term medication when being admitted to 
hospital. On average, patients took 5 drugs (SD, 3.5). The maximum number of drugs per 
patient was 18. Most drugs were only available on prescription (587/683); solely 96/683 drugs 
comprised over-the-counter (OTC) drugs. The most frequently used drug classes were 
antithrombotic agents (ATC Code B01; mostly acetylsalicylic acid, ASS), agents acting on the 
renin-angiotensin system (ATC Code C09; mostly ramipril), and diuretics (ATC Code C03; 
mostly hydrochlorothiazide). On the drug level, pantoprazole, L-thyroxine, and ASS were the 
drugs which patients received most often. Drug classes and individual drugs of patients’ long-
term medication are given in Table 4-14 and Table 4-15.  
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Table 4-14 Drug classes (ATC code level 2) of patients’ long-term medication before start of 
cancer therapy (n = 136) 
Drug class (ATC code level 2) Number of drug prescriptions 
Antithrombotic agents (B01) 70 
Agents acting on the renin-angiotensin system (C09) 65 
Diuretics (C03) 59 
Beta blocking agents (C07) 50 
Lipid modifying agents (C10) 48 
Drugs for acid-related disorders (A02) 47 
Thyroid therapy (H03) 46 
Analgesics (N02) 32 
Calcium channel blockers (C08) 30 
Drugs used in diabetes (A10) 29 
Others 207 
 
Table 4-15 Individual drugs of patients’ long-term medication before start of cancer therapy 
(n = 136); ASS, acetylsalicylic acid; HCT, hydrochlorothiazide 
Drug Number of patients Proportion of patients 
with respective drug [%] 
Pantoprazole 42 30.9 
L-thyroxine 38 27.9 
ASS 35 25.7 
Simvastatin 31 22.8 
HCT 29 21.3 
Bisoprolol 22 16.2 
Ramipril 22 16.2 
Amlodipine 21 15.4 
Metoprolol 20 14.7 
Candesartan 17 12.5 
Metamizole 17 12.5 
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4.2.2.1 Polymedication 
More than half of patients exhibited polymedication (≥ 5 drugs) and approximately every 10th 
patient experienced hyperpolymedication (≥ 10 drugs). The prevalence of poly- and 
hyperpolymedication is illustrated in Figure 4-39. 
 
Figure 4-39 Patients with polymedication (≥ 5 drugs) and hyperpolymedication (≥ 10 drugs) 
before start of cancer therapy (n = 136) 
 
4.2.2.2 Potentially inadequate medication 
Patients took in median one (IQR, 1; range, 0-5) PIM drug. More than half of patients (52.9%) 
used at least one PIM drug before start of cancer therapy. By far the most frequent PIM drugs 
were drugs for acid-related disorders (ATC A02). Consistent with this finding, pantoprazole 
was the most frequently taken PIM drug (42/136 patients). Other commonly used PIM drug 
classes comprised drugs used in diabetes (ATC code A10; mostly sitagliptin), drugs for cardiac 
therapy (ATC code C01; mostly amiodarone), and calcium channel blockers (ATC code C08; 
mostly verapamil). An overview of the PIM drug classes and individual drugs is presented in 
Table 4-16 and Table 4-17. 
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Table 4-16 Prevalence of PIM drug classes (ATC code level 2) in long-term medication before 
start of cancer therapy (n = 136) 
PIM drug class (ATC code level 2) Number of drug prescriptions 
Drugs for acid-related disorders (A02) 47 
Drugs used in diabetes (A10) 10 
Cardiac therapy (C01) 8 
Calcium channel blockers (C08) 7 
Psycholeptics (N05) 6 
Psychoanaleptics (N06) 5 
Antithrombotic agents (B01) 4 
Anti-inflammatory and antirheumatic products (M01) 3 
Beta blocking agents (C07) 3 
Urologicals (G04) 3 
Others 11 
 
Table 4-17 Prevalence of individual PIM drugs in long-term medication before start of 
cancer therapy (n = 136) 
PIM drug (ATC code) 
Number of 
patients 
Proportion of patients with 
respective drug [%] 
Pantoprazole (A02BC02) 42 30.9 
Sitagliptin (A10BH01) 8 5.9 
Amiodarone (C01BD01) 4 2.9 
Verapamil (C08DA01)  4 2.9 
Rivaroxaban (B01AF01) 3 2.2 
Omeprazole (A02BC01) 3 2.2 
Amitriptyline (N06AA09) 3 2.2 
Sotalol (C07AA07) 3 2.2 
Diclofenac (M01AB05) 2 1.5 
Diltiazem (C08DB01) 2 1.5 
Methocarbamol (M03BA03) 2 1.5 
Metoclopramide (A03FA01) 2 1.5 
Pramipexole (N04BC05) 2 1.5 
Trospium (G04BD09) 2 1.5 
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4.2.2.3 Relevant potential drug-drug interactions 
Approximately one third of patients (30.9%) exhibited relevant potential drug-drug 
interactions (rPDDI) in long-term medication before start of cancer therapy. The median of 
rPDDI per patient was 0 (IQR, 1; range, 0-9). The majority of rPDDI was classified as 
“monitoring/modification needed” (67/71) according to the ABDA database. Only 4/71 rPDDI 
were categorized as “simultaneous usage not recommended”. No contraindications were 
observed. Mostly, rPDDI consisted of pharmacodynamic interactions (40/71); 21/71 rPDDI 
occurred due to pharmacokinetic reasons. In general, a variety of interaction types was 
observed; the most frequent rPDDI comprised “anti-diabetic drugs – corticosteroids”, “agents 
acting on the renin-angiotensin system – heparinoids” and “simvastatin – amlodipine”. The 
detected rPDDI are presented in Table 4-18.  
The most frequent drug classes being involved in rPDDI were agents acting on the renin-
angiotensin system (ATC code C09), beta blocking agents (ATC code C07), and antithrombotic 
agents (ATC code B01); see Table 4-19. According to the interaction propensity, the drug 
classes with the highest potential of provoking interactions were cardiac therapy (ATC code 
C01) and corticosteroids for systemic use (ATC code H02). Surprisingly, although being the 
drug class most frequently involved in interactions, agents acting on the renin-angiotensin 
system did not exhibit such a high potential of provoking rPDDI when prevalence was 
considered. The interaction propensity of different drug classes is depicted in Table 4-19. 
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Table 4-18 Types of rPDDI, observed in patients before start of cancer therapy; NSAID, 
nonsteroidal anti-inflammatory drugs (n = 136) 
Type of interaction Number of detected 
interactions 
Anti-diabetic drugs – corticosteroids 8 
Agents acting on the renin-angiotensin system – heparinoids 8 
Simvastatin – amlodipine 8 
Beta agonists – beta blocker 6 
ACE inhibitors – allopurinol 5 
Amiodarone – beta blockers 4 
Thyroid hormones – polyvalent cations 4 
Insulins – cardio selective beta blockers 3 
NSAID – corticosteroids 3 
Thiazide-diuretics – vitamin D and derivatives 3 
Others 19 
 
Table 4-19 Frequency of drug classes being involved in rPDDI and the respective interaction 
propensity (ratio of frequency as interaction partner per total frequency of a 
drug class); n = 136 
Drug class (ATC code level 2) 
Number of detected 
interactions 
Interaction propensity 
Agents acting on the renin-
angiotensin system (C09) 
17 0.26 
Beta blocking agents (C07) 13 0.26 
Antithrombotic agents (B01) 13 0.19 
Corticosteroids for systemic use (H02) 12 0.75 
Drugs used in diabetes (A10) 12 0.41 
Lipid modifying agents (C10) 11 0.23 
Diuretics (C03) 9 0.15 
Cardiac therapy (C01) 9 1.0 
Calcium channel blockers (C08) 8 0.27 
Drugs for obstructive airway diseases 
(R03) 
6 0.25 
Others 32 - 
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4.2.3 Antineoplastic agents and supportive care medication 
In total, 128 patients could be assessed after initiation of cancer therapy. After start of cancer 
therapy, patients received in median 6 (IQR, 2.25; range, 1-12) additional drugs. This 
comprised in median 2 (IQR, 1; range, 1-5) additional drugs for antineoplastic therapy and in 
median 4 (IQR, 2.25; range, 0-7) additional drugs for supportive therapy. Regarding 
antineoplastic agents, most frequently the drug classes plant alkaloids and other natural 
products (ATC code L01C, e.g. paclitaxel) as well as platinum compounds (ATC code L01XA, 
e.g. carboplatin) were prescribed in our cohort. Concerning supportive care medication, by far 
the most frequently used drug class was antiemetics and antinauseants (ATC code A04, e.g. 
ondansetron). G-CSF (granulocyte colony stimulating factor) was administered in 21/128 
patients. Details regarding prevalence of antineoplastic agents and supportive care 
medication are presented in Appendix E, Table E-1 and Table E-2.  
 
4.2.3.1 Potentially inadequate medication 
After start of cancer therapy, 36.7% of patients received further PIM drugs being used more 
than once per cycle. In total, the median of additional PIM drugs for all patients was 0 (IQR, 1; 
range, 0-3). The most commonly used additional PIM drug was ranitidine. The prevalence 
values of additional PIM drugs after start of cancer therapy are listed in Table 4-20.  
Table 4-20 Prevalence of additional PIM drugs after start of cancer therapy which are used 
more than once per cycle (n = 128)  
PIM (ATC code) Number of 
patients 
Ranitidine (A02BA02) 32 
Clemastine (R06AA04) 17 
Proton-pump inhibitors (A02BC) 8 
Dimetindene (R06AB03) 5 
Alizapride (A03FA05) 2 
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4.2.3.2 Relevant potential drug-drug interactions 
After start of cancer therapy, 29.7% of patients demonstrated further rPDDI between the long-
term medication and the antineoplastic agents/supportive care medication which was used 
more than once per cycle. The median of additional rPDDI in all patients was 0 (IQR, 1; range, 
0-3). The types of interactions were rather diverse. Most frequently, the rPDDI “NSAID – 
corticosteroids” and “cytotoxic agent – thiazide diuretic” were observed; see Table 4-21. The 
rPDDI were usually categorized as “monitoring/modification needed” by the ABDA database 
classification (Table 4-21). Three out of hundred twenty-eight (2.3%) patients exhibited 
contraindications; no patient experienced more than one contraindication. The most severe 
interaction types involved both QT prolonging agents. Most rPDDI consisted of 
pharmacodynamic interactions (30/50); changes in pharmacokinetics only rarely caused rPDDI 
(5/50). 
Table 4-21 Types of additional rPDDI between antineoplastic agents/supportive care 
medication (being used more than once per cycle) and the long-term medication 
after start of cancer therapy (n = 128), with prevalence and ABDA database 
classifications; NSAID, nonsteroidal anti-inflammatory drugs; * interaction was 
unintended in this case 
Type of interaction 
Number of 
detected 
interactions 
ABDA database classification 
NSAID – corticosteroids 8 Monitoring/modification needed 
Cytotoxic agent – thiazide diuretic 7 Monitoring/modification needed 
Anti-diabetic drugs – corticosteroids 5 Monitoring/modification needed 
ACE inhibitors – allopurinol 4 Monitoring/modification needed 
Hyperkalemic drugs – trimethoprim 4 Monitoring/modification needed 
QT prolonging drug – antidepressant 3 
Simultaneous usage not 
recommended 
QT prolonging drug – antiarrhythmic 
agent 
3 
Serious consequences possible – 
as precaution contraindicated 
Loop diuretic – platinum compound 3 Monitoring/modification needed 
Nitrogen mustard derivatives – 
allopurinol 
3 Monitoring/modification needed 
Fluoropyrimidine – folate * 2 Monitoring/modification needed 
Others 8 - 
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Corticosteroids for systemic use (ATC code H02) was the drug class most frequently causing 
rPDDI. However, antibiotics (ATC code J01) were found to be the drug class with the highest 
interaction propensity (0.86). This was triggered by the numerous interactions between 
trimethoprim and ACE inhibitors. Respective details are illustrated in Table 4-22. 
Table 4-22 Frequency of drug classes being involved in rPDDI between antineoplastic 
agents/supportive care medication (being used more than once per cycle) and 
the long-term medication after start of cancer therapy, with the interaction 
propensity (ratio of frequency as interaction partner per total frequency of a 
drug); n = 128 
Drug class (ATC code level 2) 
Number of detected 
interactions 
Interaction propensity 
Corticosteroids for systemic use 
(H02) 
13 0.12 
Diuretics (C03) 10 0.16 
Antimetabolites (L01B) 9 0.30 
Antithrombotic agents (B01) 8 0.11 
Agents acting on the renin-
angiotensin system (C09) 
8 0.12 
Antiemetics and antinauseants (A04) 8 0.07 
Antigout preparations (M04) 8 0.13 
Alkylating agents (L01A) 6 0.13 
Drugs used in diabetes (A10) 6 0.21 
Antibiotics (J01) 6 0.86 
Others 18 - 
 
 
4.2.4 Association of long-term medication with severe toxicity 
For all 113 patients with a follow-up in the evaluation study, the associations of overall, 
hematologic, and nonhematologic grade ≥ 3 toxicity with medication risks were investigated 
by univariate logistic regression. For overall and hematologic toxicity, the occurrence of rPDDI 
was significantly associated with grade ≥ 3 toxicity: Patients with rPDDI exhibited an 
approximately 5-fold risk of developing overall toxicity (OR, 5.067; p = 0.036) and an 
approximately 4-fold risk of experiencing hematologic toxicity (OR, 3.949; p = 0.010). 
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However, the occurrence of rPDDI was not associated with nonhematologic toxicity. Instead, 
nonhematologic toxicity was significantly associated with the number of drugs per patient and 
the number of PIM drugs per patient. Corresponding details are displayed in Table 4-23. The 
distribution of toxicity regarding categorial variables is presented in Appendix E, Table E-3. 
Table 4-23 Univariate logistic regression of overall, nonhematologic, and hematologic 
grade ≥ 3 toxicity during therapy course with risks in long-term medication (n = 
113); reference: in italic; if no reference is given the variable was treated as 
continuous; Polymedication: ≥ 5 long-term drugs per patient 
 Odds ratio (95% CI) P value 
Overall toxicity   
Number of drugs per patient 1.145 (0.979-1.340) 0.090 
Patients without vs with polymedication 1.519 (0.584-3.954) 0.391 
Number of PIM per patient 1.230 (0.710-2.131) 0.460 
Patients without vs with PIM 1.310 (0.507-3.385) 0.578 
Number of rPDDI per patient 3.843 (0.965-15.312) 0.056 
Patients without vs with rPDDI 5.067 (1.109-23.140) 0.036 
Hematologic toxicity   
Number of drugs per patient 1.037 (0.930-1.157) 0.511 
Patients without vs with polymedication 1.173 (0.534-2.575) 0.691 
Number of PIM per patient 0.908 (0.604-1.364) 0.642 
Patients without vs with PIM 0.944 (0.430-2.077) 0.887 
Number of rPDDI per patient 1.587 (0.899-2.803) 0.111 
Patients without vs with rPDDI 3.949 (1.382-11.285) 0.010 
Nonhematologic toxicity   
Number of drugs per patient 1.138 (1.014-1.277) 0.029 
Patients without vs with polymedication 1.468 (0.691-3.121) 0.318 
Number of PIM per patient 1.675 (1.051-2.669) 0.030 
Patients without vs with PIM 1.926 (0.900-4.120) 0.091 
Number of rPDDI per patient 1.591 (0.952-2.658) 0.076 
Patients without vs with rPDDI 1.663 (0.715-3.870) 0.238 
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5 Discussion 
5.1  Evaluation of onco-geriatric scores 
For predicting therapy-associated toxicity in older cancer patients, the ASCO guideline 
recommends the CARG and the CRASH score. Nevertheless, it remains unclear which score to 
prefer. This study observed that the CARG and the CRASH score exhibited a similar predictive 
performance for severe overall toxicity. However, for predicting severe hematologic toxicity, 
the hematologic CRASH score should be preferred to the CARG score. Both scores performed 
better for overall toxicity than physicians’ judgment alone, emphasizing the importance of 
onco-geriatric scores in complementing the clinical prediction of therapy-associated toxicity.  
 
5.1.1 Study set-up 
Study design  
This is the first study directly comparing the CARG and the CRASH score in a clinical routine 
setting. Moreover, this study fills a gap in knowledge, being the first CARG score study which 
includes patients with hematologic malignancies. For the CRASH score, this is the first study 
investigating its predictive performance in a patient cohort different from the development 
study, hence evaluating its external validity. Furthermore, no previous study has investigated 
the scores in a cohort of patients with targeted or immunotherapies. Thus, this research 
enhances the applicability of these onco-geriatric scores in the current clinical routine where 
therapies like targeted therapy or immunotherapy play an increasing role. Another strength 
of this study is that its feasibility was verified by conducting a pilot study with 20 patients (in 
parts presented in [78]). 
A limitation of this study is the retrospective collection of follow-up data from medical records. 
Toxicity might not have been documented thoroughly. However, this study focuses on grade 
≥ 3 toxicity which is likely to be adequately documented since mostly evoking clinical 
measures. Furthermore, if blood controls were performed at general practitioners and 
oncology practices, those were contacted for the collection of medical data. This study 
therefore considers the patients’ entire therapy course by including all relevant laboratory 
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data, also the nadir of blood values, into the analysis. Moreover, the data collection was 
standardized via a toxicity documentation form (Appendix C) and was always carried out 
through the same researcher to ensure consistent data quality. 
The relatively small sample size and single-center design might limit the generalizability of the 
results. Due to lacking data, no sample size calculation could be conducted. Hence, we aimed 
at recruiting as many patients as possible in the given time frame of the project. Furthermore, 
the inclusion of patient data from external oncology practices might bear potential for bias 
due to different documentation standards. However, most patients (77.0%) were treated in 
the Johanniter Hospital Bonn, assuring a consistent documentation. Moreover, the inclusion 
of patients partly continuing treatment in an outpatient setting has the benefit of avoiding a 
selection bias since allowing for a study cohort closer to clinical routine.  
Patient population 
Broad inclusion criteria and only limited exclusion criteria were defined for this evaluation 
study because the onco-geriatric scores were designed to comprise a broad prediction scope 
across different tumor entities and cancer therapies. Furthermore, a heterogeneous study 
population better represents the real population of a hospital. Thus, the results are more 
eligible to be transferred into clinical routine and comprise a higher external validity. For 
enhancing applicability in current daily routine, not only chemotherapy but also targeted or 
immunotherapies were included, as well as inpatient and outpatient patients.  
The onco-geriatric scores are particularly important for frail patients. By setting the inclusion 
criterion to ≥ 70 years and conducting recruitment in an inpatient setting, we targeted at 
enrolling this frail patient population. However, eventually, our study cohort consisted of 
mainly fit patients (ECOG 0-2, 87.5%), thus not representing a typical cohort of geriatric 
patients. This was also the case in the development studies of the CARG and the CRASH score 
(CARG: Karnofsky performance status > 70, 80%; CRASH: ECOG 0-2, 97% [67, 68]) and might 
be caused by the common selection bias of non-frail patients in studies. This seems likely since 
in this study, a frequent reason for exclusion comprised physical constraints.  
Different eligibility criteria were used in the original development studies of the CARG score 
and the CRASH score [67, 68]. Due to the comparative character of our study, we considered 
both eligibility criteria as much as possible when designing this evaluation study. However, 
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being based on both development studies, our study featured different eligibility criteria than 
previous development and validation studies which only investigated one score. A comparison 
of the eligibility criteria of the score development studies with those of this evaluation study 
is shown in Table 5-1. 
Table 5-1 Comparison of eligibility criteria of the CARG and CRASH score development 
studies with this evaluation study; AML, acute myeloid leukemia 
 CARG score [67] CRASH score [68] Evaluation study 
Age ≥ 65 years ≥ 70 years ≥ 70 years 
Tumor entity Solid tumors 
Solid tumors and 
hematological 
malignancies (except 
AML) 
Solid tumors and 
hematological 
malignances 
Additional 
therapy 
Radiotherapy allowed 
No radiotherapy 
allowed 
Radiotherapy allowed 
Systemic 
cancer 
therapy 
Only chemotherapy 
Chemotherapy and 
combinations with 
targeted therapies 
Chemotherapy, 
combinations with 
targeted or 
immunotherapies, and 
targeted or 
immunotherapies only 
Previous 
therapy 
Starting new 
chemotherapy 
regimen 
Starting new line of 
chemotherapy (first-
line to fourth-line) 
Only first-line therapy 
 
In consequence, the study population of the score development studies and this evaluation 
study differed: The study cohort of the CARG score development was younger than our cohort 
(CARG: mean 73 years, this study: mean 77.2 years) since Hurria et al. enrolled patients ≥ 65 
years; in the CRASH score development study, the mean age was 75.5 years, also being slightly 
lower than in our study cohort [67, 68]. Gender was equally distributed in our study as well as 
in both score development studies (CARG: female 56%, CRASH: female 50.4%, this study: 
50.0%). The CARG score development study only considered patients with solid tumors, 
whereas the CRASH score and this evaluation study also included hematologic tumors. 
Lymphoma were the most frequent hematologic malignancies in our study (27.5%) as well as 
in the CRASH development study (non-Hodgkin lymphoma 15.1%). However, our study 
included more patients with hematologic malignancies than the CRASH development study. 
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In all studies, lung cancer indicated the highest prevalence among solid tumors (CARG: 29%, 
CRASH: 20.8%, this study: 24.2%). Furthermore, patients experienced in all studies later cancer 
stages (≥ stage III: CARG 83%, CRASH 78.9%, this study 72.5%). In the CARG score 
development, no concomitant radiotherapy was allowed; however, in the CRASH score 
development 18.5% of patients and in our study 30.8% of patients were additionally treated 
with radiation therapy. Whereas the development studies of the CARG and CRASH score only 
focused on chemotherapy regimens, our study also comprised modern therapies. However, 
patients were rarely exclusively treated with targeted or immunotherapy regimens in our 
study (5.8%). Instead, combinations of targeted or immunotherapy with chemotherapy were 
more common (34.2%). Thus, our results are probably of less validity for exclusively targeted 
or immunotherapy regimens but rather valid for combinations of modern therapies with 
chemotherapy.  
 
5.1.2 Risk assessment 
Onco-geriatric scores 
The time between the performance of the scores and the start of cancer therapy was only 
short, being in median 1 day. Hence, it can be assumed that the score results remained valid 
at start of therapy. However, some geriatric assessment variables like the MMSE are generally 
dependent on the daily condition of the patients. Also, some patients might have under- or 
overestimated their own performance for e.g. IADL. In general, wrong self-evaluation of 
patients is an inherent limitation of geriatric assessment variables. In order to ensure 
consistent conditions for patients, the different geriatric assessment instruments were always 
conducted in the same order and with the same interviewer. The questions of the CARG score 
were translated into German by our research group and asked orally in a patient interview. 
For allowing the use of a self-administered CARG questionnaire in the future, it would be an 
interesting field of further research to linguistically validate those questions. Regarding the 
CRASH score, it might be interesting to linguistically validate the IADL, since no validated 
German version exists.  
The CARG score results in this evaluation study indicated a mid risk as most frequent 
prediction, consistent with the results of the development study (CARG study: 48.9% vs this 
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study: 50.8%). However, compared to the development study, much less patients were 
categorized as low risk (CARG study: 27.6% vs this study: 5.8%). The high category was 
predicted more often in this evaluation study than in the original development study (CARG 
study: 23.5% vs this study: 43.3%). Those differences may originate from different eligibility 
criteria: For instance, due to the inclusion criterion ≥ 70 years in this evaluation study 
compared to ≥ 65 years in the CARG study, only 7.5% of our patient cohort comprised the low 
category for age, compared to 46% in the CARG development cohort (< 72 years: 0 score 
points assigned vs ≥ 72: 2 score points) [67]. 
Regarding the combined CRASH score in this evaluation study, most patients were categorized 
as mid to high risk for overall toxicity and only few patients as low risk (mid-high: 60.0%; low: 
2.5%); similar results were obtained for the hematologic and nonhematologic CRASH score. 
The distribution of the CRASH score results was not described in the development cohort. In 
literature, only one study was found which applied the CRASH score [127, 128]. In this study 
with non-Hodgkin lymphoma patients, the combined CRASH score predicted a higher risk (high 
or mid-high) in about half of patients [127], being slightly less than in our cohort. The results 
for the CRASH score items did not differ from the ones observed during the development 
study (e.g. MMSE: this study median 28 vs CRASH study median 28; MNA: this study median 
24 vs CRASH study median 25; IADL: this study median 28 vs CRASH study median 28) [68].  
Physicians 
In contrast to the onco-geriatric scores, mainly predicting mid-high risk, physicians mainly 
expected a mid or low risk for their patients. In general, physicians were thus more optimistic 
regarding the tolerability of treatment. These results are in line with the results of a study by 
Moth et al. where physicians primarily predicted medium and low toxicity risk as well (low: 
24%, mid: 63%, high: 12%) [73]. However, instead of asking to estimate an exact percentage 
of toxicity as Moth et al. [73], this study asked physicians to estimate risks as low, mid, or high. 
Since physicians are not trained for such assessments, we did not expect them to be able to 
estimate risks in such a detailed manner as percentages. However, physicians could have had 
different perceptions about the meaning of “low, mid, or high” which might have led to a bias 
of judgments. In addition, the physicians’ lack of training may have caused a subjectivity in the 
risk prediction and in consequence an incoherence in the risk assessment. Also, we asked the 
treating physicians who were mostly assistant physicians with limited experience. However, 
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those physicians were the ones directly treating the patients and hence were deemed to know 
the patient’s health condition best.  
 
5.1.3 Outcome 
Toxicity  
In total, 113 patients could be considered for outcome analysis. Seven patients were not 
included because the follow-up was incomplete, bearing the risk of misclassification which 
could lead to either under- or overestimation of the predictive performance. The loss to 
follow-up occurred early in all cases (mostly during or after the first cycle). Although our study 
showed that severe toxicity occurred frequently at start of therapy, the toxicity outcome of 
those patients could not be determined with adequate accuracy. The amount of missing 
laboratory data was not substantial in the follow-up (median 2.8%) and thus did not constitute 
a limitation in this study.  
This evaluation study ended the follow-up after six cycles instead of observing the therapy 
course until the end of therapy like in the CARG development study, or following until a 
maximum of six months like in the CRASH development study [67, 68]. This might have 
prevented capturing toxic symptoms occurring later during therapy course. However, for 
58.4% of patients in this evaluation study, the follow-up ended before six cycles. Moreover, 
results of the CRASH development study as well as our results indicated that severe toxicity 
mostly occurs at start of therapy: In this evaluation study, in 69.0% of patients, toxicity already 
occurred during the first cycle of therapy course; the median time until the first occurrence of 
toxicity was 22 days in the CRASH study [68] and 2 weeks in this study. The duration of cycles 
differed for each therapy regimen, resulting in different total lengths of follow-up. However, 
cycles were chosen as time frame for follow-up since this generally better reflects the therapy 
course than a certain number of months. This evaluation study did not further consider follow-
ups when patients completely changed therapy regimen or experienced a dose reduction of ≥ 
50%. In the development studies, the follow-up was not discontinued in those cases. However, 
since the therapy regimen and dosage are included in the score calculation, and thus in the 
score predictions, the therapy course after change of regimen or dosage would not reflect the 
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previous predictions anymore. Nevertheless, the regimen or dosage was mostly changed due 
to severe toxicity, implying that severe toxicity, the primary endpoint, had already occurred.  
Overall, severe toxicity incidence was by far higher in our study (81.4%) than in the CARG score 
development study (53%) as well as the CRASH development study (64%) [67, 68]. Also, severe 
hematologic toxicity (CARG study 26%, CRASH study 32% vs this study 67.3%) and 
nonhematologic toxicity (CARG study 43%, CRASH study 56% vs this study 59.3%) was more 
frequent than during the score development studies [67, 68]. Furthermore, in our study, 
hematologic toxicity occurred more frequently than nonhematologic toxicity which was the 
opposite in the development studies. These findings might be explained by the different 
eligibility criteria: Contrary to the CARG score development study, this study allowed 
concomitant radiation therapy and enrolled older patients, patients with hematologic 
malignances, and patients in an inpatient setting. In contrast to the CRASH score development 
study, this study included more patients with hematologic malignancies, being more 
susceptible to severe hematologic toxicity. Also, differences in the endpoint collection could 
have caused a higher toxicity incidence: For the CARG score development, toxicity was only 
considered if, after being reviewed by two physicians, the toxicity was regarded as therapy-
associated [67]. In the CRASH score development, only grade 4 but not grade 3 hematologic 
toxicity was defined as severe toxicity. If our study only considers grade 4 hematologic and 
grade ≥ 3 nonhematologic toxicity (similar to the CRASH score development), a prevalence of 
70% would be observed for severe toxicity, being closer to the 64% observed during the CRASH 
score development [68]. Furthermore, the CARG score development study only considered 
blood values if they were measured on the day of scheduled chemotherapy or at emergency 
visits; the CRASH score development study also accounted for weekly complete blood counts. 
To capture the whole picture, this evaluation study considered all blood values. This also might 
have led to a higher toxicity incidence than during the CARG development study [67]. 
The distribution of toxicity types was similar in this evaluation study and in the CARG 
development study [67]. Neutropenia and leukopenia were the most frequent hematologic 
toxicity types in this evaluation study as well as in the CARG development study; for 
nonhematologic toxicity, fatigue and infections were frequent toxicity types in both studies 
[67]. The time to occurrence of severe toxicity was comparable with the CRASH development 
study where the time to first severe toxicity was 22 days [68]; in this evaluation study, the first 
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severe toxicity occurred after 2 weeks. Our study indicated that the majority of overall severe 
toxicity occurred at start of treatment (69.0% of patients showed toxicity at start of therapy 
vs 81.4% of patients during complete therapy course). This result is in line with a study by 
Extermann et al., observing that 46% of patients experienced the first severe toxicity during 
the first cycle and less patients in the following cycles (second cycle: 24%, third cycle: 17%) 
[95]. 
Patient-reported symptom burden 
Evaluating patient-reported symptoms in addition to health care providers‘ information is 
essential for obtaining the complete picture of therapy tolerability [97]. It is a strength of this 
study that patient-reported outcomes were collected as well.  
The PRO-CTCAE questions were asked orally in person or via telephone. Orally, the PRO-CTCAE 
was validated for interactive voice response systems [102] but not for patient interviews. 
Results may have been influenced by the fact that patients talked to a real person, for instance 
some symptoms might have been embarrassing for them to admit. However, since a voice 
response system was not available due to financial and logistic constraints, this mode of 
application was the only one feasible in our study in order to include data from patients not 
continuing treatment in the Johanniter Hospital Bonn.  
Since the recall time of the PRO-CTCAE is seven days [94], we set the time frame for contacting 
patients to one to two weeks after the start of each cycle. As the patients were not always 
reachable via telephone or the patients experienced unforeseen therapy delays or changes, 
this time frame was slightly exceeded in some cases. However, since the length of the cycles 
differed and the chemotherapy varied from one to several administration days per cycle, this 
might not have influenced results to a large extent in this heterogeneous setting. Ideally, 
patients should be observed each week. However, since patient burden should be kept low 
due to their high age of patients, that did not seem feasible in this study. 
A high percentage of patients was missing for follow-up. This is largely caused by the fact that 
the older study cohort did not tolerate cancer therapy well – many patients refused to be 
interviewed due to bad health condition. This implies a bias since patients with bad tolerability 
could not be asked for reporting their symptoms. However, this bias is an inherent challenge 
of patient-reported symptoms.  
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Agreement of toxicity and patient-reported symptom burden 
When comparing severe patient-reported symptom burden (≥ 75% PRO-CTCAE) with severe 
physician-reported toxicity (grade ≥ 3 CTCAE), the weighted Kappa results generally indicated 
a low agreement. This is consistent with literature: A systematic review by Atkinson et al. 
summarized that the agreement between CTCAE and PRO-CTCAE was found to be low to – at 
best – moderate [129]. Furthermore, this study found that severe symptoms were reported 
more frequently by patients than by physicians. In line with this result, several studies in 
literature indicate that subjective toxic symptoms are likely of being underreported by 
physicians [96, 130, 131]. Those results were also observed in older cancer patients: Moon et 
al. found that physicians underreported toxicity in older head and neck or lung cancer patients 
during curative radiotherapy [132]. 
In this analysis, a PRO-CTCAE of 75% was used as the cut-off for severe toxicity. However, 
another cut-off may better correspond to severe toxicity being defined as CTCAE grade ≥ 3. 
The choice of a different cut-off value might be an interesting field of further investigation. 
Moreover, physicians’ reporting of toxicity might have been underestimated due to the 
retrospective collection of data in the medical records. However, our results were consistent 
with previous studies, supporting the robustness of results. 
Nevertheless, it should be kept in mind that the CTCAE and PRO-CTCAE were not developed 
for replacing but, in contrast, for complementing each other. The physicians’ perspective and 
patients’ perspective comprise both essential, meaningful information [97]. Basch et al. 
showed that the CTCAE better predict unfavorable clinical events, whereas patient-reported 
outcomes better predict the daily health status [97].    
Alterations of the planned treatment 
A high proportion of patients experienced alterations of the planned treatment in this 
evaluation study. Twenty-seven percent of patients discontinued therapy due to toxicity in 
our study, which was comparable to the results of the CRASH development study, where 
23.4% discontinued therapy due to toxicity [68]. The percentage of patients with dose delays 
corresponded to the results of the CARG score development study (this study: 33.6% vs CARG 
study: 31% [67]). Dose reductions were less prevalent in our study than in the CARG 
development study (this study: 17.7% vs CARG study: 31% [67]). In a study by Wildes et al., 
110  Discussion 
 
16.9% of patients did not complete the planned number of therapy cycles due to toxicity, 
which is less than in this study where 37.2% of patients discontinued or changed their regimen 
[133]. This might be explained by differences in the study cohort: Wildes et al. enrolled 
younger patients and overall toxicity incidence only reached 41%. A Korean study observed 
that 40% of older patients discontinued cancer therapy during or after first-line therapy 
because of death or deteriorated health condition [134]. 
 
5.1.4 Relationship between risk assessments 
Only poor agreement between the CARG and the CRASH score prediction was found. This 
indicates that both scores predict different risks for patients and are not interchangeable. 
Despite different predictions, the predictive performance of the onco-geriatric scores was 
similar. That finding suggests that the scores predict well for different patients, predicting 
complementary risks. 
Moreover, physicians’ judgments were not consistent with the predictions of the scores. 
Similar results were found in a study by Moth et al. and Alibhai et al. where physicians’ 
judgments were not correlated with the CARG score results (Moth et al.: r = -0.03; Alibhai et 
al.: r < 0.3) [72, 73]. Also, Nishijima et al. found little agreement between physicians’ treatment 
decision “reduced vs standard therapy” and “low vs high CARG score category” (Kappa value 
0.14) [74]. Clinical judgment might thus be complemented by the scores.  
 
5.1.5 Predictive performance of the onco-geriatric scores  
Predictive performance of the onco-geriatric scores for toxicity during therapy course 
The CARG and the CRASH score exhibited a similar adequate predictive performance for 
severe overall and nonhematologic toxicity. For predicting severe hematologic toxicity, the 
hematologic CRASH score should be preferred to the CARG score.  
In general, the more a ROC-AUC approaches 1, the better the discrimination [115]. For overall 
toxicity, the CARG score and the combined CRASH score were relatively far from 1, showing a 
ROC-AUC of 0.681 and 0.650, respectively. However, these ROC-AUC results were close to 
Discussion    111 
 
those reached in the validation study of the CARG score (0.65) and the combined CRASH score 
(0.64) [68, 83]. Those, in general, rather low ROC-AUC values are consistent with the finding 
that a geriatric assessment predicts therapy-related toxicity rather moderately at the 
individual patient level [20]. This might be caused by the high number of factors influencing 
the individual toxicity risk [20]. The proportion of patients with overall toxicity increased with 
higher score category in our study. However, this did not reach statistical significance which 
might be explained by the moderate sample size. For hematologic toxicity, the hematologic 
CRASH score performed better than the CARG score (AUC-ROC 0.665 vs 0.564, respectively) 
which was consistent with our expectations since the hematologic CRASH score was 
developed for this type of toxicity [68]. 
The predictive value of the CARG score has been assessed in different studies. In a recent study 
by Moth et al., the CARG score did not show a predictive value for patients with solid tumors 
(AUC-ROC 0.52; OR 1.04; p = 0.54; no increase of toxicity incidence with CARG score risk 
category) [73]. Contrary to our study, Moth et al. did not include hematologic malignancies. 
For prostate cancer patients, Alibhai et al. could not demonstrate a predictive value of the 
CARG score either (AUC-ROC 0.54; OR 1.09; p = 0.58). Toxicity increased with the CARG score 
category but not significantly (p = 0.65) [72]. However, the study of Alibhai et al. was limited 
by a relatively small sample size of 46 patients. In lung cancer patients, Nie et al. observed that 
toxicity incidence increased significantly with higher CARG risk category [71]. Of note, this 
study amended the CARG score by deleting the item tumor type as all patients were lung 
cancer patients, and by applying new cut-off values for risk categories. Nishijima et al. found 
that patients with a CARG score of ≥ 10 experienced toxicity more often than patients with a 
CARG score of < 10, being similar to our results [74]. 
For adjusting the scores to our patient cohort, the Youden index suggested that the cut-off 
values of the scores might be slightly changed. Regarding overall toxicity, the CARG score 
would exhibit an ideal cut-off between the mid and high category at ≥ 9, thus one point lower 
than the original cut-off at ≥ 10 [67]. For the combined CRASH score, a cut-off at ≥ 8 instead 
of ≥ 10 [68], might be ideal. The cut-offs for differentiating between the categories low and 
mid were difficult to assess due to the small patient numbers in the low category. The 
sensitivity and specificity for the optimal cut-offs were moderate, ranging between 0.6 and 
0.7. As discussed in section 5.1.3, more toxicity occurred in this evaluation study than during 
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the development studies of the onco-geriatric scores. Hence, only the categorization of the 
scores (low-mid-high) can be deemed appropriate, but not the exact percentages of toxicity 
risk per score value being derived from the development studies. Problems with calibration-
in-the-large (systematic under- or overprediction in external cohorts) occur frequently in 
predictive models [135].  
Since both scores indicated a similar predictive performance for overall and nonhematologic 
toxicity, other factors are decisive for determining which score to use. Since the CARG is 
quicker and easier to use compared to the CRASH score [62], the CARG score may be preferred 
in busy daily routine. However, if estimates for hematologic toxicity are needed, the CRASH 
score is preferable. The CRASH score could also be incorporated in a full CGA as it already 
comprises various detailed geriatric assessment tools [70].  
The impact and implementation of a risk prediction model are two essential issues during the 
evaluation process [136, 137]. Models which do not change behavior are not useful [138]. 
However, those steps are not yet fully assessed for the CARG score and the CRASH score. Thus, 
further studies should be conducted for evaluating their use and value in clinical routine.  
The applicability of the onco-geriatric scores is broad: Clinical trials may use these scores as 
tools for risk stratification. In clinical routine, the onco-geriatric scores could be applied for a 
shared decision-making since toxicity is an important aspect for the therapy decision of 
patients [66]. The prediction of toxicity might also allow for better therapy individualization, 
possibly reducing under- and overtreatment of older cancer patients. However, the scores 
may only support and should not fully substitute the clinical decision-making process. Clinical 
decisions should consider more than only toxicity, for instance life expectancy or patient 
preferences. For judging those areas, other instruments exist: For example, life expectancy 
can be evaluated by the Onco-MPI (Oncological-Multidimensional Prognostic Index) [139]. A 
study by Moth et al. found that 83.3% (25/30) of physicians judged the CARG score as useful 
– but for most physicians, the CARG score did not influence treatment decisions. Reasons for 
that were for example missing familiarity with the score or problems translating the score 
results into a modification of therapy [140]. Furthermore, the scores might be used in other 
fields. The CARG score has also shown to be predictive for frailty [141] and hospitalization [74]. 
Also, the CARG score and the CRASH score were deemed as useful screening tools for 
detecting geriatric patients in need for a CGA [142].  
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Predictive performance of the onco-geriatric scores for toxicity at start of therapy 
Since most of the toxicity occurred when therapy started, it was assumed that the onco-
geriatric scores may also predict toxicity at start of therapy. For overall and nonhematologic 
toxicity, this was also the case in our study – but not for hematologic toxicity. The hematologic 
CRASH did not demonstrate any superiority compared to the CARG score for predictions at 
start of therapy. This might be due to the fact that a higher proportion of hematologic toxicity 
occurred later during therapy course than nonhematologic toxicity.  
Time-related predictions 
Both scores generally indicated a faster onset of toxicity in the high category compared to the 
low category. Thus, the scores may not only give information about whether severe toxicity 
occurs but also about when. This might be critical for patients because longer times until onset 
of toxicity imply a longer preservation of an adequate quality of life and a prevention of early 
toxicity-related therapy modifications. 
The CARG score categories low vs high were significantly associated with the time to severe 
overall, hematologic, and nonhematologic toxicity. The hematologic CRASH score indicated a 
significantly faster onset of hematologic toxicity in the high category as well. In line with the 
results regarding the predictive performance for hematologic toxicity at start of therapy, the 
hematologic CRASH score was not superior to the CARG score. For overall and nonhematologic 
toxicity, however, the hazard ratio between the CRASH score categories difference in time 
until onset of severe toxicity was not significant. The lack of significance might be due to the 
uneven distribution of patients in the categories: The low CRASH category consisted of only 
24 patients, compared to 89 patients in the high category. In contrast to this, the CARG score 
split the patient cohort more evenly (low: 63 patients, high: 50 patients). In general, only the 
first part of the Kaplan-Meier plot could be reasonably assessed due to the low patient 
numbers in time points after approximately 10 weeks. Therefore, the crossing of the CRASH 
score curves towards the end of the follow-up was not considered as violation of the Cox 
regression assumption. Further research should be conducted to verify this exploratory 
Kaplan-Meier analysis in a larger patient cohort. Regarding data collection, it must be 
considered that the middle of the cycle was assumed as the time point of onset of toxicity 
since the actual day of onset was mostly not available. Thus, the results could be diluted to a 
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certain extent. However, since the scores exhibited such a clear difference in the time until 
onset of toxicity, this is unlikely to have influenced the overall conclusion. 
Predictive performance of the onco-geriatric scores for symptom burden 
Patients’ total severe symptom burden (PRO-CTCAE ≥ 75%) was better predicted by the 
combined CRASH score than by the CARG score. This is the first study investigating onco-
geriatric scores regarding patient-reported outcomes. Since a high percentage of PRO was 
missing, all patients who could be followed at least during one cycle were considered for the 
analysis to include the maximum information available. However, possible misclassification of 
patients without complete follow-up must be considered when interpreting results. Due to 
the nature of patient-reported outcomes, toxicity based on laboratory variables (e.g. 
neutropenia) could not be measured directly via PRO. Therefore, some parts of the assessed 
toxicity during the development of the scores were missing. For this analysis, the patients’ 
total severe symptom burden was considered in order to focus on the general health condition 
of the patient. In future studies, separate analyses of the different symptoms might be 
conducted for investigating if the scores can provide a higher predictive performance for one 
of the individual symptoms. As previously discussed in section 5.1.3, the mode of asking the 
questions, the time point of contacting patients, and the missing data, might limit 
generalizability of the results. However, since patient-reported outcomes play an increasing 
role in oncology, this exploratory analysis is an essential contribution to further research in 
this field.  
Predictive performance of the onco-geriatric scores for alterations of the planned treatment 
Both scores exhibited a good predictive performance for major alterations of the planned 
treatment and the time to those alterations. This is the first study evaluating the potential of 
onco-geriatric scores for the prediction of the alterations of planned treatment. Presumably, 
the prediction of major alterations with a score for toxicity prediction should be possible since 
discontinuations and changes are often caused by severe toxicity. This finding is consistent 
with literature where different domains of the geriatric assessment (e.g. ECOG performance 
status, renal function) have shown to be associated with the completion of chemotherapy as 
planned [133]. Interestingly, for minor alterations, the CARG score and the CRASH score 
demonstrated a tendency to inverse predictions: With higher risk categories, patients 
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experienced fewer minor alterations. This might be explained by the fact that for patients with 
a higher risk, and thus a worse health status, consequences of toxicity might be rather severe, 
leading to less minor modifications but instead rather to discontinuations or changes of 
therapy regimen (major modifications). 
 
5.1.6 Prediction of severe toxicity by other predictive factors  
ECOG, age, and physicians’ judgement 
Neither physicians’ judgment nor the commonly used predictors ECOG performance status 
and age indicated adequate predictive performance for overall toxicity. 
Two previous studies investigated the physicians’ judgment vs the CARG score prediction [72, 
73]. Consistent with our results, those studies did not observe an adequate predictive 
performance of physicians’ judgment. However, both studies did not find an adequate 
predictive value of the CARG score either [72, 73]. Contrary to these results, in our patient 
cohort, the CARG score and the CRASH score predicted overall toxicity better than physicians’ 
judgment. This result is also in line with the finding that a CGA may be more effective in 
selecting older patients for aggressive chemotherapy than physicians [45]. Moreover, a CGA 
was found to identify different patients as fit for chemotherapy than clinical judgment [143]. 
In general, these results underline the value of onco-geriatric scores in supporting physicians 
during the decision-making process. However, the results of the evaluation study also need to 
be differentiated between the different toxicity types: In our study, the physicians’ judgment 
for hematologic toxicity performed better than the physicians’ judgment for overall and 
nonhematologic toxicity. 
Age and ECOG are commonly used for estimating the risk of cancer therapies in older patients 
[45]. In this evaluation study, age alone did not adequately predict toxicity. This is in line with 
our expectations since aging is a highly individualized process [13]. The ROC curve for age was 
located below the line of identity, suggesting that higher age was associated with less toxicity. 
This might be caused by the tendency to treat patient of higher age with less toxic regimens 
[12]. The ECOG performance status did not adequately predict toxicity neither for overall nor 
for hematologic toxicity. However, for nonhematologic toxicity, ECOG might be more useful. 
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Those results are consistent with the poor results obtained in the comparison of the CARG 
score with the Karnofsky performance status (KPS), another commonly used performance 
status. In the development study of the CARG score, the proportion of patients with overall 
toxicity increased for the CARG score categories (low: 30%, mid: 52%, high: 83%) whereas the 
KPS did not differentiate well (KPS 90-100%: 51%, KPS 80%: 51%, KPS ≤ 70%: 62% [67]). The 
validation study of the CARG score and a study with lung cancer patients yielded similar results 
regarding the KPS [71, 83]. Nevertheless, an Australian survey indicated that the performance 
status is still the most important factor for oncologists in decision-making [144]. 
Individual CARG and CRASH score items 
Surprisingly, most individual score items did not indicate a significant association with severe 
overall toxicity when analyzed separately. This suggests a substantial synergistic power of the 
items since combined within one score, toxicity was mostly predicted significantly. For the 
CARG score, hemoglobin was the only significant item and for the CRASH score, LDH. These 
results are interesting since merely laboratory variables exhibited an association – although 
geriatric assessment variables are deemed highly important for determining the health status 
of an older patient [13]. The hemoglobin OR of 4.036 (1.110-14.683) was higher in our study 
than during the CARG development study, but the OR was located within the confidence 
interval of the CARG study (OR 2.31, CI 1.15-4.64) [67]. The OR of the LDH was 6.980 (1.432-
34.035), being higher than the OR reported in the CRASH development study for hematologic 
toxicity (no OR reported for overall toxicity) [68]. However, this value might be interpreted 
with caution since the number of patients in the low LDH category solely consisted of seven 
patients in our study.  
Tumor type was not associated with severe overall toxicity in this evaluation study. In contrast, 
Hurria et al. included tumor type (genitourinary/gastrointestinal vs others) into the CARG 
prediction model [67]. However, our results are in line with those by Extermann et al. who 
observed that tumor entities do not exhibit a substantial influence on toxicity [68]. This 
supports the assumption that both scores are valid across tumor entities, thus also for 
hematologic malignancies. The type of treatment denoted a significant association with 
toxicity, confirming the previous expectation that targeted or immunotherapies imply less 
toxicity than chemotherapy. The toxicity of treatment is already considered in the CRASH 
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score by the MAX2 index [68] and in the CARG score by the variable “monotherapy vs 
polytherapy” [67].  
In literature, heterogeneous results were found regarding predictors for toxicity: A systematic 
review reported that in five of 13 studies, tumor type and chemotherapy regimen were 
associated with chemotherapy toxicity, older age was associated with toxicity in three out of 
nine studies, and cognitive impairment was associated with chemotherapy toxicity in two out 
of six studies [145]. The only significant predictors of the CARG and CRASH score in this study, 
hemoglobin and LDH, were not mentioned as predictors in this review. A review by Versteeg 
et al. did not find any consistency in predictive factors for toxicity from a geriatric assessment 
either [54]. Contrary to the results of our study, a secondary analysis of the CARG development 
study found that renal function was associated with an increase in chemotherapy-related 
toxicity [146].  
Since some items only consisted of few patients per category, logistic regression results should 
be interpreted with caution. For further analysis, a study with a larger patient cohort should 
be conducted where a multivariate logistic regression analysis could be performed to adjust 
for covariates.  
 
5.2 Medication risk analysis 
Medication risks were common in older cancer patients even before start of cancer therapy: 
52.2% of patients were exposed to polymedication, 52.9% to potentially inadequate 
medication (PIM), and 30.9% to relevant potential drug-drug interactions (rPDDI). Their 
prevalence increased after start of cancer therapy. rPDDI were significantly associated with 
the adverse outcome of severe overall and hematologic toxicity. 
 
5.2.1 Study set-up 
Patients from the pilot and evaluation study were pooled in order to increase the sample size 
and enhance validity of the findings. Since eligibility criteria were similar, pooling was 
justifiable. The only difference in eligibility criteria, the performance of tumor therapy, was 
considered by only including patients actually starting therapy. Since merely 16/136 (11.8%) 
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patients originated from the pilot study, the patient characteristics mainly corresponded to 
those of the evaluation study, being previously discussed in section 5.1.1.  
A strength of this study was the investigation of two distinct time points which allowed 
analyzing the changes in medication before and after the start of cancer therapy. Moreover, 
we considered the association with adverse outcomes for patients, being essential for 
assessing the clinical implications of our findings.  
Regarding limitations, the retrospective character of this analysis should be mentioned. The 
documentation of drugs in the medical records might have been incomplete, leading to an 
underestimation of drug use. Probably, more drugs – in particular nonprescription drugs (only 
being 96/683 in this analysis) – could have been detected if patients had been specifically 
interviewed by a pharmacist concerning medication use. Moreover, information on the 
duration and rationale of drug use was partly missing due to the retrospective design, limiting 
judgment of PIM. However, this concern was addressed by selecting an explicit PIM list, 
requiring little additional data. A further limitation is the moderate sample size of the analysis. 
Nevertheless, by pooling of data, a higher sample size was reached. Further studies with a 
prospective design and a larger patient cohort are needed to corroborate results.  
 
5.2.2 Polymedication 
On average, patients took 5 (SD, 3.5) drugs as long-term medication before start of cancer 
therapy. Interestingly, the cohort of the CARG score development study (n = 500) was also 
investigated regarding polymedication and PIM use. This secondary analysis indicated a mean 
of 5 (SD, 4) drugs per patient [67, 147], consistent with our results. Turner et al. investigated 
the medication of 385 older cancer patients via a self-reported medication data instrument 
which patients completed before the initial appointment at an outpatient oncology clinic. This 
study found a mean of 5.7 (SD, 3.7) drugs per patient, in line with our findings [25]. Nightingale 
et al. detected an average of 9.2 drugs per patient [38]. The higher prevalence might be 
explained by the different study designs: Nightingale et al. evaluated the medication being 
documented during a pharmacist-led comprehensive medication assessment. Since patients 
were advised to bring their complete medication during this session, it seems plausible that 
the study found a higher number of drugs. The study detected that 26.5% of patients used 
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complementary and alternative medication like herbal medicines or dietary supplements in 
this cohort [148], and on average three OTC or herbal drugs were taken [38]. Neglecting those 
three nonprescription drugs per patient, which our study might not have found due to the 
study design, Nightingale et al. presented similar results as our study.  
Half of the patients demonstrated polymedication (≥ 5 drugs) and 10.3% of patients 
hyperpolymedication (≥ 10 drugs) in our analysis. Turner et al. found a prevalence of 57% for 
polymedication and 15% for hyperpolymedication [25], which is in line with our findings. 
Prithviraj et al. detected that 80% of older cancer patients used five or more drugs prior to 
start of treatment [26] whereas Alkan et al. found a prevalence of 30.8% taking at least five 
drugs [149]. A review by Sharma et al. indicated that polymedication prevalence for older 
cancer patients ranges from 11% to 96% in literature [22]. Varying definitions of 
polymedication might play a role for this variability [22] but also differences in data collection 
(e.g. interview by a pharmacist vs self-reported data collection form) and in counting of drugs 
(e.g. counting per active ingredient vs per medicinal product).  
The two most prevalent drug classes of this study cohort were antithrombotic agents and 
agents acting on the renin-angiotensin system. This corresponds with the two most frequent 
drug classes observed by Turner et al. [25].  
The high prevalence of polymedication in older cancer patients is important for health care 
providers to be aware of, due to its association with various risks, like frailty and decreased 
physical function [25, 27]. Moreover, the number of drugs was associated with a higher risk of 
therapy-related toxicity in some studies [22], see section 5.2.6. However, when considering 
the clinical impact of polymedication, it is essential to point out that a high number of drugs 
is not per se inappropriate for older patients [150].  
 
5.2.3 Potentially inadequate medication 
The appropriateness of medication use is considered in this study via PIM screening. Patients 
took in median 1 (range, 0-5) PIM drug in their long-term medication and more than half of 
the patients used at least one PIM drug in this analysis, according to the EU(7)-PIM list. This 
result is within the range of the previously reported PIM prevalence for the general older 
population: A systematic review found that using administrative data, the prevalence of PIM 
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ranged between 11.5% and 62.5%, varying widely due to different methods and cohorts [151]. 
Regarding older cancer patients, a secondary analysis of the CARG study cohort found that 
29% of patients used at least one PIM drug (2012 Beers criteria) before start of treatment 
[147]. Other studies in older cancer patients detected prevalence rates of 40% and 26.5% 
using the 2012 Beers criteria [38, 152]; a prevalence of 38% was found following STOPP criteria 
[38]. Recent studies used the 2015 Beers criteria and detected a higher prevalence of PIM 
drugs for older cancer patients, being closer to the results of this study: Analyzing an 
epidemiologic database, Feng et al. detected a PIM prevalence of 61.7% for breast cancer, 
47.3% for prostate cancer, and 66.3% for colorectal cancer patients during therapy [153]; 
Moreira Reis et al. found that 48.1% of older cancer patients receiving parenteral cancer 
therapy used at least one PIM drug [37]. Patients in these studies had already started cancer 
therapy which may have increased PIM burden. However, the 2015 Beers update also 
generally presents a higher PIM prevalence compared to its 2012 version since the 2015 
update includes proton-pump inhibitors [154].  
The EU(7)-PIM list has been used in other cohorts like cognitive impaired patients [155], but 
this is the first study assessing PIM use of older cancer patients with the EU(7)-PIM list. This 
limits comparison with literature since different explicit PIM lists are heterogeneous in 
content [156]. However, Morin et al. found that different explicit PIM lists may yield similar 
results of PIM prevalence if used at the population level [157]. 
The most frequently applied PIM drug class in the study by Moreira Reis et al. comprised 
proton-pump inhibitors (PPI) in 33.3% of patients [37], corresponding to our findings where 
PPI were the most prevalent PIM drugs by far. PPI are deemed inappropriate in long-term use, 
since they can increase the risk of Clostridium difficile infections and hip fractures [33]. The 
EU(7)-PIM list only classifies PPI as PIM if taken longer than 8 weeks. Mostly, information on 
the duration of usage was missing in this study. Since PPI are often used for a longer time 
period in general, it was assumed that counting them as PIM in case of missing information 
would reflect reality best. However, this approach might have led to an overestimation of PIM 
prevalence. 
An inherent limitation of explicit PIM lists is the generalization of drugs being inappropriate, 
instead of assessing the clinical situation of an individual patient. However, due to lacking data 
(e.g. diagnoses), implicit PIM lists would not have been reliable in this study. Moreover, 
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explicit tools are more widely used in clinical routine [158], allowing for a better 
transportability of results into clinical practice. Nevertheless, explicit criteria may not consider 
new drugs being released after compiling of the PIM list. For instance the EU(7)-PIM list does 
not mention edoxaban although rivaroxaban or apixaban are listed [33].  
Whitman et al. recommended using several PIM lists concomitantly for assessing PIM use of 
older patients since that bears complementary effects [125]. In a study with a pharmacist-led 
medication assessment, analysis via three combined tools (Beers, START/STOPP, and MAI 
score) discovered three times more PIM drugs than by using Beers criteria alone [159]. Future 
prospective studies with more clinical data, might combine the EU (7)-PIM list with other 
instruments like for instance the START/STOPP criteria or the FORTA list [34, 35].  
The clinical impact of a high PIM burden is controversial for the cohort of older cancer 
patients. Two recent studies by Karuturi et al. questioned an association of PIM with adverse 
outcome, analyzing an epidemiologic database regarding older patients with breast and 
colorectal cancer. Instead, the authors hypothesized an association of outcomes with 
polymedication [160, 161]. However, these findings still require prospective verification. 
Sharma et al. acknowledged reasons for the lack of an association in geriatric oncology: For 
example, some PIM might not be harmful in older cancer patients but instead necessary for 
supportive therapy and end-of-life medicine. There also might still exist too few and too 
heterogeneous studies to show an association [22]. 
 
5.2.4 Relevant potential drug-drug-interactions  
Approximately one third (30.9%) of patients experienced rPDDI in their long-term medication 
in this study. In literature, the results vary: Popa et al. observed a prevalence of 75.4% for 
potential drug-drug interactions of older cancer patients during therapy [43], a substantially 
higher value than in our analysis. This might be due to the inclusion of antineoplastic agents 
but probably primarily results from the inclusion of all interactions, disregarding severity 
grades. Of note, a large percentage of the interactions found by Popa et al. demonstrated only 
minor clinical significance [43]. Considering all severity grades in our study, 56.6% of patients 
would have shown interactions. Yeoh et al. found 55.1% of older cancer patients being 
exposed to potential drug-drug interactions [15]. This finding was higher than in our study and 
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might be explained by the fact that the study also included cancer therapy agents. Also, the 
study only enrolled patients taking at least three long-term drugs. In general, other studies in 
literature bear limited comparability due to the different methods for interaction detection. 
Our study used the ABDA database classification system which is very common in Germany 
but rather unknown in other countries. Different interaction information systems have 
presented deviant listing of interactions and variant severity classifications [162, 163].  
Most rPDDI detected in this analysis were classified as “monitoring/modification needed” 
according to the ABDA database classification; no contraindications were found in the long-
term medication. These are positive findings, indicating no highly serious issues for patients.  
Yeoh et al. found statins and sulfonylureas to be frequent interaction partners [15]. In our 
study, those drug classes were also involved in frequent interactions types (anti-diabetic drugs 
– corticosteroids, simvastatin – amlodipine). The most frequent interaction partners in our 
study comprised agents acting on the renin-angiotensin system and beta blockers. These drug 
classes also belonged to the most frequently administered ones in general. However, health 
care providers should be especially vigilant about the drug classes “cardiac therapy” (ATC code 
C01) and “corticosteroids for systemic use” (ATC code H02), showing the highest potential of 
provoking interactions when prevalence was considered. The high interaction propensity of 
the drug class “cardiac therapy” was caused by the interaction between amiodarone and beta 
blockers (ABDA database category: Monitoring or modification needed) which may lead to 
additive cardiodepressant effects [126]. Corticosteroids indicated a high interaction 
propensity due to a frequent interaction between corticosteroids and antidiabetic drugs 
(ABDA database category: Monitoring or modification needed) [126]. The blood glucose 
lowering effects of antidiabetics are attenuated by corticosteroids [126].  
The clinical consequences of those drug-drug interactions might be severe: A retrospective 
study indicated that about 2% of unplanned hospitalizations of cancer patients were caused 
by drug-drug interactions [44]. However, when interpreting the results of our study, it is 
important to consider that all these drug-drug interactions are merely potential. If they are 
clinically relevant remains unclear, indicating an interesting field of further research.  
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5.2.5 Antineoplastic agents and supportive care medication 
At start of cancer therapy, patients received in median six additional drugs due to either 
antineoplastic agents or supportive care medication. This finding depends largely on the 
tumor entities and the applied therapy regimens. That limits the generalizability to other 
patient cohorts with e.g. mostly targeted or immunotherapy regimens, frequently comprising 
only a low number of antineoplastic agents.  
Potentially inadequate medication 
More than one third of patients received additional PIM drugs after start of therapy. The most 
commonly used additional PIM drug after start of cancer therapy was ranitidine, bearing the 
risk of CNS adverse effects like confusion [33]. If Ranitidine was only used as premedication 
(e.g. in paclitaxel regimens) the drug was not considered as PIM since this study only took into 
account supportive therapy which was used more than once per cycle for enhancing clinical 
relevance of findings. Nevertheless, Ranitidine still remained the most common PIM drug. 
Whereas this study was interested in the additional PIM burden by antineoplastic agents and 
supportive care medication, several studies in literature analyzed the overall PIM burden after 
start of therapy. Considering our results, it would be likely for overall PIM burden to increase 
after start of therapy. Interestingly, epidemiologic studies in literature do not support this 
expectation: Karuturi et al. found a decrease of PIM prevalence in older patients after the 
diagnosis of breast or colorectal cancer (PIM prevalence breast cancer: pre-chemotherapy 
36.6% vs 0-3 months after start of chemotherapy 27.9% vs 3-6 months after start of 
chemotherapy 20%) [160]. Hence, some PIM drugs in long-term medication might be 
discontinued after the start of cancer therapy, reducing the overall PIM burden. For breast 
cancer patients, Lund et al. explained the decrease in overall PIM burden by the 
discontinuation of estrogen [164].  
This study conducted a cross-sectional analysis at the first therapy cycle. Thus, this analysis 
might have underestimated the total risk of PIM arising during therapy course. However, Leger 
et al. observed the PIM use in 122 older patients with hematologic malignancies at start of 
therapy and after three months, not finding a significant difference between percentages of 
patients with PIM [165].  
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Since some PIM are required as pre-medication or supportive care medication in cancer 
therapy, the benefit-risk assessment of some PIM drugs in cancer patients may differ from 
other older patients. The NCCN guideline lists various drugs which might be of concern for 
elderly patients but which are commonly used for supportive therapy [19]. This includes for 
example corticosteroids used in the prevention of nausea and emesis [19]. About 45% of the 
NCCN templates for therapy regimens in hematologic cancer patients comprise at least one 
PIM drug [166]. Our analysis included all PIM drugs because, regardless of its use in supportive 
therapy, they bear certain risks in older patients which physicians should be aware of. Also, 
the aim of this study was to measure the risk potential of the medication, not the 
appropriateness of physicians’ prescriptions. In literature, this issue was handled differently: 
Maggiore et al. separately analyzed PIM including and excluding the agents being used in 
supportive therapy regimens [147], Moreira Reis et al. incorporated all PIM drugs for the same 
reasons as in our study [37]. Only a slight difference in prevalence was found by Feng et al. 
when neglecting the appropriate PIM drugs for cancer patients compared to including all PIM 
drugs [153]. Therefore, the exclusion of those PIM drugs being commonly used for supportive 
therapy would probably not have altered the prevalence of PIM to a large extent. However, 
when interpreting the results, it should be kept in mind that in a cohort of cancer patients for 
some PIM drugs , the benefit-risk assessment might be positive. Maggiore et al. suggested the 
development of specific geriatric oncology-centric definitions of polymedication and PIM use 
in order to satisfy the special needs of this cohort [147].  
Relevant potential drug-drug interactions 
About one third of patients demonstrated additional rPDDI between the 
antineoplastic/supportive care medication and the long-term medication after start of cancer 
therapy. Those additional rPDDI included higher severity grades than the rPDDI between only 
long-term medication. Therefore, it is important to review medication for new rPDDI after 
initiating cancer therapy. The results of this analysis advise particular caution when prescribing 
serotonin 5-HT3 receptor antagonists due to the severity of triggered rPDDI. The two most 
severe interaction types were both caused by serotonin 5-HT3 receptor antagonists due to 
their QT prolonging properties (QT prolonging drug – antiarrhythmic agent: Serious 
consequences possible – as precaution contraindicated (n = 3); QT prolonging drug – 
antidepressant: Simultaneous usage not recommended (n = 3)). The QT prolongation might 
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be of special concern in older patients who commonly demonstrate cardiovascular risk factors. 
Moreover, special attention is required when administering corticosteroids and antibiotics. 
Whereas corticosteroids were the drug class most frequently causing rPDDI (most frequent 
interactions: NSAID – corticosteroids; anti-diabetic drugs – corticosteroids), antibiotics were 
the drug class with the highest interaction propensity due to numerous interactions between 
trimethoprim and ACE inhibitors/sartans causing a higher risk of hyperkalemia [126]. 
 
5.2.6 Association of long-term medication with severe toxicity 
Occurrence of polymedication in long-term medication was not associated with either overall, 
hematologic, or nonhematologic grade ≥ 3 toxicity in our analysis. However, the number of 
drugs per patient was associated with nonhematologic toxicity. In literature, results were not 
consistent regarding the association between the number of drugs and severe toxicity in older 
cancer patients [22]. In line with our results, a secondary analysis of the CARG development 
study did not find an association of the number of daily drugs before start of chemotherapy 
and overall chemotherapy-related toxicity [147]. In contrast, Hamaker et al. detected a 
significant association between baseline polymedication and severe toxicity during cancer 
treatment of older metastatic breast cancer patients [28].  
PIM use was associated with grade ≥ 3 toxicity for nonhematologic toxicity only. Similar results 
are found in literature: Maggiore et al. did not report any association between PIM use and 
overall grade ≥ 3 toxicity, regardless of the applied criteria (categorized according to Beers 
2012, Zhan criteria, and Drugs to Avoid in the Elderly (DAE) criteria) [147]. Likewise, Park et al. 
did not find any relationship between PIM use (Beers 2012) and treatment-related toxicity in 
head and neck cancer patients of high age [167].  
Occurrence of rPDDI was significantly associated with grade ≥ 3 overall and hematologic 
toxicity in our study. However, all but two of the patients with rPDDI experienced severe 
toxicity. This uneven distribution might have influenced results for overall toxicity. A study by 
Popa et al. indicated that potential drug-drug interactions were not associated with grade 4 
hematologic toxicity [43]. In contrast, grade ≥ 3 nonhematologic toxicity was significantly 
associated with potential drug-drug interactions of higher severity (“level 1-3”) in that study. 
126  Discussion 
 
These results might differ from our study because another software for classifying potential 
drug-drug interactions was used. 
Because different medication risks, especially drug-drug interactions, suggest an association 
with severe toxicity in this cohort, interventions for improving prescribing quality are 
warranted. Assessing polymedication, PIM, or drug-drug interactions can reveal essential risks 
but does not show the whole picture regarding quality of medication use. Thus, interventions 
should preferably consist of a medication review going beyond simple drug counting and PIM 
lists, as recommended in the NCCN guidelines [19]. If possible, a multidisciplinary approach 
including a clinical pharmacist should be pursued [41, 168]. First results of interventions are 
promising: For older cancer patients, Deliens et al. found that a clinical pharmacist could 
significantly reduce PIM of patients hospitalized in a geriatric oncology unit [169]. Nightingale 
et al. reported a reduction of the average number of drug-related problems by 45.5% via a 
pharmacist-led, individualized medication assessment [17]. For cancer patients in general, a 
systematic review concluded that interventions by pharmacists may improve outcomes of 
cancer patients [170]. Further studies are necessary to investigate if interventions may also 
improve outcomes in the cohort of older cancer patients.  
A limitation of this analysis is the relatively small sample size and the univariate approach. A 
multivariate analysis in a larger sample size should be conducted to corroborate results. 
Moreover, apart from toxicity, other patient-relevant endpoints like hospitalization or survival 
could be of interest for further analyses. 
  
5.3 Conclusion and outlook 
This is the first study directly comparing the CARG and the CRASH score for the prediction of 
therapy-related toxicity at advanced age in the clinical routine setting.  
As both onco-geriatric scores presented a similar predictive performance, in general, none 
could be recommended above the other. However, the CARG score needs less time and hence 
might be preferable in busy routine due to its ease of use [62]. The hematologic CRASH score, 
in contrast, should be preferred if a more detailed estimation of hematologic toxicity is 
required. Despite a similar predictive performance, the onco-geriatric scores predicted 
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different risks, thus not being completely interchangeable. Both scores suggested better 
toxicity predictions than the physicians’ judgment alone and hence might be useful in 
supporting clinical decisions. Moreover, the onco-geriatric scores indicated a better predictive 
performance for overall toxicity than the commonly used predictors ECOG performance status 
and age. 
This study indicated that the CARG and the CRASH score may be applied in a patient cohort 
with hematologic tumors and combinations of chemotherapy with targeted or 
immunotherapies. Since targeted therapy and immunotherapy play an increasing role in 
cancer therapy, future studies should investigate the toxicity prediction for those therapies in 
more detail. Exploratory analyses suggested that both scores may also be useful for predicting 
the time until onset of severe toxicity, as well as the occurrence of major therapy alterations 
of the planned treatment (discontinuations or changes). Furthermore, an explorative analysis 
found that the CRASH score might be valuable for predicting severe patient-reported 
symptom burden. Since patients have shown to report severe toxicity earlier and more 
frequently than physicians [97], it might be interesting to further investigate the application 
of the onco-geriatric scores for predicting patient-reported outcomes.  
The analysis of medication risks in older cancer patients indicated that even before start of 
cancer therapy, medication risks were common: More than half of patients were exposed to 
polymedication and potentially inadequate medication (PIM) use; one third exhibited relevant 
potential drug-drug interactions (rPDDI). The most frequent PIM drugs in long-term 
medication were proton-pump inhibitors. The drug classes with the highest potential of 
provoking interactions comprised cardiac therapy (ATC code C01) and corticosteroids for 
systemic use (ATC code H02). After start of cancer therapy, the risks in the medication 
increased: One third of patients exhibited additional PIM drugs and one third additional rPDDI. 
Regarding supportive therapy, especially serotonin antagonists and antibiotics should be used 
with caution, due to their high potential of interactions, respectively. In a univariate analysis, 
the occurrence of rPDDI was associated with a higher risk for patients to develop overall or 
hematologic toxicity. A multivariate analysis in a larger sample size should be conducted to 
further investigate the association between medication risks and severe toxicity in this cohort. 
Showing that risks in the medication of older cancer patients are common and may be 
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associated with toxicity, this raises the need for multi-disciplinary interventions to optimize 
medication use in this cohort.  
To conclude, by assessing onco-geriatric scores for toxicity prediction and by evaluating 
medication risks, this work contributed to further improvements in the pharmacotherapy of 
older cancer patients. 
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6 Summary 
The cancer therapy of older patients is challenging, being more complex than the therapy of 
younger patients. Older cancer patients show a higher toxicity risk during therapy and drug-
related problems are common. In order to individualize cancer care in this heterogeneous 
population, short tools combining geriatric assessment with oncologic parameters were 
developed for predicting toxicity during chemotherapy: the CARG (Cancer and Aging Research 
Group) and the CRASH (Chemotherapy Risk Assessment Scale for High Age Patients) score. 
The aim was to compare the scores regarding their predictive performance in a clinical routine 
setting. Moreover, this thesis aimed at evaluating medication-related risks in older cancer 
patients. 
In a prospective, single-center observational study, the CARG and the CRASH score were 
assessed for patients ≥ 70 years before the start of their systemic cancer treatment. The CARG 
score predicts severe overall toxicity. The CRASH score is divided into three subcategories, 
predicting severe overall, hematologic, and nonhematologic toxicity. Moreover, physicians’ 
judgments regarding the patients’ toxicity risk were documented. Grade ≥ 3 toxicity according 
to the Common Terminology Criteria for Adverse Events (CTCAE) was captured from medical 
records. The predictive performance of the scores was assessed by analyzing the proportion 
of patients with severe toxicity per risk category, logistic regression, and the area under the 
receiver operating characteristic curve (ROC-AUC). Furthermore, the prediction performance 
was compared with other commonly used predictors. The evaluation study of the CARG and 
the CRASH score comprised 120 patients (50% female, mean age 77.2 years). Severe toxicity 
was experienced by 81% of patients; 67% showed signs of hematologic toxicity. The predictive 
performances of the CARG score and the combined CRASH score were similar for overall and 
nonhematologic toxicity. For hematologic toxicity, the hematologic CRASH score performed 
better than the CARG score. Neither physicians’ judgment nor the ECOG nor age indicated 
adequate predictive performance for overall toxicity.  
Medication risks in older cancer patients were investigated regarding polymedication (defined 
as the use of ≥ 5 drugs), potentially inadequate medication (PIM; defined by the EU(7)-PIM 
list), and relevant potential drug-drug interactions (rPDDI; analyzed by the ABDA interaction 
database). Before the start of cancer therapy, patients took on average 5 drugs as long-term 
medication and 52% of patients were exposed to polymedication. More than half of patients 
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used at least one PIM (mostly drugs for acid-related disorders). Approximately one third of 
patients experienced rPDDI.  
In conclusion, the CARG and the CRASH score exhibited similar predictive performance for 
overall and nonhematologic toxicity. However, the hematologic CRASH score should be 
preferred for predicting hematologic toxicity. Both scores performed better than clinical 
judgment alone and thus may be used for supporting therapy decisions in clinical routine. 
Medication risks were common in older cancer patients, raising the need for interdisciplinary 
interventions to ensure medication safety in this cohort.  
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IADL (Instrumental activities of daily living) 
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MMSE (Mini-Mental State Examination)  
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MNA (Mini Nutritional Assessment)  
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CRASH scoring for chemotherapy toxicity (MAX2 Index) by analogy 
Score points were derived by analogy as recommended [68] or by the supplementary MAX2 
list provided by Extermann to the author of this thesis 
Therapy regimen* 
CRASH score 
points 
Rituximab-Mini-CHOP (cyclophosphamide, doxorubicin, vincristine, 
prednisone) 
1 
Carboplatin AUC2 + etoposide 1 
Carboplatin AUC2 + paclitaxel weekly 1 
Docetaxel + cyclophosphamide 2 
Decitabine 0 
Rituximab 0 
Afatinib 0 
Trastuzumab 0 
Cisplatin + vinorelbine 2 
Carboplatin AUC2 + paclitaxel 50-100 mg/m2 1 
Gemcitabine + Nab-paclitaxel 2 
Carboplatin AUC2 + gemcitabine 800 mg/m2 0 
Carboplatin AUC2 + gemcitabine 1000 mg/m2 0 
Carboplatin AUC2 weekly 0 
Doxorubicin 60 mg/m2 + cisplatin 50 mg/m2 3-weekly 2 
Fluorouracil low dose 0 
FLO (fluorouracil, oxaliplatin, folinic acid) 1 
FUFOX (fluorouracil, oxaliplatin, folinic acid) 1 
Rituximab-IMVP (ifosfamide, methotrexate, etoposide)-16  1 
Paclitaxel weekly + trastuzumab 0 
mFOLFOX6 (fluorouracil, oxaliplatin, folinic acid) + panitumumab 1 
VMP (bortezomib, melphalan, prednisone) 0 
Bortezomib + dexamethasone 0 
Rituximab + gemcitabine + oxaliplatin 2 
Paclitaxel + gemcitabine + oxaliplatin 2 
Paclitaxel 90 mg/m2 + bevacizumab 1 
Doxorubicin 25 mg/m2 + cyclophosphamide 500 mg/m2 3-weekly 1 
Pembrolizumab 0 
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Therapy regimen* 
CRASH score 
points 
Rituximab + chlorambucil 0 
Lenalidomide + dexamethasone 0 
Docetaxel + cyclophosphamide 2 
Carboplatin AUC6 + etoposide 3-weekly 2 
VCD (bortezomib, cyclophosphamide, dexamethasone) 1 
Cytarabine 0 
Epirubicine + cyclophosphamide 2 
Ruxolitinib 0 
Azacitidine 0 
Capecitabine 2 g + trastuzumab 0 
Cisplatin 50 mg/m2 + doxorubicin 60 mg/m2 2 
Rituximab + chlorambucil 0 
Ipilimumab 2 
Idarubicin + tretinoin 2 
Bevacizumab + topotecan + paclitaxel 2 
 
*if no dose is specified, all common doses used for this regimen fall into the same category [68]  
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Distribution of CTCAE grade ≥ 3 toxicity during therapy course per individual CARG and 
CRASH score items and patient characteristics 
Table D-1 Distribution of overall CTCAE grade ≥ 3 toxicity during therapy course per patient 
characteristics; Fisher’s exact test was used for p value calculation; ECOG, 
Eastern Cooperative Oncology; * Fisher’s exact test excluded missing values
  
 No toxicity Toxicity  
 n % n % P value 
Age [years]      
70-74 4 12.1 29 87.9 0.178 
75-79 12 26.7 33 73.3  
80-84 5 20.0 20 80.0  
≥ 85 0 0.0 10 100.0  
Sex      
Female 10 17.9 46 82.1 1.000 
Male 11 19.3 46 80.7  
ECOG performance status      
Fully active (0) 10 26.3 28 73.7 0.239 
Capable of all self-care (1-2) 10 16.7 50 83.3  
Limited or no self-care (3-4) 1 6.7 14 93.3  
Charlson Comorbidity Index 
No comorbidity (0) 10 20.8 38 79.2 0.282 
Little comorbidity (1-2) 8 15.1 45 84.9  
Moderate comorbidity (3-4) 2 18.2 9 81.8  
High comorbidity (≥ 5) 1 100.0 0 0.00  
Polymedication      
No polymedication (< 5) 12 21.8 43 78.2 0.743 
Polymedication (≥ 5) 7 15.9 37 84.1  
Hyperpolymedication (≥ 10) 2 14.3 12 85.7  
Tumor type      
Solid tumor 11 17.7 51 82.3 0.813 
Hematological tumor 10 19.6 41 80.4  
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Table D-1 (continued) 
 No toxicity Toxicity  
 n % n % P value 
Cancer stage      
I 0 0.0 7 100.0 0.296* 
II 3 30.0 7 70.0  
III 4 13.8 25 86.2  
IV 13 25.0 39 75.0  
Missing 1 6.7 14 93.3  
Metastasis      
No 4 16.7 20 83.3 1.000* 
Yes 7 19.4 29 80.6  
Not applicable 10 19.6 41 80.4  
Missing 0 0.0 2 100.00  
Treatment intention      
Palliative 10 17.9 46 82.1 0.419* 
Curative 8 17.0 39 83.0  
Chronic condition 3 37.5 5 62.5  
Missing 0 0.0 2 100.0  
Treatment type      
Chemotherapy 9 13.4 58 86.6 0.001 
Targeted or immunotherapy 5 83.3 1 16.7  
Combined chemotherapy 
and targeted or 
immunotherapy 
7 17.5 33 82.5  
Additional therapy      
None 13 20.3 51 79.7 0.109 
Radiotherapy 2 6.9 27 93.1  
Surgery 5 35.7 9 64.3  
Radiotherapy and surgery 1 16.7 5 83.3  
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Table D-2  Distribution of overall CTCAE grade ≥ 3 toxicity during therapy course per CARG 
score items; GI, gastrointestinal; GU, genitourinary; *Fisher’s exact test  
 No toxicity Toxicity  
 n % n % P value* 
Socio-demographics      
Age [years]      
≥ 72 20 19.0 85 81.0 1.000 
< 72 1 12.5 7 87.5  
Tumor/treatment variables      
Cancer type      
GI/GU tumor 2 11.1 16 88.9 0.518 
Others 19 20.0 76 80.0  
Dose      
Reduced 2 12.5 14 87.5 0.732 
Standard 19 19.6 78 80.4  
Number of treatment 
agents 
     
Monotherapy 3 20.0 12 80.0 1.000 
Polytherapy 18 18.4 80 81.6  
Laboratory variables      
Hemoglobin [g/dL]      
≥ 10 (female), ≥ 11 (male) 18 24.7 55 75.3 0.041 
< 10 (female), < 11 (male) 3 7.5 37 92.5  
Creatinine clearance Jeliffe 
[mL/min] 
     
< 34 0 0.0 11 100.0 0.213 
≥ 34  21 20.6 81 79.4  
Geriatric assessment variables 
Hearing abilities      
Fair/worse 4 9.5 38 90.5 0.079 
Good/excellent 17 23.9 54 76.1  
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Table D-2 (continued) 
 No toxicity Toxicity  
 n % n % P value* 
Falls in past six months      
0 18 19.8 73 80.2 0.761 
≥ 1 3 13.6 19 86.4  
Medication intake      
No assistance 21 19.1 89 80.9 1.000 
Requires assistance 0 0.0 3 100.0  
Limited in walking one block      
Not limited at all 11 18.3 49 81.7 1.000 
Limited 10 18.9 43 81.1  
Decreased social activity because of health/emotional problems 
A little or none of the time 18 23.1 60 76.9 0.074 
Some, most, all of the time 3 8.6 32 91.4  
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Table D-3 Distribution of overall CTCAE grade ≥ 3 toxicity during therapy course per CRASH 
score items; IADL, instrumental activities of daily living; LDH, lactate 
dehydrogenase; ECOG, Eastern Cooperative Oncology Group; MMSE, Mini-
Mental State Examination; MNA, Mini Nutritional Assessment; MAX2, 
chemotherapy toxicity index; *Fisher’s exact test 
 No toxicity Toxicity  
 n % n % P value* 
Hematologic score       
Diastolic blood pressure      
≤ 72 10 20.8 38 79.2 0.631 
> 72 11 16.9 54 83.1  
IADL      
26-29 18 19.8 73 80.2 0.761 
10-25 3 13.6 19 86.4  
LDH [U/L]      
> 0.74 x ULN 17 16.0 89 84.0 0.022 
≤ 0.74 x ULN 4 57.1 3 42.9  
Nonhematologic score      
ECOG performance status      
0 10 26.3 28 73.7 0.239 
1-2 10 16.7 50 83.3  
3-4 1 6.7 14 93.3  
MMS      
30 6 30.0 14 70.0 0.202 
< 30 15 16.1 78 83.9  
MNA      
28-30 2 13.3 13 86.7 0.733 
< 28 19 19.4 79 80.6  
All scores      
Therapy toxicity (MAX2)      
0 (0-0.44) 6 25.0 18 75.0 0.37 
1 (0.45-0.57) 10 21.3 37 78.7  
2 (< 0.57) 5 11.9 37 88.1  
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Incidence of severe toxicity at start of therapy (first cycle or at least 3 weeks of therapy) 
Table D-4 Toxicity at start of therapy (within the first cycle or within at least the first 3 
weeks if cycle was shorter) according to CTCAE ≥ 3 grade; AST, aspartate 
aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl 
transferase 
 Grade ≥ 3 Grade 3 Grade 4 Grade 5 
 n % n % n % n % 
Overall toxicity 78 69.0 74 65.5 36 31.9 3 2.7 
Hematologic toxicity 57 50.4 53 46.9 27 23.9 0 0.0 
Anemia 35 31.0 35 31.0 0 0.0 0 0.0 
Febrile neutropenia 12 10.6 12 10.6 0 0.0 0 0.0 
Neutropenia 32 28.3 12 10.6 20 17.7 0 0.0 
Leukopenia 39 34.5 19 16.8 20 17.7 0 0.0 
Thrombopenia 17 15.0 6 5.3 12 10.6 0 0.0 
Nonhematologic 
toxicity 
56 49.6 55 48.7 9 8.0 3 2.7 
Acute coronary 
syndrome 
2 1.8 1 0.9 0 0.0 1 0.9 
Atrial flutter 0 0.0 0 0.0 0 0.0 0 0.0 
Heart failure 1 0.9 1 0.9 0 0.0 0 0.0 
Thromboembolic 
event 
3 2.7 3 2.7 0 0.0 0 0.0 
AST 7 6.2 6 5.3 1 0.9 0 0.0 
ALT 6 5.3 5 4.4 1 0.9 0 0.0 
GGT 16 14.2 12 10.6 4 3.5 0 0.0 
Bilirubin 0 0.0 0 0.0 0 0.0 0 0.0 
Creatinine 4 3.5 3 2.7 1 0.9 0 0.0 
Proteinuria 0 0.0 0 0.0 0 0.0 0 0.0 
Dyspnea 12 10.6 11 9.7 1 0.9 0 0.0 
Erythroderma 0 0.0 0 0.0 0 0.0 0 0.0 
Urticaria 0 0.0 0 0.0 0 0.0 0 0.0 
Palmar-plantar 
erythrodysesthesia 
syndrome 
0 0.0 0 0.0 0 0.0 0 0.0 
Gastrointestinal 
bleeding 
2 1.8 1 0.9 1 0.9 0 0.0 
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Table D-4 (continued) 
 Grade ≥ 3 Grade 3 Grade 4 Grade 5 
 n % n % n % n % 
Infections 26 23.0 21 18.6 3 2.7 2 1.8 
Dehydration 2 1.8 2 1.8 0 0.0 0 0.0 
Hyponatremia 9 8.0 9 8.0 0 0.0 0 0.0 
Hypokalemia 9 8.0 9 8.0 0 0.0 0 0.0 
Dysphagia 1 0.9 1 0.9 0 0.0 0 0.0 
Dry mouth 0 0.0 0 0.0 0 0.0 0 0.0 
Mucositis 1 0.9 1 0.9 0 0.0 0 0.0 
Pain 13 11.5 13 11.5 0 0.0 0 0.0 
Anorexia 7 6.2 7 6.2 0 0.0 0 0.0 
Constipation 0 0.0 0 0.0 0 0.0 0 0.0 
Diarrhea 3 2.7 3 2.7 0 0.0 0 0.0 
Nausea 5 4.4 5 4.4 0 0.0 0 0.0 
Vomiting 2 1.8 2 1.8 0 0.0 0 0.0 
Insomnia 1 0.9 1 0.9 0 0.0 0 0.0 
Fatigue 10 8.8 10 8.8 0 0.0 0 0.0 
Peripheral sensory 
neuropathy 
0 0.0 0 0.0 0 0.0 0 0.0 
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Relationship between the hematologic/nonhematologic CRASH score with the CARG score  
Table D-5 Relationship between the hematologic and nonhematologic CRASH score with 
the CARG score (n = 120); for Spearman’s rho the scores were treated as 
continuous variables; for Fisher’s exact test and weighted kappa as categorial 
variables; CI, confidence interval; * CRASH scores pooled into three categories 
by combining mid-low and mid-high categories  
Score 
Spearman’s rho 
(p value) 
Weighted kappa * 
(CI, p value) 
Fisher’s exact test   
p value 
Hematologic CRASH 
score vs CARG score 
0.020 (0.830) 
-0.001 
(-0.062-0.061, 0.982) 
0.680 
Nonhematologic 
CRASH score vs 
CARG score 
0.188 (0.039) 
0.063 
(-0.72-0.198, 0.333) 
0.163 
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Relationship between the hematologic/nonhematologic CRASH score with the 
hematologic/nonhematologic physicians’ judgments  
Table D-6 Relationship between the hematologic/nonhematologic CRASH score with the 
hematologic/nonhematologic physicians’ judgments (n = 118); scores and 
physicians’ judgments were treated as categorial variables; CI, confidence 
interval; * CRASH scores pooled into three categories by combining mid-low and 
mid-high categories  
Score 
Spearman’s rho 
(p value) 
Weighted kappa * 
(CI, p value) 
Fisher’s exact test   
p value 
Hematologic CRASH 
score vs 
hematologic 
physicians’ 
judgments 
0.094 (0.310) 
-0.038 (-0.102-0.026, 
0.369) 
0.565 
Nonhematologic 
CRASH score vs 
nonhematologic 
physicians’ 
judgments 
0.102 (0.271) 
0.022 (-0.086-0.130, 
0.668) 
0.357 
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Comparison of the proportion of patients with hematologic toxicity per hematologic CRASH 
score value in our study with the original CRASH score development study  
Table D-7 Proportion of patients with hematologic severe toxicity during therapy course 
per hematologic CRASH score value in our study compared with the proportion 
of patients with hematologic toxicity per respective score value in the original 
CRASH development study; * from the CRASH development study [68] 
 
  
Hematologic 
CRASH score 
value 
Number of patients 
per score value in our 
study 
Proportion of 
patients with toxicity 
in our study [%] 
Proportion of 
patients with toxicity 
in development study 
[%] * 
0 1 0.0 7 
1 4 75.0 7 
2 11 36.4 23 
3 27 51.9 23 
4 34 76.5 54 
5 32 84.4 54 
6 4 50.0 100 
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Comparison of the proportion of patients with nonhematologic toxicity per nonhematologic 
CRASH score value in our study with the original CRASH score development study  
Table D-8 Proportion of patients with nonhematologic severe toxicity during therapy 
course per nonhematologic CRASH score value in our study compared with the 
proportion of patients with nonhematologic toxicity per respective score value 
in the original CRASH development study; * from the CRASH development study 
[68] 
  
Nonhematologic 
CRASH score 
value 
Number of patients 
per score value in 
our study 
Proportion of 
patients with toxicity 
in our study [%] 
Proportion of 
patients with toxicity 
in development 
study [%] * 
1 1 0.0 33 
2 2 100.0 33 
3 8 50.0 46 
4 14 42.9 46 
5 19 47.4 67 
6 49 59.2 67 
7 18 83.3 93 
8 2 100.0 93 
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Kaplan-Meier estimates of the CARG score and combined CRASH score for severe overall 
toxicity 
Table D-9  CARG score category low (n = 63): Time to occurrence of first overall severe 
toxicity (CTCAE grade ≥ 3) in Kaplan-Meier analysis; yes: severe toxicity occurred; 
no: censored 
Patient 
Time 
(weeks) 
Event 
Cumulative proportion of 
patients without toxicity Cumulative 
number of 
events 
Number of 
remaining 
patients Estimate 
Standard 
error 
1 0.25 yes 0.984 0.016 1 62 
2 0.50 yes   2 61 
3 0.50 yes   3 60 
4 0.50 yes   4 59 
5 0.50 yes 0.921 0.034 5 58 
6 0.75 yes 0.905 0.037 6 57 
7 1.00 yes 0.889 0.040 7 56 
8 1.00 no   7 55 
9 1.50 yes   8 54 
10 1.50 yes   9 53 
11 1.50 yes   10 52 
12 1.50 yes   11 51 
13 1.50 yes   12 50 
14 1.50 yes   13 49 
15 1.50 yes 0.776 0.053 14 48 
16 1.75 yes   15 47 
17 1.75 yes 0.743 0.055 16 46 
18 2.00 yes   17 45 
19 2.00 yes   18 44 
20 2.00 yes   19 43 
21 2.00 yes   20 42 
22 2.00 yes   21 41 
23 2.000 yes   22 40 
24 2.00 yes 0.630 0.061 23 39 
25 2.25 yes 0.614 0.062 24 38 
26 2.50 yes   25 37 
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Table D-9 (continued) 
Patient 
Time 
(weeks) 
Event 
Cumulative proportion of 
patients without toxicity Cumulative 
number of 
events 
Number of 
remaining 
patients Estimate 
Standard 
error 
27 2.50 yes   26 36 
28 2.50 yes   27 35 
29 2.50 yes   28 34 
30 2.50 yes 0.533 0.063 29 33 
31 2.50 no   29 32 
32 3.00 yes   30 31 
33 3.00 yes   31 30 
34 3.00 yes   32 29 
35 3.00 yes 0.467 0.064 33 28 
36 3.00 no   33 27 
37 3.25 yes 0.449 0.064 34 26 
38 3.50 yes 0.432 0.063 35 25 
39 3.50 no   35 24 
40 4.00 yes   36 23 
41 4.00 yes 0.396 0.063 37 22 
42 4.50 yes 0.378 0.063 38 21 
43 5.00 yes 0.360 0.062 39 20 
44 5.50 yes 0.342 0.062 40 19 
45 5.50 no   40 18 
46 6.00 no   40 17 
47 6.75 yes 0.322 0.061 41 16 
48 7.00 yes 0.302 0.061 42 15 
49 8.00 no   42 14 
50 8.50 yes 0.280 0.060 43 13 
51 11.50 no   43 12 
52 11.50 no   43 11 
53 13.00 yes 0.255 0.060 44 10 
54 14.00 no   44 9 
55 14.00 no   44 8 
56 16.50 no   44 7 
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Table D-9 (continued) 
Patient 
Time 
(weeks) 
Event 
Cumulative proportion of 
patients without toxicity Cumulative 
number of 
events 
Number of 
remaining 
patients Estimate 
Standard 
error 
57 17.00 no   44 6 
58 18.00 yes 0.212 0.063 45 5 
59 19.00 yes 0.170 0.063 46 4 
60 22.00 no   46 3 
61 22.00 no   46 2 
62 24.00 yes 0.085 0.068 47 1 
63 30.50 no   47 0 
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Table D-10 CARG score category high (n = 50): Time to occurrence of first overall severe 
toxicity (CTCAE grade ≥ 3) in Kaplan-Meier analysis; yes: severe toxicity occurred; 
no: censored  
Patients 
Time 
(weeks) 
Event 
Cumulative proportion of 
patients without toxicity Cumulative 
number of 
events 
Number of 
remaining 
patients Estimate 
Standard 
error 
1 0.50 yes   1 49 
2 0.50 yes   2 48 
3 0.50 yes   3 47 
4 0.50 yes 0.920 0.038 4 46 
5 0.75 yes 0.900 0.042 5 45 
6 1.00 yes   6 44 
7 1.00 yes   7 43 
8 1.00 yes   8 42 
9 1.00 yes 0.820 0.054 9 41 
10 1.25 yes 0.800 0.057 10 40 
11 1.50 yes   11 39 
12 1.50 yes   12 38 
13 1.50 yes   13 37 
14 1.50 yes   14 36 
15 1.50 yes   15 35 
16 1.50 yes   16 34 
17 1.50 yes   17 33 
18 1.50 yes   18 32 
19 1.50 yes   19 31 
20 1.50 yes   20 30 
21 1.50 yes   21 29 
22 1.50 yes 0.560 0.070 22 28 
23 1.75 yes   23 27 
24 1.75 yes   24 26 
25 1.75 yes 0.500 0.071 25 25 
26 2.00 yes   26 24 
27 2.00 yes   27 23 
28 2.00 yes   28 22 
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Table D-10 (continued) 
Patients 
Time 
(weeks) 
Event 
Cumulative proportion of 
patients without toxicity Cumulative 
number of 
events 
Number of 
remaining 
patients Estimate 
Standard 
error 
29 2.00 yes   29 21 
30 2.00 yes   30 20 
31 2.00 yes   31 19 
32 2.00 yes   32 18 
33 2.00 yes   33 17 
34 2.00 yes   34 16 
35 2.00 yes 0.300 0.065 35 15 
36 2.25 yes 0.280 0.063 36 14 
37 2.50 yes   37 13 
38 2.50 yes 0.240 0.060 38 12 
39 3.00 yes 0.220 0.059 39 11 
40 3.25 yes 0.200 0.057 40 10 
41 4.50 yes   41 9 
42 4.50 yes 0.160 0.052 42 8 
43 5.50 no   42 7 
44 5.50 no   42 6 
45 5.50 no   42 5 
46 7.50 yes 0.128 0.050 43 4 
47 7.50 no   43 3 
48 10.00 yes   44 2 
49 10.00 yes 0.043 0.039 45 1 
50 16.75 no   45 0 
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Table D-11 Combined CRASH score category low (n = 24): Time to occurrence of first overall 
severe toxicity (CTCAE grade ≥ 3) in Kaplan-Meier analysis; yes: severe toxicity 
occurred; no: censored  
Patients 
Time 
(weeks) 
Event 
Cumulative proportion of 
patients without toxicity Cumulative 
number of 
events 
Number of 
remaining 
patients Estimates Standard 
error 
1 0.25 yes 0.958 0.041 1 23 
2 0.50 yes   2 22 
3 0.50 yes 0.875 0.068 3 21 
4 1.50 yes   4 20 
5 1.50 yes   5 19 
6 1.50 yes 0.750 0.088 6 18 
7 2.00 yes 0.708 0.093 7 17 
8 2.25 yes   8 16 
9 2.25 yes 0.625 0.099 9 15 
10 3.00 yes   10 14 
11 3.00 yes 0.542 0.102 11 13 
12 4.00 yes 0.500 0.102 12 12 
13 5.00 yes 0.458 0.102 13 11 
14 5.50 no   13 10 
15 5.50 no   13 9 
16 6.00 no   13 8 
17 6.75 yes 0.401 0.104 14 7 
18 10.00 yes 0.344 0.104 15 6 
19 11.50 no   15 5 
20 16.50 no   15 4 
21 17.00 no   15 3 
22 18.00 yes 0.229 0.116 16 2 
23 19.00 yes 0.115 0.100 17 1 
24 24.00 yes 0.000 0.000 18 0 
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Table D-12 Combined CRASH score category high (n = 89): Time to occurrence of first overall 
severe toxicity (CTCAE grade ≥ 3) in Kaplan-Meier analysis; yes: severe toxicity 
occurred; no: censored 
Patients 
Time  
(weeks) 
Event 
Cumulative proportion of 
patients without toxicity Cumulative 
number of 
events 
Number of 
remaining 
patients Estimates 
Standard 
error 
1 0.50 yes   1 88 
2 0.50 yes   2 87 
3 0.50 yes   3 86 
4 0.50 yes   4 85 
5 0.50 yes   5 84 
6 0.50 yes 0.933 0.027 6 83 
7 0.75 yes   7 82 
8 0.75 yes 0.910 0.030 8 81 
9 1.00 yes   9 80 
10 1.00 yes   10 79 
11 1.00 yes   11 78 
12 1.00 yes   12 77 
13 1.00 yes 0.854 0.037 13 76 
14 1.00 no   13 75 
15 1.25 yes 0.843 0.039 14 74 
16 1.50 yes   15 73 
17 1.50 yes   16 72 
18 1.50 yes   17 71 
19 1.50 yes   18 70 
20 1.50 yes   19 69 
21 1.50 yes   20 68 
22 1.50 yes   21 67 
23 1.50 yes   22 66 
24 1.50 yes   23 65 
25 1.50 yes   24 64 
26 1.50 yes   25 63 
27 1.50 yes   26 62 
28 1.50 yes   27 61 
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Table D-12 (continued) 
Patients 
Time  
(weeks) 
Event 
Cumulative proportion of 
patients without toxicity Cumulative 
number of 
events 
Number of 
remaining 
patients Estimates 
Standard 
error 
29 1.50 yes   28 60 
30 1.50 yes   29 59 
31 1.50 yes 0.660 0.050 30 58 
32 1.75 yes   31 57 
33 1.75 yes   32 56 
34 1.75 yes   33 55 
35 1.75 yes   34 54 
36 1.75 yes 0.603 0.052 35 53 
37 2.00 yes   36 52 
38 2.00 yes   37 51 
39 2.00 yes   38 50 
40 2.00 yes   39 49 
41 2.00 yes   40 48 
42 2.00 yes   41 47 
43 2.00 yes   42 46 
44 2.00 yes   43 45 
45 2.00 yes   44 44 
46 2.00 yes   45 43 
47 2.00 yes   46 42 
48 2.00 yes   47 41 
49 2.00 yes   48 40 
50 2.00 yes   49 39 
51 2.00 yes   50 38 
52 2.00 yes 0.421 0.053 51 37 
53 2.50 yes   52 36 
54 2.50 yes   53 35 
55 2.50 yes   54 34 
56 2.50 yes   55 33 
57 2.50 yes   56 32 
58 2.50 yes   57 31 
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Table D-12 (continued) 
Patients 
Time  
(weeks) 
Event 
Cumulative proportion of 
patients without toxicity Cumulative 
number of 
events 
Number of 
remaining 
patients Estimates 
Standard 
error 
59 2.50 yes 0.342 0.051 58 30 
60 2.50 no   58 29 
61 3.00 yes   59 28 
62 3.00 yes   60 27 
63 3.00 yes 0.306 0.049 61 26 
64 3.00 no   61 25 
65 3.25 yes   62 24 
66 3.25 yes 0.282 0.048 63 23 
67 3.50 yes 0.269 0.048 64 22 
68 3.50 no   64 21 
69 4.00 yes 0.257 0.047 65 20 
70 4.50 yes   66 19 
71 4.50 yes   67 18 
72 4.50 yes 0.218 0.045 68 17 
73 5.50 yes 0.205 0.044 69 16 
74 5.50 no   69 15 
75 5.50 no   69 14 
76 7.00 yes 0.191 0.043 70 13 
77 7.50 yes 0.176 0.042 71 12 
78 7.50 no   71 11 
79 8.00 no   71 10 
80 8.50 yes 0.158 0.042 72 9 
81 10.00 yes 0.141 0.041 73 8 
82 11.50 no   73 7 
83 13.00 yes 0.121 0.039 74 6 
84 14.00 no   74 5 
85 14.00 no   74 4 
86 16.75 no   74 3 
87 22.00 no   74 2 
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Table D-12 (continued) 
Patients 
Time  
(weeks) 
Event 
Cumulative proportion of 
patients without toxicity Cumulative 
number of 
events 
Number of 
remaining 
patients Estimates 
Standard 
error 
88 22.00 no   74 1 
89 30.50 no   74 0 
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Predictive performance of the ECOG performance status and age for severe hematologic 
and nonhematologic toxicity 
Table D-13 Predictive performance of the commonly used predictors ECOG (Eastern 
Cooperative Oncology Group) performance status and age for hematologic and 
nonhematologic grade ≥ 3 toxicity; * Fisher’s exact test  
 Calibration Discrimination 
 Cross tables Logistic regression ROC curves 
 
Toxicity 
n (%) 
P value* P value 
Odds Ratio 
(CI) 
ROC-AUC (CI) P value 
Hematologic toxicity 
ECOG       
0 23 (60.5) 0.519 0.893 
1.028 
(0.687-1.539) 
0.526 
(0.408-0.645) 
0.649 
1 37 (74.0)      
2 7 (70.0)      
3 9 (60.0)      
Age [years]       
70-74 26 (78.8) 0.193 0.130 
0.934 
(0.856-1.020) 
0.390 
(0.279- 0.501) 
0.059 
75-79 30 (66.7)      
80-84 13 (52.0)      
≥ 85 7 (70.0)      
Nonhematologic toxicity 
ECOG       
0 17 (44.7) 0.006 0.002 
2.134 
(1.325-3.438) 
0.665 
(0.566-0.765) 
0.003 
1 28 (56.0)      
2 9 (90.0)      
3 13 (86.7)      
Age [years]       
70-74 21 (63.6) 0.773 0.729 
0.985 
(0.906-1.071) 
0.468 
(0.361-0.575) 
0.565 
75-79 24 (53.3)      
80-84 16 (64.0)      
≥ 85 6 (60.0)      
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Risk factors of nonhematologic and hematologic CTCAE grade ≥ 3 toxicity during therapy 
course 
Table D-14 Univariate logistic regression for CARG and CRASH score items as well as other 
items to determine risk factors of hematologic CTCAE grade ≥ 3 toxicity during 
therapy course; categories are based on original score cut-offs for respective 
items; CI, confidence interval; GI, gastrointestinal; GU, genitourinary; IADL, 
instrumental activities of daily living; LDH, lactate dehydrogenase; ECOG, 
Eastern Cooperative Oncology; MMSE, Mini-Mental State Examination; MNA, 
Mini Nutritional Assessment; MAX2, chemotherapy toxicity index; nd: not 
determinable; reference: in italic; if no reference class is denoted, variables are 
treated as continuous  
 Odds ratio (95% CI) P value 
CARG score items   
Age [years] 
< 72 vs ≥ 72 
1.253 (0.283-5.552) 0.767 
Cancer type  
Other vs GI/GU tumor 
0.549 (0.197-1.534) 0.253 
Dose  
Standard vs Reduced 
1.083 (0.347-3.382) 0.891 
Number of treatment agents  
Monotherapy vs Polytherapy 
2.719 (0.902-8.195) 0.076 
Hemoglobin [g/dL]  
≥ 10 vs < 10 (female), ≥ 11 vs < 11 (male) 
2.636 (1.066-6.520) 0.036 
Creatinine clearance Jeliffe [mL/min] 
≥ 34 vs < 34  
0.837 (0.229-3.061) 0.788 
Hearing abilities  
Good/excellent vs Fair/worse 
1.359 (0.594-3.109) 0.468 
Falls in past six months  
0 vs ≥ 1 
0.819 (0.309-2.168) 0.687 
Medication intake 
No assistance vs Requires assistance 
0.233 (0.020-2.660) 0.241 
Limited in walking one block  
Not limited at all vs Limited 
0.652 (0.296-1.437) 0.289 
Decreased social activity because of 
health/emotional problems  
A little or none of the time vs Some, 
most, all of the time 
1.324 (0.555-3.156) 0.527 
   
Appendix D    203 
 
Table D-14 (continued) 
 Odds ratio (95% CI) P value 
Hematologic CRASH score items    
Diastolic blood pressure  
≤ 72 vs > 72 
1.711 (0.774-3.783) 0.185 
IADL  
26-29 vs 10-25 
0.642 (0.246-1.676) 0.365 
LDH 
≤ 167 vs > 167 
2.949 (0.625-13.930) 0.172 
Therapy toxicity (MAX2)   
0  -  
1  3.556 (1.270-9.950) 0.016 
2  8.333 (2.617-26.535) 0.000 
Other risk factors   
Age 0.934 (0.856-1.020) 0.130 
Sex  
male vs female 
1.056 (0.481-2.316) 0.893 
ECOG performance status 1.028 (0.687-1.539) 0.893 
Charlson Comorbidity Index 1.114 (0.790-1.571) 0.540 
Creatinine Clearance (Cockcroft-Gault) 
[mL/min] 
1.016 (0.996-1.035) 0.121 
Medication number before start of 
cancer treatment 
1.037 (0.930-1.157) 0.511 
Tumor type  
Solid tumors vs Hematological tumors 
1.559 (0.699-3.477) 0.278 
Treatment type   
Chemotherapy -  
Targeted or immunotherapy 0.091 (0.010-0.831) 0.034 
Combined chemotherapy and targeted 
or immunotherapy 
1.204 (0.507-2.858) 0.675 
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Table D-15 Univariate logistic regression for CARG and CRASH score items, and other items 
to determine risk factors of nonhematologic severe toxicity CTCAE grade ≥ 3 
during therapy course; categories are based on original score cut-offs for 
respective items; CI, confidence interval; GI, gastrointestinal; GU, genitourinary; 
IADL, instrumental activities of daily living; LDH, lactate dehydrogenase; ECOG, 
Eastern Cooperative Oncology Group; MMSE, Mini-Mental State Examination; 
MNA, Mini Nutritional Assessment; MAX2, chemotherapy toxicity index; nd: not 
determinable; reference: italic; if no reference class is denoted, variables were 
treated as continuous  
 Odds ratio (95% CI) P value 
CARG score items   
Age [years] 
 < 72 vs ≥ 72 
0.462 (0.089-2.398) 0.358 
Cancer type  
Other vs GI/GU tumor 
4.135 (1.123-15.228) 0.033 
Dose  
Standard vs Reduced 
1.611 (0.520-4.993) 0.409 
Number of treatment agents  
Monotherapy vs Polytherapy 
1.324 (0.444-3.945) 0.615 
Hemoglobin [g/dL]  
≥ 10 vs < 10 (f), ≥ 11 vs < 11 (m) 
2.919 (1.247-6.830) 0.014 
Creatinine clearance (Jeliffe) [mL/min] 
≥ 34 vs < 34  
3.414 (0.702-16.598) 0.128 
Hearing abilities  
Good/excellent vs Fair/worse 
1.189 (0.545-2.596) 0.664 
Falls in past six months  
0 vs ≥ 1 
1.255 (0.479-3.288) 0.644 
Medication intake 
No assistance vs Requires assistance 
nd  
Limited in walking one block  
Not limited at all vs Limited 
1.701 (0.794-3.645) 0.172 
Decreased social activity because of 
health/emotional problems  
A little or none of the time vs Some, most, 
all of the time 
3.206 (1.297-7.928) 0.012 
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Table D-15 (continued) 
 Odds ratio (95% CI) P value 
Nonhematologic CRASH score items   
ECOG performance status   
0  -  
1-2 1.987 (0.871-4.532) 0.103 
3-4 8.029 (1.589-40.582) 0.012 
MMS 
30 vs < 30 
1.583 (0.600-4.180) 0.354 
MNA 
28-30 vs < 28 
2.473 (0.814-7.510) 0.110 
Therapy toxicity (MAX2)   
0  -  
1  0.884 (0.327-2.391) 0.809 
2  1.286 (0.460-3.594) 0.632 
Other risk factors   
Age 0.985 (0.906-1.071) 0.729 
Sex  
male vs female 
2.376 (1.099-5.136) 0.028 
ECOG performance status 2.134 (1.325-3.438) 0.002 
Charlson Comorbidity Index 0.773 (0.559-1.069) 0.120 
Creatinine Clearance (Cockcroft-Gault) 
[mL/min] 
0.991 (0.974-1.009) 0.338 
Medication number before start of 
cancer treatment 
1.138 (1.014-1.277) 0.029 
Tumor type  
Solid tumors vs Hematological tumors 
0.533 (0.249-1.139) 0.104 
Treatment type   
Chemotherapy  -  
Targeted or immunotherapy 0.105 (0.012-0.949) 0.045 
Combined chemotherapy and targeted or 
immunotherapy 
0.639 (0.287-1.424) 0.273 
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Predictive performance for the alterations of the planned treatment 
Table D-16 Predictive performance of the CARG score and combined CRASH score for total 
alterations of the planned treatment; * Fisher’s exact test 
 
  
 Calibration Discrimination 
 Cross tables Logistic regression ROC curves 
 
Total 
alterations  
n (%) 
P value * 
Wald 
statistic 
P value 
Odds Ratio 
(95% CI) 
ROC-AUC 
(95% CI) 
P value 
CARG       
Low 3 (60.0) 0.327 0.086 
1.125 
(0.983-
1.288) 
0.604 
(0.488-
0.720) 
0.077 
Mid  37 (63.8)      
High 38 (76.0)      
CRASH 
combined 
score 
      
Low 2 (66.7) 0.380 0.107 
1.200 
(0.962-
1.497) 
0.612 
(0.500-
0.725) 
0.057 
Mid-Low 12 (57.1)      
Mid-High 47 (69.1)      
High 17 (81.0)      
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Table D-17 Predictive performance of the CARG score and combined CRASH score for minor 
alterations of the planned treatment (delays or dose reductions); * Fisher’s exact 
test 
 
  
 Calibration Discrimination 
 Cross tables Logistic regression ROC curves 
 
All delays 
or 
reductions 
n (%) 
P value * 
Wald 
statistic 
P value 
Odds Ratio 
(95% CI) 
ROC-AUC 
(95% CI) 
P value 
CARG       
Low 3 (60.0) 0.615 0.410 
0.952 
(0.846-1.071) 
0.462 
(0.354-0.570) 
0.490 
Mid  24 (41.4)      
High 19 (38.0)      
CRASH 
combined 
score 
      
Low 2 (66.7) 0.632 0.227 
0.879 
(0.713-1.084) 
0.446 
(0.337-0.556) 
0.335 
Mid-Low 10 (47.6)      
Mid-High 25 (36.8)      
High 9 (42.9)      
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Kaplan-Meier analysis and Cox Regression for total and minor alterations of the planned 
treatment 
Table D-18 Kaplan-Meier analysis and Cox regression for the time until occurrence of total 
alterations of the planned treatment  
 
  
Kaplan-Meier analysis 
 
Median time to total alterations 
[weeks] (95% CI) 
P value (log-rank test) 
Total 5.000 (2.716-7.284)  
CARG   
Low/Mid 7.000 (2.420-11.580) 0.150 
High 4.500 (3.027-5.973)  
CRASH combined score   
Low/Mid-Low 7.000 (0.904-13.096) 0.319 
Mid-High/High 4.500 (2.990-6.010)  
Cox regression   
 Hazard ratio (95% CI) P value 
CARG 
Low/Mid vs High 
1.371 (0.879-2.137) 0.164 
CRASH combined score 
Low/Mid-Low vs Mid-
High/High 
1.330 (0.745-2.374) 0.335 
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Table D-19 Kaplan-Meier analysis and Cox regression for the time until occurrence of minor 
alterations (delays or dose reductions) of the planned treatment  
 
  
Kaplan-Meier analysis 
 
Median time to minor alterations 
[weeks] (95% CI) 
P value (log-rank test) 
Total 12.000 (6.255-17.745)  
CARG   
Low/Mid 11.500 (4.889-18.111) 0.927 
High 12.000 (-)  
CRASH combined score   
Low/Mid-Low 9.000 (1.819-16.181) 0.574 
Mid-High/High 12.000 (4.697-19.303)  
Cox regression   
 Hazard ratio (95% CI) P value 
CARG 
Low/Mid vs High 
1.027 (0.571-1.848) 0.929 
CRASH combined score 
Low/Mid-Low vs Mid-
High/High 
0.830 (0.429-1.606) 0.580 
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Kaplan-Meier estimates of the CARG score and the combined CRASH score for major 
alterations of the planned treatment (discontinuations or changes) 
Table D-20 CARG score category low (n = 63): Time to occurrence of major alterations of 
treatment (discontinuations or changes) in Kaplan-Meier analysis; yes: severe 
toxicity occurred; no: censored  
Patients 
Time  
(weeks) 
Event 
Cumulative proportion of 
patients without toxicity Cumulative 
number of 
events 
Number of 
remaining 
patients Estimates Standard 
error 
1 0.25 yes 0.984 0.016 1 62 
2 0.50 no   1 61 
3 0.75 yes 0.968 0.022 2 60 
4 1.00 no   2 59 
5 1.50 no   2 58 
6 1.75 yes 0.951 0.027 3 57 
7 2.00 yes   4 56 
8 2.00 yes   5 55 
9 2.00 yes   6 54 
10 2.00 yes   7 53 
11 2.00 yes 0.868 0.044 8 52 
12 2.50 yes 0.851 0.046 9 51 
13 2.50 no   9 50 
14 2.50 no   9 49 
15 3.00 no   9 48 
16 3.25 no   9 47 
17 3.50 yes 0.833 0.048 10 46 
18 4.50 yes 0.815 0.051 11 45 
19 5.50 no   11 44 
20 5.50 no   11 43 
21 5.50 no   11 42 
22 5.50 no   11 41 
23 6.00 no   11 40 
24 6.00 no   11 39 
25 6.50 no   11 38 
26 6.75 no   11 37 
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Table D-20 (continued) 
Patients 
Time  
(weeks) 
Event 
Cumulative proportion of 
patients without toxicity Cumulative 
number of 
events 
Number of 
remaining 
patients Estimates Standard 
error 
27 8.00 yes 0.793 0.054 12 36 
28 8.00 no   12 35 
29 8.00 no   12 34 
30 9.00 no   12 33 
31 9.00 no   12 32 
32 10.00 yes 0.768 0.057 13 31 
33 11.00 no   13 30 
34 11.00 no   13 29 
35 11.00 no   13 28 
36 11.50 no   13 27 
37 11.50 no   13 26 
38 11.50 no   13 25 
39 11.50 no   13 24 
40 11.50 no   13 23 
41 12.00 no   13 22 
42 12.00 no   13 21 
43 12.00 no   13 20 
44 12.50 no   13 19 
45 13.00 no   13 18 
46 13.000 no   13 17 
47 14.00 yes   14 16 
48 14.00 yes 0.678 0.079 15 15 
49 15.50 no   15 14 
50 16.50 no   15 13 
51 17.00 no   15 12 
52 17.00 no   15 11 
53 18.00 no   15 10 
54 18.50 no   15 9 
55 22.00 no   15 8 
56 22.00 no   15 7 
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Table D-20 (continued) 
Patients 
Time  
(weeks) 
Event 
Cumulative proportion of 
patients without toxicity Cumulative 
number of 
events 
Number of 
remaining 
patients Estimates Standard 
error 
57 23.00 no   15 6 
58 23.00 no   15 5 
59 24.00 no   15 4 
60 24.00 no   15 3 
61 26.00 no   15 2 
62 26.50 no   15 1 
63 30.50 no   15 0 
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Table D-21 CARG score category high (n = 50): Time to occurrence of major alterations of 
treatment (discontinuations or changes) in Kaplan-Meier analysis; yes: severe 
toxicity occurred; no: censored 
Patients 
Time 
(weeks) 
Event 
Cumulative proportion of 
patients without toxicity Cumulative 
number of 
events 
Number of 
remaining 
patients Estimates Standard 
error 
1 0.50 yes   1 49 
2 0.50 yes   2 48 
3 0.50 yes 0.940 0.034 3 47 
4 0.75 yes 0.920 0.038 4 46 
5 1.00 yes 0.900 0.042 5 45 
6 1.50 yes   6 44 
7 1.50 yes 0.860 0.049 7 43 
8 1.75 yes 0.840 0.052 8 42 
9 2.00 yes   9 41 
10 2.00 yes   10 40 
11 2.00 yes   11 39 
12 2.00 yes 0.760 0.060 12 38 
13 2.00 no   12 37 
14 4.50 no   12 36 
15 4.50 no   12 35 
16 5.00 yes   13 34 
17 5.00 yes   14 33 
18 5.00 yes 0.695 0.066 15 32 
19 5.00 no   15 31 
20 5.50 no   15 30 
21 5.50 no   15 29 
22 5.50 no   15 28 
23 6.00 no   15 27 
24 7.00 yes 0.669 0.068 16 26 
25 7.50 yes 0.643 0.070 17 25 
26 7.50 no   17 24 
27 8.50 no   17 23 
28 10.00 yes   18 22 
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Table D-21 (continued) 
Patients 
Time 
(weeks) 
Event 
Cumulative proportion of 
patients without toxicity Cumulative 
number of 
events 
Number of 
remaining 
patients Estimates Standard 
error 
29 10.00 yes 0.587 0.075 19 21 
30 11.00 no   19 20 
31 11.00 no   19 19 
32 11.50 yes 0.557 0.077 20 18 
33 12.00 yes 0.526 0.078 21 17 
34 12.00 no   21 16 
35 12.50 yes 0.493 0.080 22 15 
36 12.50 no   22 14 
37 13.00 yes 0.458 0.082 23 13 
38 14.00 yes 0.422 0.083 24 12 
39 14.50 yes 0.387 0.083 25 11 
40 15.00 yes 0.352 0.083 26 10 
41 16.75 no   26 9 
42 17.00 no   26 8 
43 18.50 no   26 7 
44 18.5 no   26 6 
45 20.00 no   26 5 
46 22.50 no   26 4 
47 23.00 no   26 3 
48 23.00 no   26 2 
49 24.50 yes 0.176 0.131 27 1 
50 40.50 no   27 0 
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Table D-22 Combined CRASH score category low (n = 24): Time to occurrence of major 
alterations of treatment (discontinuations or changes) in Kaplan-Meier analysis; 
yes: severe toxicity occurred; no: censored 
Patients 
Time 
(weeks) 
Event 
Cumulative proportion of 
patients without toxicity 
Cumulative 
number of 
events 
Number of 
remaining 
patients 
   Estimates Standard error   
1 0.25 yes 0.958 0.041 1 23 
2 0.50 yes 0.917 0.056 2 22 
3 0.50 no   2 21 
4 1.50 no   2 20 
5 2.00 no   2 19 
6 5.50 no   2 18 
7 5.50 no   2 17 
8 6.00 no   2 16 
9 6.00 no   2 15 
10 6.75 no   2 14 
11 10.00 yes 0.851 0.082 3 13 
12 11.50 no   3 12 
13 11.50 no   3 11 
14 12.00 yes 0.774 0.105 4 10 
15 12.00 no   4 9 
16 12.00 no   4 8 
17 16.50 no   4 7 
18 17.00 no   4 6 
19 18.00 no   4 5 
20 22.50 no   4 4 
21 23.00 no   4 3 
22 24.00 no   4 2 
23 24.00 no   4 1 
24 26.00 no   4 0 
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Table D-23 Combined CRASH score category high (n = 89): Time to occurrence of major 
alterations of treatment (discontinuations or changes) in Kaplan-Meier analysis; 
yes: severe toxicity occurred; no: censored  
Patients Time 
(weeks) 
Event Cumulative proportion of 
patients without toxicity 
Cumulative 
number of 
events 
Number of 
remaining 
patients 
   Estimates Standard error   
1 0.50 yes   1 88 
2 0.50 yes 0.978 0.016 2 87 
3 0.75 yes   3 86 
4 0.75 yes 0.955 0.022 4 85 
5 1.00 yes 0.944 0.024 5 84 
6 1.00 no   5 83 
7 1.50 yes   6 82 
8 1.50 yes 0.921 0.029 7 81 
9 1.75 yes   8 80 
10 1.75 yes 0.898 0.032 9 79 
11 2.00 yes   10 78 
12 2.00 yes   11 77 
13 2.00 yes   12 76 
14 2.00 yes   13 75 
15 2.00 yes   14 74 
16 2.00 yes   15 73 
17 2.00 yes   16 72 
18 2.00 yes   17 71 
19 2.00 yes 0.796 0.043 18 70 
20 2.50 yes 0.785 0.044 19 69 
21 2.50 no   19 68 
22 2.50 no   19 67 
23 3.00 no   19 66 
24 3.25 no   19 65 
25 3.50 yes 0.773 0.045 20 64 
26 4.50 yes 0.760 0.046 21 63 
27 4.50 no   21 62 
28 4.50 no   21 61 
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Table D-23 (continued) 
Patients Time 
(weeks) 
Event Cumulative proportion of 
patients without toxicity 
Cumulative 
number of 
events 
Number of 
remaining 
patients 
   Estimates Standard error   
29 5.00 yes   22 60 
30 5.00 yes   23 59 
31 5.00 yes 0.723 0.048 24 58 
32 5.00 no   24 57 
33 5.50 no   24 56 
34 5.50 no   24 55 
35 5.50 no   24 54 
36 5.50 no   24 53 
37 5.50 no   24 52 
38 6.00 no   24 51 
39 6.50 no   24 50 
40 7.00 yes 0.709 0.049 25 49 
41 7.50 yes 0.694 0.050 26 48 
42 7.50 no   26 47 
43 8.00 yes 0.679 0.051 27 46 
44 8.00 no   27 45 
45 8.00 no   27 44 
46 8.50 no   27 43 
47 9.00 no   27 42 
48 9.00 no   27 41 
49 10.00 yes   28 40 
50 10.00 yes 0.646 0.054 29 39 
51 11.00 no   29 38 
52 11.00 no   29 37 
53 11.00 no   29 36 
54 11.00 no   29 35 
55 11.00 no   29 34 
56 11.50 yes 0.627 0.056 30 33 
57 11.50 no   30 32 
58 11.50 no   30 31 
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Table D-23 (continued) 
Patients Time 
(weeks) 
Event Cumulative proportion of 
patients without toxicity 
Cumulative 
number of 
events 
Number of 
remaining 
patients 
   Estimates Standard error   
59 11.50 no   30 30 
60 12.00 no   30 29 
61 12.00 no   30 28 
62 12.50 yes 0.605 0.058 31 27 
63 12.50 no   31 26 
64 12.50 no   31 25 
65 13.00 yes 0.581 0.061 32 24 
66 13.00 no   32 23 
67 13.00 no   32 22 
68 14.00 yes   33 21 
69 14.00 yes   34 20 
70 14.00 yes 0.501 0.067 35 19 
71 14.50 yes 0.475 0.069 36 18 
72 15.00 yes 0.449 .070 37 17 
73 15.50 no   37 16 
74 16.75 no   37 15 
75 17.00 no   37 14 
76 17.00 no   37 13 
77 18.50 no   37 12 
78 18.50 no   37 11 
79 18.50 no   37 10 
80 20.00 no   37 9 
81 22.00 no   37 8 
82 22.00 no   37 7 
83 23.00 no   37 6 
84 23.00 no   37 5 
85 23.00 no   37 4 
86 24.50 yes 0.337 0.110 38 3 
87 26.50 no   38 2 
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Table D-23 (continued) 
Patients Time 
(weeks) 
Event Cumulative proportion of 
patients without toxicity 
Cumulative 
number of 
events 
Number of 
remaining 
patients 
   Estimates Standard error   
88 30.50 no   38 1 
89 40.50 no   38 0 
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Appendix E 
Results of the medication risk analysis  
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Prevalence of antineoplastic agents and supportive care medication after start of cancer 
therapy 
Table E-1 Drug classes (ATC code level 2) and individual drugs which patients received as 
antineoplastic agents after start of cancer therapy (n = 128) 
Drug class (ATC code level 2) 
Number of drug 
prescriptions 
Plant alkaloids and other natural products (L01C) 76 
Platinum compounds (L01XA) 54 
Alkylating agents (L01A) 45 
Monoclonal antibodies (L01XC) 40 
Antimetabolites (L01B) 30 
Corticosteroids for systemic use (H02) 29 
Cytotoxic antibiotics and related substances (L01D) 29 
Others 8 
Drug Number of patients 
Paclitaxel 38 
Carboplatin 37 
Rituximab 33 
Cyclophosphamide 30 
Doxorubicin 25 
Vincristine 23 
Prednisolone 13 
Predisone 11 
Oxaliplatin 10 
Fluorouracil 9 
Etoposide 9 
Bendamustine 8 
Gemcitabine 8 
Cisplatin 7 
Decitabine 6 
Bortezomib 5 
Dexamethasone 5 
Methotrexate 4 
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Table E-2 Drug classes (ATC code level 2) and individual drugs of supportive care 
medication which patients received after start of therapy (n = 128) 
Drug class (ATC code level 2) Number of drugs 
prescriptions 
Antiemetics and antinauseants (A04) 116 
Antihistamines for systemic use (R06) 71 
Corticosteroids for systemic use (H02) 62 
Drugs for acid-related disorders (A02) 60 
Antigout preparations (M04) 49 
Analgesics (N02) 35 
Detoxifying agents for antineoplastic treatment (V03AF) 34 
Others 38 
Drug Number of patients 
Ondansetron 109 
Dexamethasone 62 
Ranitidine 52 
Clemastine 50 
Allopurinol 49 
Paracetamol 35 
Mesna 32 
Dimetindene 21 
Calcium folinate 11 
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Distribution of CTCAE grade ≥ 3 toxicity during therapy course regarding medication risks 
Table E-3 Distribution of CTCAE grade ≥ 3 toxicity during therapy course per medication 
risks; PIM, potentially inadequate medication; rPDDI, relevant potential drug-
drug interactions; * Fisher’s exact test  
 n (%) P value* 
Overall toxicity   
Patients without polymedication 43 (78.2) 0.471 
Patients with polymedication 49 (84.5)  
Patients without PIM 42 (79.2) 0.633 
Patients with PIM 50 (83.3)  
Patients without rPDDI 60 (75.9) 0.033 
Patients with rPDDI 32 (94.1)  
Hematologic toxicity   
Patients without polymedication 36 (65.5) 0.841 
Patients with polymedication 40 (69.0)  
Patients without PIM 36 (67.9) 1.000 
Patients with PIM 40 (66.7)  
Patients without rPDDI 47 (59.5) 0.008 
Patients with rPDDI 29 (85.3)  
Nonhematologic toxicity   
Patients without polymedication 30 (54.5) 0.344 
Patients with polymedication 37 (63.8)  
Patients without PIM 27 (50.9) 0.125 
Patients with PIM 40 (66.7)  
Patients without rPDDI 44 (55.7) 0.298 
Patients with rPDDI 23 (67.6)  
 
